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1 POTASSIUM CHANNELS  
1.1 Introduction 
Potassium channels are an ubiquitous group of ion channels involving in a 
multitude of physiological functions. They are multimeric integral membrane 
proteins forming transmembrane aqueous pores through which K+ specifically 
permeates at a rate of 106-108 ions/s.1 Many molecular subfamilies of K+ 
channels are known and these correspond to the physiological signals by which 
pore opening is controlled such as voltage; Ca2+; ATP; G proteins or 
polyamines, but a unique set of functional determinants characterize this 
superfamily of membrane proteins. These include (i) a water-filled permeation 
pathway (pore) that allows K+ ions to flow across the cell membrane, (ii) a 
selectivity filter that specifies K+ as permeant ion species, and (iii) a gating 
mechanism that serves to switch between open and closed channel 
conformations.1  
K+ channels are classified on the basis of primary amino acid sequence of the 
pore containing unit (α subunit) into three major families: the voltage gated 
(Kv) containing six-transmembrane-regions with a single pore; the inward 
rectifier (Kir) containing only two-transmembrane-regions and a single pore; 
the two-pore tandem K+ channels containing four transmembranes with two 
pores. A tripeptide sequence Gly-Tyr(Phe)-Gly is common to the pore of all K+ 
channels and constitutes the signature motif for determining K+ ion selectivity. 
The “slowpoke” Ca2+-activated K+ channels are architecturally similar to Kv 
subtypes and present an extra transmembrane segment near the amino terminus, 
while the twin-pore K+ (K2P) channels are weak inward rectifier with four 
putative transmembrane domains and two pore domains.2  
 
Figure 1.1General architecture of K+ channel families. 
Chapter 1 
 8 
1.1.1 ATP-sensitive potassium channels 
ATP-sensitive potassium (KATP) channels, discovered in the early 1980s in 
cardiac muscle and pancreatic β-cells, 3-6 are a weakly inward-rectifying K+ 
channels that are inhibited by the non-hydrolytic binding of ATP, but activated 
by interactions with Mg2+-bound nucleotides (Mg-nucleotides) at separate sites. 
KATP channels are postulated to act as sensors of intracellular metabolism, 
tuning the potassium permeability, and therefore the electrical activity, of a cell 
to its energetic balance7. The inhibitory effect dominates, and channels are 
closed, when cellular phosphorylation potential is high, but as metabolism 
decreases, the activating effect wins out and channels open. This metabolic 
sensing role is involved in many physiological processes, for example, it plays a 
role in the cascade linking insulin secretion to glycaemia in the pancreatic β-cell 
and participates in ischaemic pre-conditioning and thereby cardio-protection 
during heart failure.6,8,9 
1.1.2 Protein architecture of KATP channels 
KATP channels are formed by the combination of two types of proteins:10 one, 
Kir6, is a ~50 kDa protein belonging to the inwardly rectifying potassium (Kir) 
channel family, the other, SUR (for sulphonylurea receptor), is a ~140-180 kDa 
member of the ATP-binding cassette (ABC) transporter family.  The channel is 
a functional octamer of four Kir6 subunits assemble to form the pore, and each 
subunit is associated to four SUR subunits generating the regulatory site.11,12 
 
Figure 1.2 Protein architecture of KATP channels. a) Inward rectifier K+ channel Kir6 subunits 
generate the channel pore and sulphonylurea receptor (SUR) subunits generate the regulatory 
subunit. TMD, transmembrane domain; NBF, nucleotide-binding fold; M1, M2, transmembrane 
helices; P, pore. b) The channel is a functional octamer of four Kir6 subunits, and each subunit 
is associated with four SUR subunits. c) Images at 18 Å resolution of the entire KATP complex 
viewed in the plane of the membrane (left) or from above the membrane (right). 
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Kir6 consisting of two transmembrane helices (M1 and M2) bridged by an 
extracellular loop that generates the narrow portion of the pore (H5) and control 
ion selectivity. Two members of the Kir6 family are known, Kir6.1 and Kir6.2 
encoded by KNCJ8 and KNCJ11 genes respectively, which have about 70% 
aminoacid identity. SUR has strong homologies with other members of 
subfamily C of ABC proteins and are encoded by two genes, SUR1 and SUR2 
with 70% homology. The SUR2 gene has two major splice variants, SUR2A 
and SUR2B, which differ by 42 aminoacids in the C-terminus. SURs possess 
the core domain composed of two transmembrane domains TMD1 and TMD2, 
with six transmembrane regions, and two cytoplasmic nucleotide binding folds 
NBF1 and NBF2.12 In addition, it has a supplementary N-terminal domain 
TMD0 composed of five transmembrane helices which is linked to the core 
ABC domain by a cytosolic loop L0. Both Kir6, in the C-terminus, and SUR, in 
the sixth intracellular loop, have endoplasmatic reticulum (ER) retention 
sequences which prevent trafficking to the cell surface in the absence of the 
other subunit13. There is evidence14 that TMD0 is crucial for trafficking Kir6.2 
subunits to the surface membrane, and its role in controlling the gating of 
Kir6.215,16 suggests an intimate relationship with the poreforming subunit. In 
recombinant cells, truncation of the C-terminus of Kir6.2 (Kir6.2∆C) removes 
its retention sequence (Arg-Lys-Arg), allowing it to form functional channel 
without SUR subunits17 and indicating that channel inhibition by ATP is a 
property of Kir6 subunit. However, the ATP-sensitivity of Kir6.2∆C is 10-20 
fold lower than that of Kir6.2/SUR1 channels. 
1.1.3 Nucleotide gating KATP channels 
Several ligands affect KATP channel activity. These channels are inhibited by 
ATP (with or without Mg2+) and activated by phosphatidylinositol-4,5-
bisphosphate (PIP2) by a direct interaction with Kir6.2 subunits of the channels. 
Sulphonylureas inhibit, and potassium channel-opener drugs activate, by 
interaction with the SUR subunit. In addition, in the presence of Mg2+, ATP and 
ADP can activate the channel through interaction with the NBFs of SUR. 
Inhibition by ATP binding to Kir6.2 and activation by Mg-nucleotides is almost 
certainly the primary physiological regulatory mechanism. The metabolically 
controlled gate of the channel is located at the cytoplasmic end of the inner 
cavity. PIP2 interaction provides an energetic pull to open channels, and ATP 
binding provides the energetic push to close the ligand-operated gate, perhaps 
through the physical link provided by a “slide helix”, that lies along the plane of 
the membrane and physically connects the N terminus, which in Kir6.2 forms 
part of the ATP-binding site, to the cytoplasmic end of M1. MgATP binds to 
each of the ATP-binding sites (ABSs) that are formed at the interface between 
nucleotide-binding domains NBF1 and NBF2 in each sulphonylurea receptor 
subunit. ATP hydrolysis at the second site results in a conformational 
“activated” state that is transduced to an “override” of ATP inhibition at the 
Chapter 1 
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Kir6.2 subunit. The “activated” state persists through MgADP dissociation, and 
can be maintained by MgADP rebinding7. 
1.1.4 KATP channels diversity  
KATP channels were first described by Noma3 in cardiac ventricular myocytes, 
but they are also expressed in several tissue types including kidney, brain, 
skeletal muscle, heart, pancreatic β-cells and smooth muscle18-21 and have been 
clearly identified in both sarcolemmal and mitochondrial membranes (sarc- and 
mito-KATP, respectively). Their functional role in many tissues occurs in 
response to metabolic changes: in the pancreas KATP channels underlie insulin 
secretion in response to an increase blood glucose concentration; in the heart 
they have a protective function in response to hypoxia or ischaemia. In the brain 
KATP channels have a similar protective function and are also involved in 
sensing the level of blood glucose. Opening of smooth muscle KATP channels 
causes relaxation, and in particular activation of vascular KATP channels suggest 
a role in contributing to the increase of blood flow in response to increased 
tissue metabolic demand. In skeletal muscle, KATP channels may play roles both 
in fatigue and in glucose uptake.22 
KATP channels in different tissues are formed by different combination of Kir 
and SUR subunits, accounting for the tissue-specific properties of the channels. 
For example, the pancreatic β-cells are made up of SUR1/Kir6.223,24; while 
SUR2A is associated with Kir6.2 in the cardiac sarcolemmal channel25,26; 
Kir6.1 and SUR2B probably constitute the major KATP channel in the vascular 
smooth muscle27, while the channels in non-vascular smooth muscle are formed 
by SUR2B and Kir6.1 or Kir6.2. Different SUR subtypes respond differently to 
intracellular nucleotides, sulfonylureas, and potassium channel openers 
(KCOs), while Kir6.1 and Kir6.2 have similar ATP sensitivities. Therefore, the 
metabolic sensitivities  and the pharmacological properties of a KATP channel 
are largely determined by its constituent SUR. 
 1.1.5 Potential therapeutic 
The efflux of K+ ions following opening of potassium channels is a mechanism 
for recovering (repolarization), maintaining (clamping) and/or enhancing 
(hyperpolarization) the resting state of the cell. Thus, the opening of potassium 
channels is a fundamental physiological means for reversal or prevention of 
depolarizing activity of the membrane and the role of these ion channels in 
cellular control and their opening by endogenous mediators, such as 
neurotrasmitters and hormones, is recognized as an inhibitory mechanism.  
Potassium channels are a diverse and ubiquitous group of ion channel 
exhibiting a wide range of physiological roles in cell control processes, so drugs 
that decrease cell excitability by opening these channels could have a broad 
clinical potential. 
Potassium channels 
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In particular, considering the unique role that KATP play in the maintenance of 
the cellular homeostasis, potassium channel openers (KCOs) add to existent 
pharmacotherapy with potential in promoting cellular protection under 
conditions of metabolic stress, for example, preclinical evidences28-35 have 
shown their potential therapeutic in asthma, urinary incontinence, hypertension, 
cardiac ischaemia, CNS desease. 
The therapeutic usefulness of KCOs ultimately depends on their tissue 
selectivity which was majorly not achieved with first generation compounds. 
Thus, only four KCOs were introduced to clinical practice32 including 
nicorandil (angina, hypertension), diazoxide (refractory hypertension), 
minoxidil sulfate (alopecia, refractory hypertension), and pinacidil 
(hypertension).  
1.1.6 Asthma 
Therapeutic potential of KCOs in lung disease primarly refers to asthma and 
chronic obstructive pulmonary disease (COPD)36-41. Bronchial asthma is 
characterized by wide variations over short periods of time in the resistance to 
flow in intrapulmonary airways. Accordingly, this disease is commonly treated 
with bronchodilators. Nowadays asthma is no longer viewed simply as a 
reversible airways obstruction, but is considered as an inflammatory illness 
resulting in bronchial hyperreactivity and bronchospasm. Thus, 
pharmacological treatment of asthma deserves anti-inflammatory and 
bronchodilator drugs. Recent trends in the development of new anti-asthmatic 
include PDE inhibitors, thromboxane A2 antagonists as well as KCOs40. 
Evidence for a bronchodilator potential KCOs dates back to 1986, when Allen 
et al.42 showed cromakalim to reduce spontaneous, and to a lesser extent, 
cholinergic and histaminergic tone in preparations of guinea-pig trachealis. 
Effective relaxion of tone by KCOs was also shown in bovine43 and in human 
airways44. KCOs exhibit stronger spasmolytic rather than anti-spasmogenic 
activity which resembles other classes of smooth muscle relaxants36. 
Corresponding to their spasmolytic efficacy in vitro, KCOs relax established 
bronchocostriction in vivo. However, in contrast to in vitro findings these drugs 
exhibit pronounced protective effects in vivo also when given prior to 
challenge. In vivo studies preferentially addressed the anti-spasmogenic activity 
of KCOs. Orally administration inhibited dyspnoea evoked by histamine in 
conscious guinea-pigs45 while intravenously or intraduodenal administration 
inhibits bronchocostriction elicited by histamine, serotonin and bombesin.45-49 
Bronchoconstriction often involves a reflex parasympathetic component, thus, 
neural effects of KCOs might be relevant for their therapeutic utility in asthma. 
Several studies show KCOs to potently inhibit the neurotransmitter release from 
cholinergic and non-adrenergic, non-cholinergic (NANC) neurons. KCOs more 
effectively inhibit Ach- or NANC-mediated bronchoconstriction because of 
stimulated neurotransmitter release as compared to bronchoconstriction because 
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of an exogenous supply of Ach or NANC neurotransmitters such as substance P 
or neurokinin A.50,51 Inhibitory effects are probably mediated by 
hyperpolarizaion of sensory nerve endings via activation of prejunctional K+-
channels32. Beyond their effects on bronchoconstriction NANC 
neurotransmitters stimulate mucus secretion and the leakage of plasma from 
post-capillary venules, both of which are important in the pathology of asthma. 
These inflammatory effects of NANC neurotransmitters seem to be primarly 
due to the action of substance P.52 
Airways hyper-responsiveness (AHR) to a plethora of physiological and 
pharmacological stimuli is a commonly observed characteristic of asthmatic 
patients. KCOs acutely reverse AHR by a direct effect on airways smooth 
muscle and they are able to prevent the development of AHR.  
Molecular mechanism underlying the prevention of AHR by KCOs remain to 
be clarified. 
1.1.7 Urinary incontinence 
Urinary incontinence is classified in four major types: 1) stress incontinence; 2) 
urge incontinence; 3) reflex incontinence; 4) overflow incontinence (Table 1.1). 
 
Table 1. 1 Subtypes of urinary incontinence53 
Stress 
incontinence 
Involuntary loss of urine during coughing, sneezing or 
physical activities; it occurs when intravescical pressure is 
higher than maximum urethral pressure but in the absence of 
detrusor activity 
Urge 
incontinence 
Characterized by abnormal spontaneous detrusor contraction 
unrelated to bladder volume; broadest category of urinary 
incontinence 
Reflex 
incontinence 
Involuntary loss of urine because of abnormal reflex activity in  
the spinal corde 
Overflow 
incontinence 
Involuntary loss of urine when the intravescical pressure 
exceeds the maximum urethral pressure because of an 
elevation of intravescical pressure associated with bladder 
distention but in the absence of detrusor activity 
 
The etiology is multivariant and includes neurogenic and myogenic instabilities. 
Most incontinence is because of failure to store urine (storage dysfunction), 
only overflow incontinence is because of failure to empty urine (emptying 
dysfunction). 
Pharmacological treatment of storage dysfunction should be aimed at 
decreasing detrusor overactivity, increasing bladder capacity, and/or increasing 
outlet resistance. 
Potassium channels 
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Pharmacological treatment of emptying dysfunction should be aimed at 
increasing detrusor contractility and/or decreasing outlet resistance53-57. Most 
widely used in pharmacological treatment are anti-muscarinic agents, which 
effectively inhibit bladder hyper-reflexia, but suffer from main side-effects, 
such as the inhibition of normal bladder smooth muscle contractility and the 
blockade of muscarinic receptors in other organs. 
As an alternative to anti-muscarinics, KCOs should be able to decrease the 
bladder overactivity. Several KCOs were shown in vitro to relax the bladder 
smooth muscle in various species including man58-61. 
1.1.8 Nervous System 
 
1.1.8.1 Peripheral Nervous System 
The KCOs interfere with neurotransmission in peripheral parasympathetic 
neurones in the airways and the gastrointestinal tract62. This has led to 
suggestions of a presynaptic site of action, whereby the KCOs control the 
release of neurotransmitter. In contrast, cromakalim, nicorandil, and pinacidil 
failed to exert an inhibitory effect on noradrenaline release in rat isolated 
mesenteric artery63. The presynaptic inhibitory role of KCOs, therefore, appears 
to be selective for parasympathetic (cholinergic) innervation. Interestingly, 
cromakalim and pinacidil inhibited nicotinic acetylcholine receptor-mediated 
and voltage-dependent catecholamine secretion from bovine adrenal chromaffin 
cells64. Thus, KATP channels could be involved in regulation of catecholamine 
secretion mainly indirectly through voltage operated channels (VOCs). 
1.1.8.2 Central Nervous System  
Potassium channels play a pivotal role in the control of neuronal excitability, 
action potential, and neurotransmitter release within the CNS65,66. Activation of 
a variety of receptors (e.g., opioid, 5-HT3, somatostatin, α2-adrenoceptors) by 
the appropriate neurotransmitter alters the flux of K+ ions from neurons67. 
Because of this role in normal CNS physiology, derangements in the function 
of K+ channels may underlie several CNS diseases. Localization in the cerebral 
cortex and hippocampus would suggest that this channel may have a role in the 
processing of memory. Studies in vitro and in animal models indicate the 
potential clinical utility of KCOs for diseases of the CNS.  
The genesis and propagation of non physiologic electrical impulses are the 
hallmark of epilepsy. Thus, the hyperpolarization (and restraining) of excitable 
cells through the opening of K+ channels could demonstrate therapeutic benefit 
in this setting. Opioids exert their analgesic effects by binding to opiate 
receptors, which leads to opening of K+ channels and neuronal 
hyperpolarization67. Morphine induced antinociception in mice tail-flick tests is 
mediated by the opening of KATP channels68. These observations would suggest 
a potential role for KCOs as analgesics. During anoxic conditions, neuronal 
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depolarization is due, at least, to the release of large concentrations of 
excitatory amino acids, such as glutamate, which may be involved in long-term 
ischaemia-induced damage to the brain69. In in vitro experiments, diazoxide and 
somatostatin were shown to prevent anoxia-induced depolarization of CA3 
hippocampal neurons following the opening of K+ channels70; these effects 
were inhibited by pretreatment with glyburide. The authors proposed that KCOs 
may prevent anoxia-induced damage to hippocampal neurons by inhibiting the 
release of excitatory amino acids. Schmid-Antomarchi et al. 71 noted that the 
order of potency of the KCOs (levcromakalim > nicorandil > cromakalim > 
diazoxide > pinacidil) was found to be different from that in either the 
pancreatic β-cell or in smooth muscle, possibly indicating a difference between 
the target K+ channel in this brain region and that in other tissues. The KATP 
channel in neuronal tissue is not the classical (Type 1) channel found in 
pancreatic β -cells or heart, but a large-conductance non-rectifying version 
(Type 2) 72. 
1.1.9 Skeletal Muscle 
In skeletal muscle, KATP channel activity has been shown to increase upon 
intracellular acidification73. Falls in intracellular pH reduce the inhibitory effect 
of ATP on K+ channels in frog skeletal muscle. This could mean that during 
increased muscle exercise and consequent lowering of pH, KATP channel-
induced hyperpolarization could compensate for a decrease in electrical 
excitability and prevent spontaneous contractions from occurring. KCOs, 
however, increased open probability of an ATP-sensitive and an ATP-
insensitive K+ channel in human skeletal muscle74; the effect of the KCOs on 
both channels were blocked by glibenclamide. Ischaemia-induced damage in a 
rat skeletal muscle, like cardiac and neuronal ischaemia, has been shown to be 
prevented by cromakalim75. This result, and the observation that cromakalim 
restores the membrane potential of depolarized human skeletal muscle fibres76, 
indicate that KCOs may be useful for the treatment of peripheral vascular 
disease. In rat skeletal muscle, Angersbach and Nicholson77 demonstrated that 
KCOs, but not Ca2+ antagonists or hydralazine, selectively increase blood flow 
to collateral vessels in a previously ischemic limb. Weselcouch et al. 78, 
however, suggested that KCOs would not be beneficial in treatment of skeletal 
muscle ischaemia in vivo, but may be useful in preserving skeletal muscle 
function in cases of ischaemia followed by reperfusion. Studies in human 
muscle have implicated SKCa, (apaminsensitive) channels in the condition 
myotonic muscular dystrophy, characterised by muscle stiffness79. Although K+ 
channel subtypes other than KATP channels exist in skeletal muscle (SKCa, 
BKCa, delayed rectifier K+ channel)80, however, selective openers are awaited to 
determine their role and the therapeutic potential of activation. 
Potassium channels 
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1.1.10 Myocardial Ischaemia 
A beneficial role of KCOs in myocardial ischaemia81-84 was first suggested by 
investigations on nicorandil85. Later, Grover et al. 86 studied the anti-ischaemic 
effects of KCOs in a model of ischaemia and reperfusion in which complicating 
vasodilator effects were avoided and thus direct cardioprotective activity could 
be verified. These authors showed pinacidil and cromakalim to protect isolated 
rat heart subjected to 25 min global ischaemia followed by 30 min reperfusion; 
concentrations needed to increase the time to ischaemic contracture by 25% 
were used as indicators of anti-ischaemic potency. Cardioprotective properties 
of other KCOs including bimakalim and aprikalim could be shown in similar 
models87-92. Putative involvement of  KATP channels with the mechanism of 
myocardial preconditioning  further increased the interest in these channels. 
KCOs mimic preconditioning in the absence of ischaemia, whereas KATP 
blockers such as glibenclamide93 and 5-hydroxydecanoate (5-HD)94 were 
shown to antagonize preconditioning. The original hypothesis to explain these 
observations involved sarcolemmal KATP channels; shortening of action 
potential duration (APD) was viewed as a putative mechanism of the 
cardioprotection by KCOs. However, KCOs exert their cardioprotective effects 
without a significant cardiodepression indicating a lack of importance of 
sarcolemmal KATP channels to mediate cardioprotection. This view is supported 
by the abolition of cardioprotective effect of KCOs in the presence of 5-HD94 
that is a selective blocker of mitochondrial KATP channels95, while the 
sarcolemmal KATP channels blocker HMR1883 failed to abolish 
preconditioning96. 
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2 MYOCARDIAL ISCHAEMIC PRECONDITIONING (IPC) 
2.1 Ischaemia-Reperfusion (I/R) Injury  
I/R injury of the heart is characterized by reversible contractile dysfunction, 
known as stunning, and irreversible injury leading to cardiomyocytes death and 
myocardial infarction. Myocardial stunning, is defined by the mechanical 
dysfunction that persists after reperfusion, despite the absence of irreversible 
damage and despite restoration of normal coronary flow.1  
Two major hypotheses have been proposed to explain the mechanism of 
myocardial stunning:2 1) the oxyradical hypothesis, in which it is caused by the 
generation of ROS; 2) the Ca2+ hypothesis, in which it is caused by a transient 
Ca2+ overload on reperfusion. The final lesion responsible for the contractile 
depression appears to be a decreased responsiveness of contractile filaments to 
Ca2+. Recent evidence suggests that Ca2+ overload may activate calpains, Ca2+-
dependent neutral proteases, resulting in selective proteolysis of myofibrils. The 
time required for resynthesise damaged proteins would explain in part the 
delayed recovery of function in stunned myocardium. The ROS and Ca2+ 
hypotheses are not mutually exclusive and are likely to represent different 
component of the same pathophysiologic cascade. For example, increased ROS 
formation could cause cellular Ca2+ overload, which would damage the 
contractile apparatus of the cardiomyocytes. ROS generation could also directly 
alter contractile filaments in a manner that renders them less responsive to Ca2+ 
(e.g., oxidation of critical thiol groups). An important implication of the 
phenomenon of myocardial stunning is that so-called chronic hibernation may 
be the result of repetitive episodes of stunning, which have a cumulative effect 
and cause protracted post-ischaemic dysfunction. Besides direct effects of ROS 
and Ca2+ on Ca2+-regulatory proteins and contractile machinery, ROS and 
intracellular Ca2+ overload modulate cardiomyocyte contractility through 
phosphorylation of contractile proteins. A variety of protein kinases are 
activated in response to oxidative stress, and this process is pivotal in regulating 
the contractility. Particularly, PKC and p38 mitogen-activated protein kinase 
(MAPK) have been implicated in the pathogenesis of ischemic contractile 
dysfunction.3,4  
Paradoxically, reperfusion can exacerbate the damage occurring during the 
ischaemic period. This is known as reperfusion injury and is accompanied by 
enzyme release and morphological changes characteristic of necrosis.5-7  
In addition to the necrotic cell death that represents the major damage to the 
reperfused heart there is also evidence that some myocytes around the periphery 
of the infarct die by apoptosis.8,9 The myocardial cell appears to be primed by a 
sequence of events during the ischaemic period that “sets up” the cell for an 
irreversible injury, which is then triggered by reperfusion.  
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During ischaemia the intracellular acidosis that results from anaerobic 
glycolysis drives a series of coupled exchanges in which the Na+/H+ exchanger 
removes H+ and accumulates Na+ in the cell, which is then coupled to Ca2+-
influx by reverse-mode Na+/Ca2+ exchange activity, resulting in a Ca2+ 
accumulation. Moreover, during ischaemia, the intracellular ATP concentration 
falls with consequent reduction in activity of the Na+/K+ ATPase and increase 
in [Na+]i. Additional effect of ischaemia includes inihibition of the 
sarcoplasmic reticulum Ca2+-release channel (RyR). At the moment of 
reperfusion, the cell is characterized by high levels of intracellular Na+, Ca2+ 
and possibly mitochondrial reducing power (NADH, FADH2) and the 
sarcoplasmic reticulum is loaded with Ca2+. Reperfusion triggers an injury 
cascade that combines reactivation of electron transport and oxidative 
phosphorilation, which increases the availability of ATP, with the existing Ca2+ 
load to produce a strong hypercontracture, which in the intact tissue leads to 
mechanical damage. There is also a secondary Ca2+ influx in the Na+/Ca2+ 
exchanger driven by a reperfusion induced influx of Na+ via the Na+/H+ 
exchanger stimulated by the washout of extracellular acidosis. In addition to 
these metabolic effects, re-energization of the mitochondria products a burst of 
reactive oxygen species and rapid mitochondrial repolarization which leads to 
Ca2+ accumulation and opening of mitochondrial permeability transition pores 
(MPTP) and thus the initiation of cell death at reperfusion. 
Understanding the causes of reperfusion injury and devising ways of preventing 
it is of major clinical importance in cardiac surgery and the treatment of 
coronary thrombosis. There is increasing evidence that mitochondrial 
dysfunction plays a central role in mediating both the necrotic and apoptotic 
components of reperfusion injury, and that one of the most effective ways of 
protecting hearts from such injury is to subject them to brief ischaemic periods 
with intervening recovery periods before the prolonged period of ischaemia is 
initiated. This phenomenon is known as ischaemic preconditioning (IPC).5,7,10-13 
Some authors have also hypothesized that functional recovery after ischaemia is 
predicated on the ability of the myocyte to maintain sufficient substrate 
metabolism during ischaemia. This hypothesis starts from the observation that 
glucose metabolism via the polyol pathway, and consequently aldose reductase 
(AR) activity, is increased in ischemic hearts14-17 and recently, it was 
demonstrated that inhibition of AR protects rat hearts from ischemic injury and 
improves functional recovery upon reperfusion.  
During ischaemia, lack of oxygen leads to rapid stimulation of glucose uptake, 
glycogenolysis and glycolytic flux.18,19 Moderate reduction in blood flow and 
oxygen supply result in increased glucose extraction and glycolysis with no 
changes in glucose uptake, whereas severe reductions result in increased 
myocardial glucose uptake, glucose extraction and significantly increased 
glycolysis. The induction of ischaemia is followed by recruitment of the 
glucose transporters GLUT-4 and GLUT-1 from the intracellular stores to the 
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plasma membrane.20-22 Stimulation of glucose transport during ischaemia is 
reflected by the increased glycolytic flux.18-22 However, prolonged ischaemia 
results in inhibition of glycolysis due to the increased levels of lactate, protons 
and decreased availability of NAD+.16,17,19 Recent studies have shown that 
ischaemia increases aldose reductase activity and NAD+ use via this pathway. 
As a result glycolysis is impaired due to shortage of NAD+ for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH).14,16,17  
Sustaining glycolysis during ischaemia is an important source of ATP for 
maintaining the activities of sarcolemmal Na+/K+ATPase and the 
sarcoendoplasmic Ca2+-ATPase.23-25 There is evidence to suggest that 
glycolysis preferentially supplies ATP for these critical ion pumps24,25 and thus, 
even if glycolytic metabolism does not provide sufficient energy for to provide 
enough ATP to maintain cardiac contraction, it may provide adequate energy to 
maintain the ionic homeostasis and thus preserve viability during the ischaemic 
insult. 
Fatty acids have been shown to be detrimental to ischaemic myocardium. 
Accumulation of long-chain fatty acids may adversely affect intermediary 
metabolism by increasing NADH/NAD+ ratio; increasing acetyl-CoA/CoASH 
with consequent increases in citrate levels and inhibition of PFK; inhibiting 
pyruvate carboxylase and increasing the amounts of long chain acyl carnitine 
(LCA).  
Numerous experimental studies have convincingly demonstrated that 
maintenance of glycolytic metabolism by the ischaemic myocardium can 
preserve viability,16,17,26-28 can delay ischaemic contracture and can prevent 
reversible cell damage.29 Glycolysis is required to support membrane function 
and in particular, maintain sodium and calcium homeostasis.23-25,30 It has been 
shown repetely in numerous studies that protection myocardium during 
ischaemia by favourably modifying metabolism reduces ischaemic injury and 
improves functional recovery upon reperfusion.17,28,31-34 Thus, there is excellent 
experimental and clinical data to support the concept that increased glycolytic 
flux, induced by increased exogenous glucose and reduced serum fatty acids, 
assists in protecting the ischaemic myocardium and improving survival and 
function after acute ischaemic episodes. Moreover, recent studies have shown 
that targeting aldose reductase may provide a novel approach to protecting 
ischaemic myocardium.35The reduction in ischemic injury due to aldose 
reductase inhibition was associated with attenuation of the rise in cytosolic 
redox (NADH/NAD+ ratio) and improved glycolysis in ischemic 
myocardium.16,34,36  
Furthermore, AR inhibition improved myocardial glucose oxidation upon 
reperfusion34and beneficial changes in ATP and ion homeostasis.16,34  
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Figure 2.1 Involvement of MPTP in I/R induced cell death. ATP dissipation during ischaemia 
leads to rises in resting cytosolic free [Ca2+] and Pi. Reperfusion leads to excessive 
mitochondrial Ca2+  uptake. Mitochondrial Ca2+ overload together with oxidative stress and the 
prevailing  high Pi and low ATP provoke MPTP opening.  
2.2 Preconditioning 
Ischaemic Preconditioning (IPC) has been exploited as a powerful endogenous 
form of cardioprotection. IPC was first discovered by Murry37 and associates, 
who demonstrated that a brief period of repetitive cardiac I/R exerts a protective 
effect against subsequent lethal periods of ischaemia, resulting in a marked 
reduction in infarct size, the extent of stunning and the incidence of cardiac 
arrhythmias.38,39 This “self-defence” mechanism also induces an improvement 
of the post-ischaemic recovery40 and a protection of the coronary 
endothelium.41 
The development of IPC shows two distinct phases: an early phase (or classic 
IPC) that lasts for 1 to 3 hours following the preconditioning stimulus and  a 
delayed one (or second window of IPC) that lasts for 24 to 96 hours. The initial 
early IPC does not appear to depend on new protein synthesis because of the 
rapid onset and because the inhibition of protein synthesis does not block this 
phase, while the second window of IPC involves up-regulation of genes rather 
than post-traslactional modification of proteins.42-44  
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The exact mechanisms involved in preconditioning are still being debated, but 
several processes have been implicated. In the longer-term effects, probably 
caused by stimulation of the transcription of specific genes, perhaps through a 
mechanism activated by free radicals and stress-activated protein kinases, of 
particular interest may be the up-regulation of heat shock proteins since recent 
data have shown that heat shock specifically up-regulates the expression of 
liver mitochondrial Hsp25 and this is associated with desensitisation of 
mitochondrial permeability transition pore (MPTP) opening to Ca2+ and HgCl2 
in isolated mitochondria.45 It is also known that heart mitochondria from mice 
in which Hsp25 is down-regulated are more sensitive to MPTP opening and 
also exhibit hallmarks of oxidative stress including oxidatively damaged 
adenine-nucleotide traslocase (ANT).46 The mechanisms responsible for the 
short-term effects of preconditioning include the activation of protein kinase C 
(PKC). This may be mediated either by reactive oxygen species (ROS) released 
during the short intervening reperfusion periods, or by factors released during 
the brief ischaemic periods such as adenosine, bradykinin, noradrenaline, and 
opioids. Thus, PKC inhibitors and free radical scavengers antagonise IPC, 
whilst adenosine agonists and PKC activators mimic the effect.47-49 The 
ultimate target of these kinases is unknown, although it may be significant that 
activation of PKCε and its translocation to mitochondria has been reported to be 
important for preconditioning.50,51 There is also evidence for an involvement of 
sulphonylurea-sensitive KATP channels, since KATP channel openers such as 
diazoxide can mimic IPC whilst blockers such as glibencamide inhibit.52,53 
Furthermore, PKC-dependent activation of plasma membrane KATP channels by 
IPC has been demonstrated.54 The mechanism of protection from 
cardiomyocyte apoptosis by IPC appears to be due to protection of 
mitochondria. It has been shown that IPC reverses many aspects of 
mitochondrial dysfunction induced by I/R, including loss in the activity of the 
redox-sensitive Krebs cycle enzyme α-ketoglutarate dehydrogenase, declines in 
NADH-linked ADP-dependent mitochondrial respiration, insertion of the pro-
apoptotic Bcl-2 protein Bax into the mitochondrial membrane, and release of 
cytochrome c into the cytosol.55  
This protection of mitochondria by IPC is mediated by activation of survival 
signaling that converges on prevention of the MPTP opening.56-58  
The survival signalling includes the PKCε–mitochondrial KATP (mito-KATP) 
channel pathway,59 the phosphatidylinositol 3-kinase (PI3K)/ Akt pathway,60 
the Janus kinase (JAK)/signal transducers, and activators of transcription 
(STAT) pathway.61  
2.2.1 MPTP and its role in cell death 
Mitochondria play critical roles in both the life and death of cells. In healthy 
cardiac myocytes, their primary function is the provision of ATP through 
oxidative phosphorylation to meet the high energy demands of the beating 
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heart. Glycolysis alone is unable to meet these demands even in the resting state 
and inhibition of oxidative phosphorylation, as occurs in anoxia or ischaemia, 
leads to impairment or cessation of normal heart function. However, latent 
within mitochondria, there are mechanisms that, once activated, convert the 
mitochondria from organelles that support the life of the cell to those that 
actively induce both apoptotic and necrotic cell death. The switch in roles is 
mediated by the opening of a nonspecific pore in the mitochondrial inner 
membrane, known as the mitochondrial permeability transition pore (MPTP). 
This normally remains closed, but can open under conditions of cellular stress 
with dire consequences. 
The release of proapoptotic molecules, such as cytochrome c or apoptosis-
inducing factor, from mitochondria triggers the activation of caspases that 
finally leads to cellular destruction.62 This process is associated with opening of 
the MPTP, a ‘‘megachannel’’ spanning both the inner and the outer 
mitochondrial membrane. It can exist in various subconductance states. In the 
fully opened state, it allows molecules up to a molecular weight of 1.5 kDa to 
pass.63 Accordingly, opening of the MPTP leads to a breakdown of the 
mitochondrial membrane potential, causing failure of oxidative phosphorylation 
and ATP depletion.64 The pore is formed from a complex of the voltage 
dependent anion channel (VDAC), the adenine-nucleotide traslocase (ANT) 
and cyclophilin-D (CyP-D) at contact sites between the mitochondrial outer and 
inner membrane. Ca2+ is the major physiological activator of the MPTP, other 
triggers are ROS and nitrogen species, mitochondrial depolarization and high 
levels of inorganic phosphate (Pi). In contrast, hyperpolarization of the 
mitochondrial membrane as well as high levels of ATP and adenosine 
diphosphate (ADP) are known to inhibit the pore.63 
The MPTP opens under condition of high matrix Ca2+, ROS, high NADH, 
depletion of  adenine nucleotides and loss of membrane potential (∆ψ),65-67 
conditions that occur during ischaemia-reperfusion.68,69 
Low pH, as occurs during ischaemia, inhibits MPTP, but intracellular pH is 
rapidly restored on reperfusion, thus allowing activation of the pore. 
Furthermore, the reduced ∆ψ during ischaemia would limit uptake of 
mitochondrial Ca2+, but the reintroduction of oxygen on reperfusion would 
reconstitute ∆ψ (stimulating Ca2+ uptake into the mitochondria) and the 
introduction of oxygen will also allow generation of ROS. Thus the conditions 
that exist right at the start of reperfusion are ideal to stimulate opening of the 
MPTP.  
Recent data shown that mito-KATP  channels interact with MPTP. In particular, 
it has been shown that activation of the mito-KATP channel leads to a 
depolarization of mitochondria by increasing K+ influx, thus reducing the Ca2+ 
influx into mitochondria.70 A reduced intramitochondrial Ca2+ concentration is 
known to prevent opening of the MPTP. Accordingly, inhibition of mito-KATP 
channel might hyperpolarize mitochondria by decreasing K+ input, thus 
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increasing the Ca2+ influx and facilitating MPTP opening. On the other hand, 
hyperpolarization of mitochondria is commonly considered to be a MPTP-
inhibiting factor.71 A fall in mitochondrial potassium concentration due to 
inhibition of the mito-KATP channel should alkalize the mitochondria matrix 
because of a reduced activity of the K+/H+exchanger. 
A rise in pH is known to increase the open probability of the MPTP.72. 
Furthermore, an alkaline pH elevates the activity of the Pi/OH- antiporter of the 
inner mitochondrial membrane and, consequently, matrix phosphate 
concentrations. Phosphate is a physiological modulator of the MPTP as high 
phosphate increases the open probability. A different explanation of the 
interaction between the mito-KATP channel and the MPTP has been suggested 
by Costa et al.,73 who reported that inhibition of the MPTP by mito-KATP 
channel opening can be abolished by inhibitors of protein kinase C (PKCε) as 
well as by a scavenger of reactive oxygen species. They proposed that mito-
KATP channel activation increases production of H2O2, which in turn blocks the 
MPTP by activating PKCε. The mito-KATP channel is able to modulate the 
opening probability of the MPTP74 that is related to both apoptotic and necrotic 
cell death (e.g., in ischaemia), so modulation of this mitochondrial 
‘‘megachannel’’ by controlling the state of the mito-KATP channel may offer 
therapeutic benefit for various diseases. 
2.2.2 Signal trusduction in  IPC 
IPC involves variuos signaling as triggers and/or end effectors and an important 
role is undoubtely played by the activation of cardiac KATP. 
The triggers of IPC can be classified as receptor-dependent and receptor-
independent: the former are activators that elicit their action by specific receptor 
interaction, such as adenosine, bradykinin and opioids which bind to G protein-
coupled receptors (GPCRs); the latter are endogenous substances that do not 
need a selective binding with the receptor such as nitric oxide (NO), free 
radicals and Ca2+. 
 
Receptor-dependent Triggers 
GPCRs are coupled with Gi/o, wich consists of heterotrimeric G protein Gαβγ, or 
with a Gq family, which consists of the heterotrimeric G protein, Gαq. Activation 
of Gi/o-coupled receptors induces dissociation of Gα from Gβγ which activates 
phospholipase C (PLC) and a resultant generation of the second messengers D-
myoinositol 1,4,5-triphosphate and diacylglycerol, leading to activation of 
PKC, an essential step for mediating IPC.75 Conversely, signaling pathways 
linked with activation of Gαq also converge at the level of PLC.76 General 
agreement exists that adenosine is a major GPCR in triggering IPC.77 Cardiac 
adenosine levels are increased by brief periods of ischaemia in rats, dogs and 
pigs78-82 and improve the oxygen supply-demand balance through the dilatation 
of resistance vessels and the reduction of the cardiac inotropism. These effects 
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are mediated by A1 and A3 receptors, while the A2 receptor subtypes in the IPC 
seems to be excluded.83,84 
Like other Gq-coupled receptors, the activation by autacoid in preconditioned 
tissue triggers a multiple kinase cascade through phosphorylation reactions, 
leading to the rapid post-translational modifications of proteins that regulate 
cellular resistance to I/R injury.85,86 Among the autacoids, kinins have been 
implicated in myocardial IPC.87 The most abundant of these, bradykinin, play 
an important role, during a short IPC in pigs82 or a single cycle of  ischaemia-
reperfusion  in rabbits, and it has been suggested that adenosine and bradykinin 
can act synergistically.88 
In addition to GPCR coupled agonists, it was found that growth-factor receptor 
(GFR) agonists that are coupled with receptor tyrosine kinase (RTK) are 
equally effective in cardioprotection. The mechanism of GFR-mediated 
preconditioning effects is not well understood but may share common 
intracellular signaling pathways to GPCRs. These pathways ultimately 
converge on activation of end-effector systems because GFR activation is also 
known to be coupled with activation of PLC and resultant activation of PKC.89 
Moreover, recent studies suggest that GPCR activation induces transactivation 
of GFRs via a redox-sensitive mechanism.90,91 Thus, it is conceivable that 
coordinated activation of GPCR and GFRs provokes efficient cardioprotective 
signal transduction in IPC.  
Opioid receptors are expressed in rat cardiac myocytes and their activation is 
involved in the reduction of infarct size.92,93 Several experimental data 
demonstrate  that the δ opioid receptor type is involved in IPC.94,95 In particular, 
the δ1 subtype stimulation can induce a delayed cardioprotection96, while a 
possible role of the κ opioid receptor in IPC is controversial.97 
The JAK-STAT pathway is a stress-responsive mechanism that transduces 
signals from the cell surface to the nucleus, thereby modulating gene 
expression. Recent studies have demonstrated that myocardial I/R induces 
various members of the cytokine superfamily, such as interleukin (IL)-698 and 
tumor necrosis factor (TNF)-α, and induces rapid activation of the JAK-STAT 
pathway.99 Although an immediate effect of JAK/STAT signaling during 
ischaemia and reperfusion may be detrimental to cardiomyocyte survival and 
cardiac function,100 activation of this signaling pathway ultimately promotes 
cytoprotection.101 Emerging evidence suggests that JAK/STAT signaling plays 
an important role in the development of the cardioprotective phenotype 
associated with IPC. 
A potential role of other triggers, such as prostaglandins, noradrenaline, 
angiotensin and endothelin is still debated.102-106 
 
Receptor-independent Triggers 
Nitric oxide (NO), whose cardiac levels are increased during ischaemia, has 
been indicated as an important endogenous factor involved in cardioprotection. 
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Data from several laboratories have implicated activation of cyclic GMP 
dependent protein kinase (PKG), perhaps by nitric oxide, in the signalling 
pathway for IPC. Thus it has been reported that exogenous NO-donors and 
PKG activators can induce preconditioning whilst NO scavengers and PKG 
inhibitors prevent preconditioning.107-109  Pharmacological studies from Garlid's 
laboratory have led them to conclude that PGK and PKCε work in concert to 
induce IPC through an effect on the mito-KATP. They propose that cGMP 
activates PKG localized at the cytosolic surface of the mitochondrial outer 
membrane and that this phosphorylates some target proteins which in turn can 
somehow activate PKCε residing in the intermembrane space of mitochondria. 
This PKCε then would phosphorylate the mito-KATP channel to mediate 
preconditioning.108  
A growing body of evidence suggests that ROS play a crucial role in signal 
transduction mediated by IPC. Vanden Hoek and associates48 first demonstrated 
the loss of preconditioning protection with antioxidants in cardiomyocytes. 
 
Mediators and end-effectors in IPC 
PKC has been indicated as one of the main intracellular mediators of IPC since 
inhibition of PKC has been shown to block the protection afforded by IPC and 
pharmacological activators of PKC are cardioprotective.110 There remains some 
controversy over which of the many PKC isoforms may be involved in IPC, 
whether they translocate to the particulate fraction and how they exert their 
effects.110,111  Nevertheless, there is a large body of evidence to implicate PKCε 
a novel PKC isoform that has consistently been implicated in the 
cardioprotective signal transduction,112,113 as an important player in IPC.110 
Thus hearts from PKCε knockout mice do not exhibit IPC110,114 whereas 
transgenic mice with cardiac specific over-expression of PKCε or expression of 
an activator of PKCε are protected from reperfusion injury.110,115-117  
Although a role for PKCε in IPC seems established, the mechanism(s) by which 
it exerts its effects are less clear, some studies have reported PKCε translocation 
to the particulate fraction, including mitochondria110,118-120 and have suggested a 
direct inhibition of the MPTP by PKCε involving phosphorylation of 
components of the MPTP such as VDAC.110,119-121 
It is also uncertain how ischaemic preconditioning activates PKCε, although 
several pathways may be involved. Factors released during the brief ischaemic 
periods such as adenosine, bradykinin, noradrenaline and opioids may bind to 
their G protein-coupled receptors to stimulate phospholipase C, producing 
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diacylglycerol that activates PKC. Indeed, all of these factors can 
pharmacologically precondition the heart.110,112  
Accumulating evidence supports a role for the modest increase in ROS that 
occurs during IPC protocol in the activation of PKC.122,123  Thus ROS are 
known to activate PKC in the isolated heart123-125 and IPC can be prevented if 
free radical scavengers are present during the preconditioning phase.110,123,126-128 
Oxidation of critical cysteine residues on PKC isoforms is known to cause their 
activation110,129,130 and thus provides a mechanism by which ROS could activate 
PKC. 
The unique feature of IPC is the memory of cardioprotection, which lasts for up 
to 2 h after the discontinuation of the preconditioning stimulus.131 The 
underlying mechanisms for memory of cardioprotection generated by IPC have 
been a subject of extensive research for many years. It has been suggested that 
mito-KATP channels and PKC create a self-perpetuating cycle during the memory 
of IPC.132 Recent studies133,134 raised the hypothesis that ROS generated 
through the activation of mito-KATP channels play a pivotal role in the memory 
of cardioprotection. In line with this hypothesis, Juhaszova and associates134 
suggested that the characteristic memory of IPC is mediated by moderate, 
reversible, and sustained mitochondrial swelling, which causes increased 
generation of ROS and consequent redox activation of PKCε, A growing body 
of evidence indicates that PKCε and PI3K play a crucial role in cardioprotective 
signal transduction mediated by IPC.135 Important cross-talk between PKCε and 
PI3K exists in mediating the memory of cardioprotective signal transduction in 
IPC. It has been demonstrated that PI3K exists upstream of PKC in 
cardioprotection mediated by IPC in the isolated and perfused rat heart 
model.136 However, more recent study137 suggests that PKCε and PI3K exist in 
parallel positions, and the activities are regulated at least in part by each other’s 
kinase. 
Although the end- effector phenomena of IPC have not yet been completely 
identified, several observation report that in IPC  there is a reduced 
accumulation of catabolites, such as lactate.138 Furthermore, IPC reduces 
intracellular acidification, an indication of decreased anaerobic glycolysis. 
Other putative end-effector include: Na+/H+ axchanger, cytoskeleton changes 
down regulation of TNFα and the activation of cardiac, and in particular, 
mitochondrial KATP channels.139,140  
2.2.3 Cardiac KATP channels 
KATP channels exist in high density in the sarcolemmal membrane (sarc-KATP) 
as well as the mitochondrial membrane (mito-KATP) of cardiomyocytes. Both 
sarc- and mito-KATP channels in the cardiovascular system might have a 
physiological role in modulating cardiac function, particularly under conditions 
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of metabolic stress, such as hypoxia, ischaemia, and metabolic inhibition when 
intracellular ATP stores are reduced. Under normoxic conditions, the KATP 
channel exists mainly in a closed, inactive form. However during myocardial 
ischaemia, as the intracellular ATP concentration falls and ischemic metabolites 
(ADP, lactate, H+) accumulate, the probability of the channel being open 
increases. This results in an enhanced outward repolarizing flow of K+ and cell 
membrane hyperpolarization. Consequently, the myocardial action potential 
duration (APD) is shortened, the voltage-dependent calcium current and 
myocardial contractility are decreased thereby leading to ATP preservation 
during ischaemia. Thus, it is thought that KATP channels exert a protective 
property in myocardial ischemic diseases.141  
 
Anti-ischaemic properties of  cardiac KATP 
It is well known that the plateau phase of the cardiac action potential (AP) 
shortens markedly and contractions decrease during metabolic depression 
induced by ischaemia, hypoxia, anoxia. However, the mechanisms responsible 
for these functional alterations and their significance to myocardial survival 
during ischaemia remain to be fully understood. The more rapid repolarization 
of the AP could be due to:  
1) a decrease in inward current; 
2) an increase in outward current, or 
3) a combination of these changes. 
Voltage-clamp studies imply that the primary alteration in membrane currents 
during metabolic poisoning, anoxia, and hypoxia is the development of a very 
large time-independent outward K+ conductance,142,143 resulting from the 
activation of KATP.144-147  
Noma148 postulated that KATP activation and a fall in AP duration might lead to 
a preservation of cellular ATP and prevention of irreversible ischemic injury. 
The mechanism by which a KATP-induced decline in AP duration protects the 
myocardium during ischaemia remains to be defined, but two possible 
mechanisms have been suggested. The first is a marked reduction of the time 
for Ca2+ influx via voltage sensitive Ca2+ channels, and the second is an 
increased window of time during which the Na+-Ca2+ exchanger may operate in 
forward mode activity to extrude Ca2+. Decreased Ca2+ influx could directly 
improve the ability of cells to maintain appropriate [Ca2+]i levels by reducing 
the load on the Ca2+ pump and the Na+-Ca2+ exchanger at a time when both of 
these Ca2+  extrusion mechanisms are very likely depressed: the former because 
of reduced energy supply and the latter because of the marked depolarization 
that occurs during ischaemia as a result of the shift in the K+ equilibrium 
potential (EK). 
The presence of a short AP also means that the cell will spend a greater period 
of time at membrane potentials negative to the reversal potential of the Na+-
Ca2+ exchanger and favourable for Ca2+ extrusion via forward mode activity. A 
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short AP and reduced Ca2+ influx may also indirectly reduce the consumption 
of high energy phosphate stores. This energy would be used in contractile 
activity and, to a lesser extent, for the maintenance of [Ca2+]i. Noma148 
originally postulated that since contraction would be indirectly depressed by a 
decline in AP duration, KATP activation would indirectly inhibit a major site of 
cellular energy consumption and reduce the rate of decline in [ATP]i  during the 
no-flow period. It is clear that contractile failure during anoxia146  and 
metabolic poisoning147  is principally the result of activation of KATP, Ca2+ 
current, Ca2+ release from the sarcoplasmic reticulum.  
The ability of KATP to alter AP duration may be the most important mechanism 
by which these channels contribute to myocardial preservation during 
ischaemia.149 
2.2.4 Sarcolemmal KATP channels 
It was initially believed that opening of sarcolemmal KATP channels (sarc-KATP) 
was protective because it shortened action potential duration (APD), thereby 
reducing Ca2 + entry to the cytosol.149 
Sarcolemmal KATP in cardiac muscle are formed from Kir6.2 and SUR2A 
subunits and have a unitary conductance of 70-90pS. They open in the absence 
of ATP and are closed by micromolar concentrations of ATP ( Ki ~23-30 µM). 
However, while free ATP4+ as well as MgATP are able to close the channel, 
maintenance of channel activity relies upon MgATP through channel 
phosphorylation, which may explain the transient nature of channel opening 
observed during prolonged metabolic inhibition. The ATP-sensitivity of the 
channel is decreased by nucleotide diphosphates (ADP, GDP, UDP) and 
acidosis, conditions likely to exist in the ischaemic myocardial cell. Sarc-KATP 
are also regulated by phosphorylation with PKC, which increases channel 
activity in the presence of millimolar levels of ATP. Sarc-KATP coupling to 
mitochondrial function through phosphotransfer system, so that changes in 
mitochondrial production of ATP are rapidly translated to changes in 
subsarcolemmal nucleotide levels, it could be of particular relevance when the 
mitochondrial membrane potential is depolarized, as occurs in metabolic 
inhibition or ischeamia. Under this conditions, mitochondrial F0/F1 ATPase and 
phosphotransfer systems can lead to a rapid depletion of ATP at the cell surface 
membrane and so sarc-KATP activation.150 
The activation of sarc-KATP channel, due to hypoxia, ischaemia or 
pharmacological agents, accelerates the repolarisation of the myocardiocyte 
membrane, shortens the APD and prevents the reversal of the Na+/K+ 
exchanger, with a consequent inhibition of Ca2+ entry into the cell and Ca2+ 
overload, increased cell viability, readjusting the balance between energy 
supply and energy demand. These events can account for an increased 
resistance against ischaemic injury due to the activation of sarc-KATP channels; 
however several features then arose that raised doubts about this mechanism. In 
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particular, it was shown that cardioprotection was preserved in conditions 
where there was no APD shortening.151,152 A number of recents reports attribute 
to the mito-KATP channel activation a preminent role in anti-ischaemic cardiac 
protection.153-155  
This hypothesis is supported by the observation that some KATP openers, such as 
bimakalim and cromakalim, are able to produce cardioprotective effects also at 
doses devoid of any influence on APD, i.e. without affecting sarcolemmal 
membrane potential. This evidence suggest indirectly the exsistance of an 
intracellular site, independent of sarcolemmal channels, responsible for the 
cardioprotective action.156-159 
The observation that, in bovine heart mitochondria,  the KATP opener diazoxide 
induced the opening of the mito-KATP channel at concentration lower than that 
necessary for the opening of the sarc-KATP channel, represented the first direct 
suggestion about a role of mito-KATP channels. 
Consistently, in isolated rat hearts, cromakalim and diazoxide, at low 
concentrations not affecting the sarc-KATP, produced a cardioprotective effect 
that is abolished by the selective mito-KATP blocker 5-hydroxydecanoate (5-
HD), demonstrating the key role of this channel type.160  
2.2.5 Mitochondrial KATP channels 
Mitochondrial KATP, located in the inner mitochondrial membrane,161 is a 
distinct pharmacological receptor, in particular there are some biochemical and 
biophysical differences between mito- and sarc-KATP. In the heart, the 
conductance of these channel subtypes  is very different: 10 and 70-90pS, 
respectively. Moreover, mito-KATP is unique in its absolute requirement for 
Mg2+ for ATP inhibition and MgADP and long-chain acyl CoA esters inhibit  
this channel type,  while they could be open by sarc-KATP (Table 2.1).  
 
Table 2.1 Nucleotide modulation of mito-KATP 
Ligand Action K 1/2 value
ATP (no Mg2+) 
ATP (+ Mg2+) 
ADP (+ Mg2+) 
Palmitoyl CoA (+ Mg2+) 
Oleoyl CoA (+ Mg2+) 
GTP (+ATP+ Mg2+) 
GTP ( +PCoA+ Mg2+) 
GDP (+ ATP+ Mg2+) 
UDP (+ATP + Mg2+) 
no effect 
inhibit 
inhibit 
inhibit 
inhibit 
open 
open 
open 
open 
- 
39 µM 
280 µM 
260 µM 
40 µM 
7 µM 
232 µM 
140 µM 
13 µM 
 
When cardiac mito-KATP and sarc-KATP were studied under identical conditions, 
diazoxide, was found to be 1000 times more potent in opening mito-KATP than 
sarc-KATP and 5-hydroxydecanoate (5-HD) was found to inhibit mito-KATP but 
not sarc-KATP Moreover, triethylammonium ion (TEA+) inhibits most Kir 
subunits of the plasma membrane, but has no effect on mito-KATP. 
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The subunit structure of mito-KATP appears qualitatively similar to the sarc-
KATP:  mito-KATP also consists of two subunits: a ~ 55 kDa mitoKir and a 63 
kDa mitoSUR. On the basis of its molecular size and its biochemical similarity 
to plasma membrane SUR, predicts that mitoSUR will turn out to be a half-
molecule ABC protein. Also this channel receptor is subject to a rich variety of 
regulation by biochemical and pharmacological agents, some of which interact 
with mitoSUR, whereas others interact with mitoKir.162  
 
 
 
Figure 2.2 Model of the interactions of regulatory ligands with mito-KATP structure. Mito-KATP 
is thought to be composed of four subunits of a 55-kDa inwardly rectifying K+ channel 
(mitoKIR) and at least four subunits of a 63-kDa sulfonylurea-binding regulatory subunit 
(mitoSUR). MitoSUR is thought to contain one or two nucleotide binding folds (NBF). ATP 
binds to both subunits. ATP inhibition of holo-mito-KATP exhibits an absolute requirement for 
Mg2+, whereas ATP inhibition of mitoKIR does not, suggesting that Mg2+ binds to mitoSUR. 
GTP, which reverses ATP inhibition, interacts with mitoSUR. The classical KATP channel 
openers (diazoxide, cromakalim, and P1075) and blockers (glibenclamide and 5-HD) interact 
with mitoSUR and have no effect upon mitoKIR. The openers UDP and DEB, and the blocker 
TPP+, acts upon mitoKIR.  
 
 
The inner membrane potential controls the flow of K+ ions into the 
mitochondrial matrix, and their leak is counterbalanced by a K+/H+ antiporter. 
Mito-KATP plays a role in normal cell signaling processes leading to cell 
growth. Opening mito-KATP appears to have two distinct consequences, 
depending on the underlying bioenergetic state. When the membrane potential 
(∆ψ) is high, as in the normoxic heart, membrane permeability for ADP and 
ATP is quite modest and energy transfers between mitochondria and cytosol is 
efficiently controlled by creatine and creatine-phosphate. It has also been 
reported that K+ influx via mito-KATP causes matrix alkalinization and a 
consequent rise in mitochondrial production of ROS.163 The increased ROS 
levels, in turn, activate a variety of kinases involved in the signaling pathways 
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of cardioprotection against ischaemia-reperfusion injury and in pathways 
leading to gene transcription and cell growth. When ∆ψ is reduced, as occurs 
during ischaemia or inotropic stress, mito-KATP opening provides matrix volume 
homeostasis. In hypoxic conditions, the outer membrane conductance increases, 
following matrix contraction and subsequently the expansion of the 
intermembrane space (IMS). This change causes the dissociation of octomeric 
creatine kinase (CrK)  from the channel and an increase in the outer membrane 
permeability. In this conditions,  the additional K+ influx through mito-KATP,  
accompanied by diffusion of water and uptake of anions (mainly phosphates 
and Cl-), results in a matrix swelling, compensating for the lower driving force 
and maintains structure and function of the IMS volumes.163,164 
For mitochondrial K+ channels to play a role in preconditioning there would 
have to be a mechanism by which their opening might be linked to improved 
recovery. Several possible mechanisms have been proposed. 
It is known that an increase in matrix volume can stimulate respiration and 
oxidative phosphorylation165,166 and so might improve ATP production during 
reperfusion leading to enhanced haemodynamic recovery.167,168 Although we 
were able to measure an increase in mitochondrial volume and rates of ADP-
stimulated respiration in mitochondria isolated from hearts immediately 
following ischaemic preconditioning or diazoxide treatment, the effects were 
largely lost during reperfusion when they are predicted to be most important.169  
Furthermore, 5HD-treatment was shown to exhibit a similar increase in matrix 
volume but was not cardioprotective.169 Garlid and colleagues164 have proposed 
an alternative, but not unrelated mechanism in which it is the maintenance of 
the IMS and the close association between the outer an inner membrane that is 
the critical factor resulting from KATP channel opening .They argue that during 
ischaemia the loss of membrane potential would decrease electrogenic K+ entry 
into mitochondria and that this would cause contraction of the matrix. It is 
proposed that this would disrupt the interaction between VDAC in the outer 
membrane, CrK in the intermembrane space and the ANT in the inner 
membrane leading to faster permeation of ATP through VDAC into the 
intermembrane space. Further translocation of this ATP into the matrix through 
the ANT would lead to its hydrolysis, that would be detrimental to the heart. It 
is suggested that opening of the mitochondrial KATP channel would prevent this 
matrix condensation and so decrease ATP breakdown during ischaemia leading 
to less damage. There is some evidence that ATP decline during ischaemia is 
slowed by ischaemic preconditioning or diazoxide treatment, although the 
mechanism originally proposed was through inhibition of the F1/Fo ATPase by 
enhanced binding of the ATPase inhibitor protein.170,171 Furthermore, other data 
report the opposite effect of preconditioning, with the decline in ATP and the 
development of contracture being faster than in control hearts.170-173  
Garlid and colleagues further propose that during reperfusion, keeping the 
mitochondrial KATP channel open maintains the VDAC, CrK, ANT complex 
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which is vital to export ATP rapidly from the mitochondria to the cytosol where 
it is used to drive contraction. Although this may be true, other data showed that 
the slight increases in matrix volume of diazoxide-treated and ischaemic 
preconditioned hearts compared to control hearts was not significant at 
reperfusion. The more probable determinant of the efficiency of myocardial 
ATP production during reperfusion is the extent to which the mitochondria are 
damaged.169 It has been suggested by several workers that mito-KATP opening 
protects the heart by uncoupling of oxidative phosphorylation due to increased 
K+  cycling. Uncoupling is thought to be protective by virtue of the fact that 
decreased ∆ψ would reduce mitochondrial Ca2+ uptake and Ca2+ overload 
during ischaemia.174-179 When the cellular energy metabolism is compromised, 
as in ischaemia, the intracellular Ca2+ levels increase (due to the entry of 
extracellular Ca2+) and this rise of cytosolic concentration of free Ca2+ is 
partially compensated by Ca2+ uptake into mitochondria, mainly ensured by a 
highly selective ion channel known as Ca2+ uniporter, and into other storage 
compartments. These high mitochondrial Ca2+ levels, togheter with other 
factors which are present during reperfusion (but not during ischaemia), are 
causally related to MPTP formation, which, during reperfusion produces Ca2+ 
release from the matrix. This opening of MPTP represents a critical cause of 
reperfusion-induced irreversible inury of myocardiocytes , since it leads to 
release of pro-apoptotic proteins.  
It has been proposed that opening of K+ channels would depolarise the 
mitochondria sufficiently during reperfusion to reduce ROS production and 
calcium accumulation and hence prevent MPTP opening.177,180-185  
However, the amount of depolarisation predicted from K+ channel opening is 
unlikely to cause much if any depolarisation186,187 and this is confirmed by 
direct measurements of mitochondrial membrane potential that failed to detect 
any depolarisation.188,189 Furthermore, should significant depolarisation occur at 
reperfusion, ATP synthesis would be compromised leading to poorer rather 
than better recovery of the heart. Yet NMR spectroscopy measurements have 
shown that the bioenergetic state of the preconditioned heart improves during 
reperfusion, consistent with the better haemodynamic function.170,190,191 
Nevertheless, it is not possible to rule out the possibility that opening of mito-
KATP channels might cause a minor depolarisation during reperfusion, or 
slightly reduce the repolarisation, sufficient to reduce ROS formation without 
having a significant effect on ATP production. Although significant uncoupling 
during the reperfusion phase seems unlikely to be protective, it is known that 
adding low doses of uncoupler prior to ischaemia can precondition hearts.192,193 
Indeed, any interference with oxidative phosphorylation during the 
preischaemic phase seems able to exert a similar protective effect whether it is 
brought about by a brief ischaemic episode as in IPC, by addition of a 
respiratory chain inhibitor194-197 or a succinate dehydrogenase inhibitor.198 Since 
many of the mitochondrial K+ channel openers have also been shown to have 
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direct uncoupling effects199-202 or to inhibit components of the respiratory chain 
including succinate dehydrogenase,203-205 this provides a common mode of 
action for these agents. How this might be translated into a protective effect at 
reperfusion is not clear, although a signalling pathway involving AMP-
activated protein kinase provides one possibility. Another potential mechanism 
would be through increased levels of ROS production causing PKC activation 
and respiratory chain inhibitors such as antimycin are known to increase ROS 
production which is critical in mediating its protective effects.194,206 It has also 
been reported that low doses of uncoupler can increase ROS production in 
isolated myocytes,193 although how this might occur is unclear since in isolated 
mitochondria it is well established that even very modest uncoupling greatly 
decreases ROS production.207 In the case of antimycin, PKCε translocation has 
been demonstrated and its protective effects shown to be abolished in PKCε 
knockout mice supporting a role for ROS and PKCεactivation in its protective 
mechanism.206 Nevertheless, the hypotheses about the relationship between 
mito-KATP activation and regulation of ROS production is quite controversial 
and it has been proposed, in an opposite theory, that mito-KATP channels 
opening might protect the heart by a further pathway: the reduction of release of 
reactive oxygen species linked to uncoupling of oxidative phosphorilation. It 
has been proposed that mito-KATP channels can acts as sensor of the 
mitochondrial redox balance, regulating this state under normoxic conditions 
and efficiently preventing the release of mitochondrial ROS and oxidative stress 
under pathological conditions, such as ischaemia and post-ischaemic 
reperfusion.  
Another possible mechanism would be via an increase in matrix volume 
causing a stimulation of electron flow from complex 1 into complex 3.165,208  
Indeed, there are reports that low doses of valinomycin can increase ROS 
formation in isolated mitochondria209 and myocytes,164,183,210 whilst 
pretreatment of the perfused rabbit heart with valinomycin substantially 
decreased the infarct size on reperfusion.211 However, in unpublished 
experiments was used Amplex Red to measured ROS production by isolated 
heart mitochondria incubated with a variety of respiratory substrates in State 4 
and the authors were unable to detect an increase in ROS production with any 
mitochondrial potassium channel opener tested, or when matrix volume was 
increased by decreasing the osmolarity of the incubation medium. Indeed, in the 
latter case they detected a decrease ROS production. This is consistent with the 
major locus of ROS production being at a highly reduced site on complex 1 that 
is oxidised by an increase in matrix volume as electron flow out of complex 1 
and into complex 3 is stimulated.165,208 Another consequence of opening a 
mitochondrial K+ channel would be an increase in the mitochondrial pH 
gradient coincident with a decrease in membrane potential.212 Whereas the latter 
would be predicted to decrease ROS formation as outlined above, there is 
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evidence to suggest than an increase pH gradient or matrix pH can increase 
ROS formation from complex 1.213 However, in view of the ability of many of 
the mitochondrial KATP channel openers to inhibit components of the respiratory 
chain,170,186,199,203-205 its is perhaps more likely that their ability to increase ROS 
is through a direct interaction with a redox centre in one of the respiratory 
complexes. 
2.2.6 Impaired glycolitic flux 
Reduced blood flow  and oxygen delivery to the myocardium result in 
metabolic and functional changes, characterized by impaired production of 
high-energy phosphates, intracellular acidosis, reduced developed pressure, 
onset of contracture, and an increased dependence on anaerobic glycolysis for 
energy.18,214-216 During ischaemia, production of ATP ceases because of 
feedback inhibition of glycolysis by protons, lactate, and fatty acid 
metabolites.18, 217,218 Numerous studies have demonstrated that maintenance of 
glycolytic metabolism can preserve viability in some circumstances and delay 
contracture, a hallmark of glycolytic failure and irreversible cell damage.15,18,216  
As a consequence of this dependence on glycolysis, conditions that impair 
glycolytic flux can have deleterious effects under low-flow conditions. 
Some experiments have demonstrated that aldose reductase inhibition 
maintained higher levels of high energy phosphates and improved functional 
recovery on reperfusion in diabetic and control hearts subjected to low-flow 
ischaemia. These beneficial effects were coupled with evidence of increased 
glycolysis and lactate efflux, providing further evidence that increased 
glycolysis and lactate efflux can contribute to metabolic adaptation during low-
flow ischaemia.16 Mechanisms by which glycolysis affords beneficial effects 
during low-flow ischaemia are numerous. First, metabolism of glucose via 
glycolysis yields ATP (the process does not require oxygen), thus increasing the 
total amount of ATP produced under conditions of low-flow and oxygen 
supply. Second, although total production of ATP is clearly important in 
maintaining cellular function, studies suggest that the source of ATP (glycolytic 
vs. mitochondrial) is important for specific cellular functions and that inhibition 
of ATP production via glycolysis impairs the activity of Na+/K+-ATPase 
activity and the ATP-sensitive potassium channels.219-221  The dependence of 
Na+-K+-ATPase on glycolysis has been previously established under both 
normoxic and hypoxic conditions.Weiss and Hiltbrand221 have shown that 
inhibition of glycolysis under normoxic conditions results in significant 
impairment of the Na+/K+-ATPase. Under low-flow conditions,  some 
studies222,223 indicated that maintenance of Na+/K+-ATPase activity limited 
reperfusion injury. Similarly, it was demonstrated recently that ischaemia219 in 
the absence of glucose resulted in more marked abnormalities in high-energy 
phosphates and intracellular sodium in the perfused heart. 
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2.3 Aldose Reductase 
Aldose reductase is a monomeric, nicotinamide adenine dinucleotide phosphate 
(NADPH)–dependent enzyme and it is a member of the aldo–keto reductase 
family. This enzyme catalyzes the reduction of aldo sugars and other saturated 
and unsaturated aldehydes.224-226 High levels of glucose in diabetic tissues lead 
to the accumulation of sorbitol via the aldose reductase pathway or polyol 
pathway. In this pathway, glucose is reduced to sorbitol by aldose reductase, 
and sorbitol is then oxidized by sorbitol dehydrogenase (SDH) to fructose. The 
flux through AR requires NADPH, whereas SDH requires nicotinamide adenine 
dinucleotide (NAD+). Aldose reductase constitutes the first and the rate-limiting 
step of the polyol pathway. This pathway has been suggested to play an 
important role in the development of vascular and neurological complications in 
diabetes.227-231 Several studies have shown improvements in neuronal, retinal, 
renal, and cardiac function of diabetic subjects after treatment with aldose 
reductase inhibitors,227-231 suggesting that increased activity of the polyol 
pathway is related to many diabetic complications. Mechanisms implicated in 
these polyol pathway–linked functional abnormalities include myoinositol 
depletion and associated impaired phosphatidylinositol metabolism, osmotic 
imbalance due to accumulation of sorbitol, decreased availability of NADPH, 
and a cascade of metabolic alterations brought about by an increased ratio of 
free NADPH/NAD+ resulting from increased oxidation of sorbitol to fructose by 
SDH in the polyol pathway.232 Recent studies have indicated that generation of 
advanced glycation end products (AGEs) is facilitated by the aldose reductase 
pathway, thus influencing the progression of diabetic complications.233   
Recently, was uncovered an important role for this pathway in mediating 
myocardial ischemic injury in diabetics. Because aldose reductase activity 
increases under ischemic conditions, considerable attention has been focused on 
studying the benefits of aldose reductase inhibition.14-17,234 
Starting from the observation that the activity of aldose reductase increased 
during low-flow ischaemia, were perfomed kinetic studies in order to examine 
for any potential differences in catalytic activity or turnover rate between the 
isolated enzyme from control and ischaemic rat hearts. Data obtained235 suggest 
that increased aldose reductase activity in ischaemic heart is not due to 
increased transcription or translation, but to activation of the enzyme by 
endogenous factors, such as nitric oxide (NO), which levels are increased 
during myocardial ischaemia, or reactive oxygen species (ROS). 
Pharmacological inhibition of aldose reductase significantly reduced ischaemic 
injury and improved functional recovery: in zopolrestat treated hearts creatine 
kinase (CK) release, a marker of ischaemic injury, was significantly reduced; 
the rise of the end  diastolic pressure (EDP) during ischaemia is lower and the 
left ventricular developed pressure (LVDP) recovery, measured upon 
reperfusion, is significantly greater. In addition, aldose reductase inhibition 
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improves myocardial glucose metabolism. Rates of glycolysis and glucose 
oxidation were significantly higher in zopolrestat-perfused hearts whereas rates 
of palmitate oxidation remained unaffected. Under ischaemic conditions, rates 
of glycolysis remained significantly higher in aldose reductase-inhibited hearts. 
Consistent with increased glycolysis, ATP was significantly higher in aldose 
reductase-inhibited hearts during ischaemia. Lactate/Pyruvate (L/P) ratio, a 
measure of cytosolic redox state NADH/NAD+, was increased during ischaemia 
and inhibition of aldose reductase with zopolrestat attenuated the increases in 
L/P. One mechanism by which cytosolic redox state is likely to be attenuated by 
aldose reductase inhibition is by attenuating the flux of substrate through 
sorbitol dehydrogenase (which uses NAD+). Increases in flux via sorbitol 
dehydrogenase may decrease flux via glyceraldehyde-3-phosphate 
dehydrogenase by competing for NAD+. L/P ratio data suggest that aldose 
reductase inhibition likely conserves NAD+ and aids glycolysis by reducing 
NAD+ use by sorbitol dehydrogenase. 
 
Aldose Reductase Inhibition and Glycolysis 
One possible mechanism for the observed effect of aldose reductase inhibition 
on glycolysis can be explained on the basis of changes in the cytosolic redox 
state. It has been suggested that the flux via glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) is a rate-limiting step for glycolysis under ischemic 
conditions because of increases in NADH/NAD+ ratio.15,18,236 Conservation of 
NAD+ in any of the cytosolic pathways is likely to attenuate the increases in the 
cytosolic redox state. In this context, was recently demonstrated that inhibition 
of aldose reductase conserves NAD+ (because of lower flux via sorbitol 
dehydrogenase) and lowers the NADH/NAD+.15 The NAD+ conserved by aldose 
reductase inhibition is readily available for conversion of glyceraldehyde-3-
phosphate to 1,3-bisphosphoglycerate by GAPDH15,237 in the glycolytic 
pathway. Thus aldose reductase inhibition can increase glycolysis by providing 
NAD+ for GAPDH. 
 
Acidification during ischaemia.  
Acidification during ischaemia results from the balance of proton production 
(primarily from anaerobic glycolysis and ATP hydrolysis)238 and proton 
utilization either by buffering mechanisms239 or proton efflux pathways,240-
242Experimental data16 suggests that acidosis during ischaemia in diabetic hearts 
was reduced by aldose reductase inhibition. The higher pH in aldose reductase-
inhibited hearts, coupled with preservation of ATP and increased lactate release 
during ischaemia, is consistent with lower ATP hydrolysis and/or greater proton 
efflux via the lactate-H+ cotransporter. Because reduced lactate-H+ cotransporter 
activity has previously been reported in diabetics,241 these observations, 
coupled with greater lactate release, suggest that aldose reductase inhibition 
likely improves proton efflux via this mechanism. 
Myocardial ischaemic preconditioning 
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Recovery on reperfusion.  
The rate of intracellular pH recovery on reperfusion is primarily mediated by 
lactate and CO2 efflux, with smaller contributions by Na+/H+ exchanger and 
HCO3- influx via the Cl-/HCO3- exchanger. Consistent with previous 
reports,15,241 was observed16 that pH recovery in diabetic hearts was slower than 
in control hearts, presumably because of impaired flux of protons via the 
lactate-proton cotransporter and Na+/H+ exchanger in diabetics.241 As during 
ischaemia, normalization of pH recovery by zopolrestat further supports the 
postulate that aldose reductase inhibition can positively influence proton efflux 
mechanisms. 
 
Aldose Reductase and Oxidative Stress 
The cofactor NADPH is required for aldose reductase activity. It has been 
suggested that an increase in substrate flux via aldose reductase can increase 
oxidative stress237,243 secondary to diminished NADPH dependent reduction of 
glutathione.243 In addition to the reduction of glutathione, flux of substrate via 
aldose reductase can diminish nitric oxide synthase activity because of 
competition between these enzymes for NADPH.244 Therefore, inhibition of 
aldose reductase can protect any tissue from oxidative stress. It is possible that 
the cardioprotection observed may, in part, be because of lowering of oxidative 
stress.16. 
It is clearly demonstrated that both mito-KATP openers (mito-KCOs) and 
aldose reductase inhibitors (ARIs) could have a fundamental role in the 
treatment of the myocardial ischaemia, in particular, the former may afford a 
“chemical preconditioning” that confers on the heart the ability to better 
withstand the oxygen deprivation and, consequently, to suffer less tissue 
damage during acute myocardial infarction; the latter as a potential therapeutic 
adjuncts in treating acute myocardial ischaemia and evolving infarction. 
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3 KCOs and ARIs 
3.1. Potassium channel openers 
The potassium channel openers are a diverse group of agents originally 
characterized by their ability to open smooth muscle potassium channels, 
however their opening action is additionally exerted in a variety of tissue types, 
including the pancreatic β-cells, neurones, skeletal and cardiac muscle. Most of 
the effects of these molecules can be blocked by potassium channels inhibitors 
like the sulfonylurea glybencamide. 
3.1.1 Chemical Classification 
KATP channel openers (KCOs) exhibit chemical diversity and comprise several 
structural classes: 
• Benzopyrans 
• Cyanoguanidines 
• Thioformamides 
• Benzothiadiazines 
• Pyridyl nitrates. 
A second generation of KCOs includes: 
• Cyclobutendiones 
• Dihydropyridyne related structures  
• Tertiary carbinols 
3.1.2 Benzopyrans 
Benzopyran KCOs have a broad spectrum of chemical modification and 
represent the most investigated chemical class of KCOs. Cromakalim1 1, 
developed in the 1980s, is the prototype of this class. 
Cromakalim contains two chiral carbons; the 3-OH group and the 4-
pyrrolidinone ring are trans-positioned. The KCO activity resides in the 3S, 4R-
enantiomer levcromakalim 2. 
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Figure 3.1 Structure activity relationship of benzopyran KCOs 
 
 
4-Position 
Most extensive variations were applied to the 4-position of the benzopyran ring. 
The carbonyl group of the pyrrolidinyl moiety of the lead cromakalim was 
considered to be essential for biological activity as lactams1 were more potent 
vasodilators than the original cyclic amines.2 
Main chemical variations in 4-position comprise the insertion of: 
• unbridged cyclic substituents 
• bridged cyclic substituents, or 
• acyclic substituents 
 
Ring size of  the unbridged cyclic substituents have a strong impact on potency 
with 6-membered rings exhibiting a superior potency as compared to 5-
membered rings, that in turn were significantly more potent than 4-, 7- and 8-
membered rings.1,3 Additional heteroatoms,1,4 4-ring substituents or bicyclic 
replacements almost exclusively reduce potency, with the exception of 
celikalim 3, which is as potent as cromakalim in lowering blood pressure. X-ray 
analysis of the spirocyclic compound U96501 4 afford important informations 
regarding the bioactive conformation of this KCOs class: in the eutomers the 
carbonyl moiety points backwards with respect to the plane of the benzopyran 
nucleus.5,6 The enforced orthogonality within the spirocyclic compounds 
supports the assumption that the bioactive conformation of freely rotable 4-
substituents exhibits corresponding orthogonality. 
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Linking the cyclic 4-substituent to the benzopyran ring via O- or NH-bridges 
often confers higher potency of these derivatives. Structure-activity 
relationships (SAR) for benzopyran with bridged cyclic substituents in 4-
position differ from their non-bridged analogues. Positioning of the carbonyl 
moiety is of secondary importance. Function of the carbonyl oxygen is often 
mimicked by a ring nitrogen. Additional heteroatoms in the ring and ring 
substituent do not reduce potency. The additional methyl probably stabilizes the 
bioactive conformation of the bridged molecules.7,8 
Substitution of the original lactam ring with acyclic substituents is optimal. In 
particular, the thioamide class includes several extremely active congeners such 
as KC-399 5,9-12 that exhibits an N-β-cyanoethyl group within the thioamide 
function and a di-fluoromethylic substitution in 2-position. 
 
O CH2F
CH2F
N
+
O
-
O
NHS
N
5
 
3-Position 
Most benzopyrans are either unsubstituted or exhibit a hydroxy group in 3-
position, replacement of this group usually diminishes antihypertensive 
potency. In a series of 3-variations, 3-CHO or 3-CH2OH retained moderate 
potency, while 3-Br or 3-CH3 did not possess any antihypertensive potency.13 
Some authors14 investigated the effect of transposing the 3- and 4-substituents 
and compound 6 is approximately equipotent to cromakalim. 
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The importance of the 3-OH group is ambigous, whereas its presence in 
levcromakalim increases the potency 15-fold as compared to the 3-H analogue, 
chromenes such as KC-399, which lack the 3-substituent, are by far more potent 
than levcromakalim. Thus, 3-OH presumably does not interact with the binding 
site, but more probably stabilizes the bioactive conformation.15 Only in the 
presence of 3-OH group the high eudismic ratio of cromakalim enantiomers is 
observed, whereas the eudismic ratio of the 3-H analogues is marginal. 
 
2-Position 
The influence of 2-substituents on the potency of benzopyran KCOs depending 
on the nature of the 4-substitution. For cromakalim optimal substitution is 
attributed to the dimethyl group, which is superior to the monomethyl and 
better than diethyl. The dihydro compound was virtually devoid of activity.16 In 
a series of benzopyran-4-carbothioamides larger substituents are advantageous: 
2-methyl-2-n-propyl and the spirocyclic cyclobutyl or cyclopentyl moieties 
yielded the most potent derivatives. Methoxymethyl substitution like in JTV-
506 7 confers selective coronary vasodilation in vivo.17 
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Aromatic Substitution 
Positioning and nature of the aromatic substituents exhibit a strong influence on 
potency.1,3,18 Substitution in 6-position is superior to 7-position; whereas in 5- 
and in 8-position abolishes activity. In early investigation, optimum substitution 
was attributed to small, electronegative substituents (NO2, CF3, CN, OCF3, 
C2F5>MeCO>CHO>H). In NIP-121 8 the cyanophenyl moiety is replaced by a 
benzoxadiazole ring.19 Later on it was found that also larger substituents like 
phenyl sulfonyl are able to confer high potency.20 Further variations21 of 6-
substitution led to 6-arylsulfonamido derivatives and 6-N-phenyl-N-methyl-
sulfonamido derivative 9 is the most potent KCO among 4-pyridone–
chromenes. From SAR studies and conformational analysis was postulated that 
6-sulfonamido substituents extend the binding site for benzopyran KCOs, in 
particular beyond a site interacting with negatively polarized partial structure 
such us SO2, a spatially restricted site enabling π-interactions with a phenyl 
moiety is assumed. 
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Transformation of the Benzopyran Nucleus 
The binding site for benzopyran KCOs accomodates replacements both of the 
aromatic ring and of the pyran moiety. Pyridyl can replace cyanophenyl as for 
10 and the pyridyl-nitrogen is preferred in position 6 instead of 7-, while 5- or 
8-position are detrimental.18 
Favourable aromatic ring modification is represented by a thiophenic ring such 
as in RWJ29009 11. Replacement of the pyran ring often yield moderately 
active compounds. Exchange of the pyran oxygen by sulfur represents one of 
the few examples of nearly retained potency.22 Compared to cromakalim, the 
introduction of NH or CH2 reduces potency by a factor of 10 and CO by a 
factor of 30. Oxidation to sulfoxide or sulfone is detrimental. 
Dialkylnaphthalenones23 such as UR-8225 12 are remarkable because some 
derivatives are selective towards  tracheic KATP. Advantageous replacements of 
the pyran ring comprise 1,4-benzoxazine such as YM934 13, which is a potent 
vasodilator with particularly pronounced effects on coronary arteries.24,25 The 
best activities was found for 1,4-benzothiazines, such as compounds 14, 15, 
which exhibit vasodilator potencies on rat aortic ring in the subnanomolar range 
both in vitro and in vivo.26 
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3.1.3 Cyanoguanidines 
Prototype of the cyanoguanidines KCOs is Pinacil 16, which was developed 
from a series of N-alchyl-N′- pyridyl thioureas with known hypotensive 
properties27 and the KCO activity resides in the R(−) enantiomer.  
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Early SAR of pinacidil derivatives were based on in vivo data in spontaneously 
hypertensive rats. 3-Pyridyl derivatives were more potent than their 4-pyridyl 
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analogues except pinacidil being superior to its 3-pyridyl isomer. Exchange of 
the CN group in the cyanoguanidine moiety by the other polar groups resulted 
in compounds almost devoid of activity. In the terminal lipophilic chain region 
short, branched alkyl moieties proved to be optimal. 
Several pharmacological studies28-32 showed that pinacidil relaxes blood vessels 
by additional mechanism unrelated to KATP channel opening, thus blood 
pressure data are untrustworthy for SAR analyses of the KCO properties of 
cyanoguanidines. In consequence, some authors33 measured the spontaneous 
myogenic activity and the stimulation of 86Rb+ efflux from rat portal veins in 
order to evaluate the KCO activity of pinacidil-type cyanoguanidines, 
nitroethane-diamones, thioureas and ureas. A pharmacophoric model was then 
elaborated, which include different receptor interactions: 1) a hydrogen bond 
donor site, represented by the pyridyl attached NH; 2) a hydrogen bond 
acceptor site, represented by the pyridyl nitrogen; 3) a hydrophobic interaction 
site, represented by the terminal lipophilic alkyl chain. 
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Figure3.2 Pharmacophoric model of pinacidil type KCOs  
 
Substitution on the pyridine ring of cyanoguanidines and thioureas were 
investigated and substituent positioning did not  significantly effect the in vitro 
potency, but maximal hypotensive response was obtained from 6-substitution. 
NH2 was found the best substituent in this position and larger groups were 
detrimental. Corresponding with other studies, cyanoguanidines derivatives 
were superior to their thiourea congeners. More rigid cyclic moieties such as 
norbornyl derivative in the terminal lipophylic region were better than alkyl 
chains. SAR studies34 on substituted phenyl cyanoguanidines showed that 
electron withdrawing and lipophilic substituents in 3- and 5-position confer the 
strongest smooth muscle relaxing activity. The pyridine ring is not essential for 
binding to the KATP channel and the ring attached NH and the terminal 
lipophilic moiety are sufficient pharmacophoric features.  
The cyanoguanidines 17, 18 are reported as KATP channel blockers. Their main 
chemical variation is the presence of a phenyl ring in the lipophilic side chain. 
Compound 17 antagonized the pinacidil-induced relation of norepinephrine 
contractions in isolated rabbit mesenteric arteries with an IC50 value of 18nM.35 
For racemic congeners, blocking activity was shown related to the (R)-
enantiomers, and patch-clamp experiments and binding studies on enantiomers 
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of compound 18 showed a weak opener activity related to the (S)-enantiomer. It 
was hypothesized that it is not the ligand binding per se, but its modulation of 
ATP binding site and ATPase activity of the SUR subunit that determines 
opener or blocker properties of a ligand.36 
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3.1.4 Thioformamides 
Aprikalim 19 is the proptotype of this KCOs class.37 Thioamide derivatives of 
tetrahydrothiophene, tetrahydrofuran, 1,3-oxathiane or 1,3-dithiane, bearing a 
2-pyridyl moiety in 2 position, with known anti-ulcera and anti-secretory 
properties  
served as precursory models. Picartamide 20, with a 10-fold higher potency 
than cimetidine, and a series of derivatives were subjected to biological 
profiling and the 3-pyridyl isomer was found to possess marked hypotensive 
activity, without anti-ulcera and anti-secretory properties. Further modification 
on 20 revealed a superiority of the tetrahydrothiopyran over the 
tetrahydrothiophene ring and the antihypertensive effect could be attributed to 
the sulfoxide metabolite.  
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SAR data38,39 for this class of KCOs regard three constituting substructures: 
1) the thioamide function; 
2) the heterocyclic aromatic group; 
3) the saturated heterocycle       
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Figure3.3 SAR of  thioformamide KCOs 
 
Thioamide Function 
Only very limited modification are allowed in this region of the molecule and 
the preference of small lipophilic group indicates the presence of a narrow 
hydrophobic pocket in the receptor site. Ethyl or propyl are preferred, butyl or 
phenyl are already exceed acceptable size, while a loss in activity is observed 
with the substitution of the thioamide group with an amide, indicating the 
precise structural requirements for the receptor interaction in this site of the 
molecule. 
 
Heterocyclic Aromatic Group 
Positioning of the nitrogen in the pyridyl ring has a high impact on potency, as 
indicated by the loss in activity of 2-pyridyl and 4-pyridyl congeners. Also the 
substitution of 3-pyridyl by phenyl reduces potency, but it could be compensate 
by substitution with electron-withdrawing sustituents like for the 3,4-dichloro 
derivative. 
Particularly interesting is the high potency exhibited by the 3-quinolyl for the 3-
pyridyl and the superiority of the 2-naphthyl over the phenyl, indicating a 
higher size tolerance in the receptor site for this region of the molecule and 
suggesting a hydrophobic effect. 
 
Saturated Heterocycle 
Modification of the thiopyran-1-oxide group indicate that this moiety rather 
precisely fits the receptor demands. Sulfone, thiane, 1,3-oxathiane, 1,3-dithiane, 
tetrahydrothiophene and tetrahydrofuran analogues exhibit a drastic drop in 
activity. Only with the cyclohexane substitute the loss of activity is quite 
limited, so this moiety was used as lead for further chemical variation. Among 
the cyclohexanone analogues40 the alkene 21, sulfonamide 22 and the 
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benzylamine 23 are examples for highly potent structures. The chirally pure 
trans-benzylamine is one of the most potent known KCOs.  
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SAR within the cyclohexanone analogues correspond with those of the 
aprikalim series in all features regarding enantioselectivity, absolute 
configuration of the eutomers, as well as modifocations of the pyridyl and 
thioformamide moieties. The significant gain in activity for compounds 
containing an additional aromatic nucleus within the 1-substituents supports the 
assumption of an extended pharmacophore. 
3.1.5 Benzo- and Pyridothiadiazines 
Prototype of the thiadiazine KCOs is diazoxide 24, which KCO properties were 
determined by functional assays41 and binding studies.42 The binding site for 
diazoxide is different from that of benzopyran and cyanoguanidines43: it is 
located in other region of SUR protein. Diazoxide is the only KCO which binds 
with similar affinities to SUR1 and SUR2B, consequently it relaxes vascular 
smooth muscle and inhibits insulin secretion almost equipotently.44 
Starting from diazoxide as a lead were developed both pancreas and smooth 
muscle selective derivatives.45-48 The new structure are hybrids between 
diazoxide and pinacidil type KCOs and the series of pyridothiadiazine dioxides 
bearing a variety of 3- or 4-alkyl and 3-aminoalkyl side chains were used to 
elaborate a pharmacophoric model for the agonistic activity on β-cell KATP 
channels. 
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Figure3.4 Pharmacoporic model for KCO activity on pancreatic KATPchannels. Structural 
requirements include the presence of a short branched chain on the nitrogen in 3-position for 
hydrophobic receptor interactions. Hydrogen bond interactions with the receptor site are 
assumed for the NH goups. Also the electron-withdrawing group in 1-position could establish 
hydrogend bond interactions with the receptor site. Regarding the aromatic moiety, 7-halo-
substituted benzene or a 7-aza-bioisostere were shown to be optimal. 
In particular, the replacement of the 7-chlorobenzene moiety by the bioisosteric 
pyridinic nucleus significantly improves selectivity, like for the prototypical 
example BPDZ-44 25.  
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Changing the nitrogen position in the pyridine ring yields compounds with an 
opposite tissue selectivity: both compounds 26 and 27 were found to be more 
selective for relaxing the art aorta over inhibiting insulin secretion.48 More 
potent and selective compounds were obtained by the replacement of the 
pyridine with a thiophene moiety, in particular compound 26 activates 
pancreatic KATP channels in the low nanomolar range and is at least 1000 times 
more potent than diazoxide in the insulin secretion  inhibition.49 
Hybrids between the benzothiadiazines and sulfonylureas were also synthesised 
and 27 exhibits vasodilator properties comparable with cromakalim.50 
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3.1.6 Pyridyl nitrates 
Prototype of this class is nicorandil 28, its vasodilator properties are due to 
KATP channels activation and stimulation of guanilate cyclase activity in 
vascular smooth muscle.51,52 
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A few of structural modifications were operated  and SAR data on pyridyl 
nitrates are scarce. Some nicorandil analogues present the replacement of the 
pyridyl moiety with a piperazinyl,53 pyrazyl54 or thiazyl55 ones. Compound 28 
presents a cyanoamidine group instead of the amide function and an additional 
exchange of the nitrate group led to the pure KCO 29.56 
3.1.7 Benzopyranyl-Cyanoguanidines 
Early studies57 with cromakalim showed its cardioprotective effects in vitro and 
in vivo. Clinical efficacy, however, was limited because of equipotent systemic 
vasodilation.58 A hybrid between benzopyrans and cyanoguanidines, BMS-
180448 30, was the first derivative reported as cardioselective KCO.59-61 BMS-
180448 is not cardioselective in vitro; in comparison with cromakalim, 
however, the selectivity ratio was shifted by a factor of nearly 200 towards 
cardioprotective potency indicating a putative in vivo selectivity. 
Cardioprotection in the dog was observed with BMS-180448 at intravenous 
doses of 2.5-5 µmol/kg, whereas 21.5 µmol/kg were required to reduce blood 
pressure by 20%. Thus, BMS-180448 is free of hemodynamic effects at 
relevant cardioprotective doses. Starting from BMS-180448 Atwal et al.62-66 
performed detailed SAR studies to further optimize its cardioselective anti-
ischemic properties. 
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Figure3.5 SAR for the anti-ischaemic properties of the benzopyranyl-cyanoguanidine KCOs. 
 
 
Regarding modifications of the benzopyran ring,27g an exchange of the oxygen 
in 1-position by methylene is tolerated, whereas replacement by NH is 
detrimental. The geminal 2-ethyl groups are essential; corresponding desmethyl 
analogs are devoid of activity. Presence of  the 3-OH group is not mandatory, 
but, if present, trans-OH is strongly superior to cis-OH. Introduction of a  3,4-
double bond abolishes anti-ischemic activity indicating that an sp3 carbon is 
preferred at C4. In contrast, chromenes exhibit increased vasodilator properties 
as compared to chromanols. Thus, different SAR exist for the anti-ischemic and 
vasodilator properties of benzopyranyl cyanoguanidines. Urea or thiourea 
counterparts of the 4-cyanoguanidinyl moiety offer no advantage because they  
moderately improve both the anti-ischemic and the vasodilator properties. From 
a limited number of 6-variations, it was concluded, that small,  electronegative 
substituents favour the anti-ischemic properties with a particularly high 
selectivity found for the 6-CF3 substituted compound 31. A later study66 
revealed larger  6-sulfonamido substituents as, for example, present in 32 to 
significantly  improve cardioprotective potency and selectivity relative to BMS-
180448. 
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Modifications of the cyanoguanidine portion63 show that the phenyl 
cyanoguanidine or phenyl urea moiety strongly favour cardioselectivity, since 
increasing or decreasing the distance between the aniline nitrogen and the 
pendant aromatic ring attenuates potency and selectivity. Replacements of the 
aniline nitrogen by O, S, or CH2 are detrimental as well. Exchange of phenyl by 
2-pyridyl or 3-pyridyl is tolerated. In addition, an advantageous phenyl 
substitution by small, electronegative groups such as Cl, NO2, or CF3 as well as 
small alkyl groups is found indicating favourable interactions of phenyl 
substituents. The impact of urea conformation on anti-ischemic activity and 
selectivity was evaluated via conformationally restrained analogous such as 33. 
A moderate drop in anti-ischemic activity is coupled with a profound 
diminution of the vasodilator activity. 
Attempts to further reduce the retaining vasodilator activity of BMS-180448 led 
the group of Atwal65 to synthesize 4-(N-aryl)-substituted benzopyrans; within 
this series BMS-191095 34 exhibited the highest anti-ischemic potency and 
selectivity. BMS-191095 is at least 30-fold more selective than BMS-180448. 
The anti-ischemic activity of BMS-191095 mainly resides in the 3S, 4R-
enantiomer which is opposite to the enantioselectivity of BMS-180448. 
Reasons for this reversal of stereochemical requirements presently unknown, 
but may be related to different receptor binding modes. The  pharmacological 
profile of BMS-191095 has been intensively studied in vitro and in vivo.67-69 
BMS-191095 will not be further developed for clinical use because of neuronal 
toxicity,68 but it  remains an interesting research tool for future drug 
development. 
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3.1.8 Diaminocyclobutenediones 
Diaminocyclobutenediones,  such as WAY- 133537 35 and WAY-151616 36 
were developed at Wyeth-Ayerst.70-72 The starting idea was to utilize the 1,2-
diaminocyclobutene-3,4-dione template as a putative bioisostere for the N-
cyanoguanidine moiety well known from the pinacidil class of KCOs.  
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Detailed SAR studies70 on both the central cyclobutenedione moiety as well, as 
the arylamino and alkylamino side chains were  reported. The central part 
proved to be essential. Replacing the squarate with other carbocyclic, 
heterocyclic or acyclic isosteres led to loss of activity. In the arylamino side 
chain, a phenyl group is preferred. Ortho-substituents enhance and meta-
substituents reduce potency; 4-cyano is optimal. In  the alkylamino side chain, 
rather voluminous, α-branched lipophilic groups  are preferred; dilator potency 
resides in the  R-enantiomers.  
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Figure3.6 SAR data of diaminocyclobutenedione KCOs. 
 
Development candidate from these studies was WAY-133537. Efforts to 
improve the overall pharmacological profile of WAY-133537 were focused on 
metabolic stability and finally led to the design of WAY-151616.71 
WAY-133537 and WAY-151616 relaxed rat bladder smooth muscle strips with 
IC 50 values of 0.09 and 0.10 µM  respectively. Similar to the results with other 
bladder-selective KCOs (e. g., ZM-244085), WAY-133537 did not display an 
in vitro bladder selectivity versus aorta. Both compounds exhibit in vivo 
selectivity in conscious rats after oral application. WAY-133537 was 18-fold 
and WAY-151616 was 166-fold selective, when comparing the ED50 for 
inhibition of unstable bladder contractions and the ED20 for lowering mean 
arterial pressure. 
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3.1.9  DHP-Related Structures 
Dihydropyridines (DHPs) are primarily known as clinically established  anti-
hypertensives; block of voltage-dependent L-type  calcium  channels, reduction 
of calcium entry, and relaxation of smooth muscle are the underlying 
mechanisms of action of  their clinical use. For the enantiomers of chiral DHPs 
opposite molecular modes of action  could be shown: the S-enantiomers of Bay-
K8644 or PN 202791 are able to activate L-type calcium channels.73 
Additionally, DHPs have been shown  to interact with other ionic channels. 
Nifedipine blocks the Ca2+ activated K+ transport in human erythrocytes74 and 
(+)-niguldipine activates Ca2+ dependent, large conductance potassium (BKCa) 
channels in human mesenteric vascular smooth muscle.75 Accordingly, it is not 
surprising that DHP-like structtues were detected which interact with KATP 
channels.  Acridinediones were identified as putative KCOs from screening of 
in-house databases at Zeneca. Working hypothesis for the search was the 
benzopyran-analogous pharmacophoric model of an electron deficient aromatic 
ring  in perpendicular position to a second ring containing an adjacent hydrogen 
bond acceptor goup.  An example for DHP-like KCOs is ZM-244085 37.76-78 
The typical profile of the classical KCOs was also found for ZM-244085. In a 
subsequent study, electrophysiological measurements showed the membrane 
potential of the guinea-pig detrusor to be hyperpolarized 6.8 mV by 10 µM ZM-
244085; in addition the compound failed to activate BKCa channels.77 ZM-
244085 possesses in vivo bladder selectivity.78 Over a dose range from 0.1 to 
3.0 mg/kg given orally, ZM-244085 inhibited bladder activity in conscious rats 
without effects on mean arterial pressure, indicating a 30-fold in vivo 
selectivity. However, ZM-244085 showed a 5.6- fold greater in vitro potency 
for the guinea pig portal vein versus guinea pig  bladder  strips, underlining 
again the poor correspondence between in vitro and in vivo data of  bladder 
selectivity. 
Replacing one of the cyclohexenone  rings in ZM-244085 resulted in a further 
series of DHP-related KCOs including ZD-0947 38, A-278637 39, and 
compound 40. ZD-094779is reportedly under going clinical trials. 
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In A-278637 39, a thiophene 1,1 dioxide replaces one of the cyclohexenone 
rings present in ZM-244085. Compound 39 was subjected to a comprehensive 
pharmacological profiling both in vitro  and in vivo.80,81  
A novel series of tricyclic dihydropyrimidines82 as represented by 40 deserves 
mentioning in the subgroup of DHP-related KCOs.  
3.1.10 Tertiary Carbinols 
In contrast to the above decribed KCOs, the tertiary  carbinols represent entirely 
new chemotypes. They were derived from a series of potent anti-androgenic 
propanamides such as hydroxyflutamide 41.83 Some of these anti-androgens 
exhibited unwanted hypotensive effects which were later attributed to KCO 
properties.84,85 First step in the structural optimization was to minimize the anti-
androgen and to improve the KCO potency. A larger size tolerance for anti-
androgen activity in the alkyl region and a larger size tolerance for KCO 
activity in the N-aryl  region enabled this separation.  In addition, KCO activity 
and selectivity could  be  shown to increase with the degree of fluorination in 
the alkyl region. Thus, ZM-226600 42 is a representative of compounds with 
pronounced KCO, but lacking anti-androgen activity. Second step was 
dedicated to achieve in vivo bladder selectivity; the normotensive conscious rat 
bladder model was used as biological test system that allows the simultaneous 
measurement of cardiovascular and bladder effects.86,87 
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 Compounds with large electron withdrawing 4- substituents as present in ZD-
6169 43 and in compound 44 exhibit rather high in vivo bladder selectivity, 
which resides in the S-(-)-enantiomers. 
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From these studies, ZD-6169 was selected as a development candidate for 
treating urge urinary incontinence. KCO properties of ZD-6169 were 
intensively studied in vitro and in vivo.84-90 Chemical variations of ZD-6169 
particularly include rigidization products in various parts of this lead; 
compounds 45-49 are the corresponding examples. The tertiary carbinols 45 
and 46 differ in several ways from ZD-6I69: (i) the tertiary carbinol is ortho- 
instead of para-positioned relative to the carbonyl, and (ii) the flexible 
benzophenone moiety is transferred into a rigid tricyclic ring via an 
interconnecting seven-membered heterocycle. In vitro, both compounds relax 
15 mM KCI- stimulated guinea-pig bladder strips (compound 45 IC50 = 2.1 µM 
and compound 46 IC50 = 2.5 µM) with similar potency to ZD-6169. For 
compounds 45 and in vivo bladder selectivity was reported in conscious rat 
cystometry at an oral dose of 3 mg/kg.91,92  
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In structures 47 and 48, the carbinol moiety itself is replaced by rigid rings.93 
KCO activity and selectivity of N-arylated derivatives of oxazolidinedione, 
pyrrolidin-2-one, piperidin-2-one, and morpholin-3-one were determined in 
vein and bladder detrusor strips of male Wistar rats. 47 (IC50 = 7.4 µM) and 48 
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(IC50 = 6.7 µM) were less potent dilators of bladder detrusor strips than 
levcromakalim (IC50 = 0.34 µM), but exhibited pronounced in vitro bladder 
selectivity because of a very weak activity in rat portal veins with selectivity 
factors of >41 and 51, respectively. 
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The most far-reaching modification of the lead ZD-6169 was realized  in A-
151892 49, retaining only the carbinol moiety.94 A-151892 was  shown to be a 
potent KCO in vitro  in guinea-pig bladder cells and pig bladder strips. 
Additionally, this compound was found to selectively inhibit unstable bladder 
contractions in vivo.  
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3.1.11 Potassium channel blockers  
Compared to developments in KATP channel openers, medicinal chemistry 
research in the area of KATP blockers has seen less activity. Glibenclamide 50 
has been in use since 1984 for the treatment of type II diabetes, and the 
pharmacology of this agent has been thoroughly described in the literature.95  
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The vascular selective KATP blocker U-37883A 51 was shown preclinically to 
possess diuretic and natriuretic activity.96 The adverse cardiovascular side 
effects seen with 51 in dogs and rats,97 although not believed to be due to its 
KATP blocking properties, precluded its further development.  
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Other types of KATP blockers known are weak and nonselective; these include 
phentolamine (imidazolines), tetraethylammonium (quaternary ammonium 
salt), guanethidine, and bretylium. In contrast to the sulfonylurea analogues that 
interact at SUR1 and SUR2 proteins, phentolamine 52 and cibenzoline 53 have 
been suggested to directly block the channel poreforming subunit of the KATP 
channel.98 
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Considerable attention recently has been directed toward the potential of 
selective KATP blockers in the treatment of ventricular arrhythmias.99 HMR-
1883 54 (clamikalant) is a novel sulfonylurea KATP blocker, currently being 
investigated in phase II clinical trials as the sodium salt (HMR-1098) for the 
treatment of ventricular arrhythmias and sudden cardiac death. HMR-1883 
differs structurally from glibenclamide, in several respects: (i) exchange of the 
sulfonylurea for a sulfonylthiourea, (ii) the smaller size of the lipophilic 
substituent attached to the nitrogen of the sulfonylthiourea, (iii) the position of 
attachment of the sulfonylthiourea to the aromatic ring relative to the left-hand 
portion, and (iv) the addition of a methoxy substituent adjacent to the 
sulfonylthiourea. Although less potent than glibenclamide, HMR-1883 shows 
selectivity for cardiac KATP (guinea pig cardiomyocytes or recombinant 
SUR2A-Kir6.2) over the pancreatic KATP channels (rat insulinoma or 
recombinant SUR1-Kir6.2). 
The sulfonylurea KATP channel blockers are believed to bind to a region of the 
SUR subunit that is adjacent to, but distinct from, that of KATP openers such 
cromakalim.100,101 Indeed, the absence of obvious structural overlap between 
openers and blockers supports this. It is intriguing, therefore, that the potent 
KATP blocker PNU-99963 55 is a member of the cyanoguanidine class. The site 
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of interaction of 55 is presently unknown, but this compound is an interesting 
new tool to probe interactions between openers and blockers at the SUR/Kir 
combinations. 
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Sodium 5-hydroxydecanoate (5-HD) 56 is regarded as a specific inhibitor of 
mito-KATP channels,102 and in several studies 5-HD has been used as a tool to 
test the involvement of mito- KATP in the ischaemic preconditioning.103,104 
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3.2 Aldose Reductase Inhibitors  
Aldose reductase (alditol:NAD(P)+ 1-oxidoreductase, EC 1.1.1.21) is a 
monomeric, nicotinamide adenine dinucleotide phosphate (NADPH)–dependent 
enzyme that is a member of the aldo–keto reductase family. This enzyme 
catalyzes the reduction of aldo sugars, including glucose, and other saturated 
and unsaturated aldehydes. Its crystal structure has a single domain folded into 
an eight-stranded parallel α/β-barrel motif, with the substrate-binding site 
located in a cleft at the carboxy-terminal end of the β-barrel. The coenzyme 
NADPH is bound in an extended conformation with the nicotinamide moiety 
positioned to allow a hydride transfer from the C-4 atom to the carbonyl group 
of the substrate while a proton is provided by the enzyme.105,106 The 
pyrophosphate bridge of NADPH is tied down by loop B (residues 214-230), 
holding NADPH tightly in place, and loop B is fastened by the interaction of 
Asp 217 with lysine residues 23 and 263.105,106 Models for the catalytic 
mechanism of ALR2 have recently been proposed on the basis of kinetic and 
crystallographic studies of wild-type and mutant forms of the enzyme. In the 
direction of aldehyde reduction, the enzyme follows a sequential ordered 
mechanism in which NADPH binds before the aldehyde substrate and NADP+ 
is released after the alcohol product.107,108 A kinetically detectable 
conformational change involving a hingelike movement of a surface loop 
(residues 213-217) occurs upon binding of NADPH (E·NADPH 
→*E·NADPH)2 and immediately prior to release of NADP+.108-110 Reorientation 
of this loop (*E·NADP+→E·NADP+) to permit release of NADP+ appears to 
represent the ratelimiting step in the catalytic mechanism.107,108,111,112 
Crystallography of human ALR2 complexed with NADP(H) revealed three 
residues that could potentially function as the proton donor in the catalytic 
mechanism: tryrosine-48, histidine-110, and cysteine-298.109,113 Mutagenesis 
and structural-modeling studies, together with detailed kinetic analysis, 
provided compelling evidence that tyrosine-48 is most likely the proton 
donor.111,112,114 Together with the nicotinamide moiety of the cofactor they 
compose the so-called anion-binding pocket. The composite picture of the 
various crystal structures suggests that the AR binding site splits into two parts 
with distinct flexibility properties (Figure 3.7). The part which is well 
superimposable across all known structures and shows virtually no variance is 
mainly formed by the residues of the catalytic site (Trp20, Tyr48, Val47, 
His110, Trp79 and Trp 111) and the flanking cofactor. Trp111 borders the 
anion binding pocket and exposes its π-face to the hydrophobic specificit 
pocket. In contrast, the second binding site portion is flexible and shows 
frequent, but recurring changes. Most strongly affected is the segment Val297 
to Leu300 and the adjacent region composed by Trp219, Cys303 and Tyr309. 
To a minor extent also the residues Thr113, Phe121 and Phe122 can be 
involved. However, the most variable residue among all is Leu300, being the 
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determinant for the appearance of the occasionally formed hydrophobic binding 
pocket. In addition, the Cys298 to Leu300 backbone plays an important role by 
modulating the exposed hydrogen-bond donor and acceptor functionalities 
towards the ligand binding site. Additional adaptations involve Cys303, 
Tyr309, Thr113 and the aromatic portions of Phe115 and Phe122. Flexibility is 
clearly exhibited by a limited number of binding site residues: most of the 
mobility is transmitted by about a third of the 15 binding site amino acids. 
Among these, Leu300 and the backbone stretch from residue number 297 to 
300 play the key role. The side-chain motions of Leu300 amplified by the 
backbone movements lead to significant alterations and are responsible for the 
major part of conformational adaptations of the binding pocket. Among the 
other residues, mainly Phe122 and Trp219 show the most pro-nounced 
mobility, both being in spatial proximity to Leu300. The molecular dynamics 
simulations support the dual character of the AR binding site being split into a 
dynamically rather rigid catalytic centre and a flexible area obviously 
responsible for accommodating the side chains of different substrates. In this 
context, it appears appropriate to think of the observed binding site adaptations 
not simply as a result of a ligand-induced fit, but of a preferential selection of 
protein conformations populated in an equilibrium.115,116  
 
Figure 3.7 Binding site of aldose reductase 
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Some studies show that in vitro homogenous AR catalyzes the reduction of a 
large series of saturated and unsaturated aldehydes with 10-3 to 10-4 fold higher 
efficiency than glucose.117 The enzyme is particularly efficient in reducing 
medium- to long chain (C-6 to C-18) aldehydes such as those generated in high 
abundance during lipid peroxidation.118,119 The enzyme also catalyzes the 
reduction of the glutathione conjugates of unsaturated aldehydes, in many cases 
with efficiency higher than that of the parent free aldehyde.120-122 Aldose 
reductase has a low catalytic efficiency for D-glucose, as shown by its 
Michaelis-Menton Costant (Km=100 mM). In normal tissue the glycaemic 
levels are =5 mM and the majority of glucose would be phosphorylated and 
flux through the polyol pathway is minimal. In diabetic patients the hexokinase 
pathway is saturated and the excess of glucose is shunted to the polyol pathway. 
The metabolic imbalance caused by the increased flux through the polyol 
pathway is particularly pronounced in insulin insensitive tissues. In this 
pathway, glucose is reduced to sorbitol by aldose reductase, and sorbitol is then 
oxidized by sorbitol dehydrogenase (SDH) to fructose. The flux through AR 
requires NADPH, whereas SDH requires nicotinamide adenine dinucleotide 
(NAD+). Aldose reductase has been identified as the first enzyme involved in 
the polyol pathway of glucose metabolism which converts glucose into sorbitol. 
Glucose over-utilization through the polyol pathway has been linked by altering 
intracellular tonicity, generating AGEs precursors, and exposing cells to 
oxidative stress to tissue-based pathologies associated with diabetes 
complications, which make the development of potent aldose reductase 
inhibitors (ARIs) an obvious and attractive strategy to prevent or delay the 
onset and progression of the complications. 
 
NADPH    NADP+                 NAD+       NADH 
Glucose                  Sorbitol                  Fructose 
AR                           SDH 
Figure3.8 Metabolism of glucose via the polyol pathway 
 
 
Several generalizations have been made for the classification of AR inhibitors 
and some structural requirements have been identified for the enzymatic 
interaction: 
the inhibitor must have a primary lipophilic moiety, generally  an aromatic one 
with a polar and ionisable group, such as a  carbonyl/thiocarbonyl group, 
located within a certain distance away from the center of the primary lipophilic 
moiety and a second lipophilic moiety larger that the primary one. 
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3.2.1 Chemical classification 
ARIs can be categorized into six main groups: 
• Cyclic imides 
• Carboxylic  acid derivatives 
• Phenolic compounds 
• Arylsulfonyl nitromethanes 
• Amino acid derivatives 
• Other compounds 
 
3.2.2 Cyclic imides 
Sorbinil 1, developed in 1978, is the first cyclic imidine (spirohydantoin) 
compound. Several inhibition studies indicated that sorbinil may not be a 
successful compound for the exploration of AR enzyme inhibition within the 
vascular system,123 moreover no beneficial effects on the development 
nephromegaly, glomerular enlargement and albumina excretion, which are 
common changes in renal physiology of diabetes-induced complication, have 
been detected. One of the main adverse effects of sorbinil is hypersensitivity 
reaction in the early weeks of therapy, which is most likely emerged from 
hydantoin moiety.  
 
O
NH
NH
F
O
O
1
 
To solve this problem, compounds possessing thiazolidinedione moiety were 
introduced as hydantoin bioisoster.124 This kind of chemical manipulation led to 
compounds with antioxidative effects125 and cardioprotective properties.126 
Sorbinil is still a main appropriate aim for bioisosteric replacements since it has 
chromane backbone and orthogonal spirohydantoin ring. 
 
2-Position 
Compounds derived from sorbinil present various substituent in 2-position of 
the chromane backbone. In a series of 2-variations, 2-fluoromethyl derivatives 
retained similar behaviour, 2-chloromethyl and 2-bromomethyl increases the 
activity 3 or 4 fold, respectively, as compared with sorbinil. The 2-CH2OH 
derivative was found to be half-fold to sorbinil, while the 2-methylamino 
derivative showed a drastic decrease in inhibition. The 2-amido derivative 
fidarestat 2 increases the activity 10-fold as compared with sorbinil and is also 
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found to be more active than the halogenomethyl derivatives in vitro, but less 
active in vivo.127   
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Spirohydantoine Ring 
Spirocyclic oxazolidinediones 3, spirothiazolidinedione 4, and 
spirosuccinimides 5 were synthesised in order to limit the hypersensitivity side 
effect linked to the hydantoine moiety of sorbinil.  
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Cl
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4 5
 
 
The orthogonal spirohydantoine moiety is also transferred into a more flexible 
one, which is bridged by sulfonyl group leading to obtain benzofuransulfonyl 
hydantoine 6 characterised by a potent inhibition profiles on the AR enzyme 
and decreased the sorbitol accumulation in isolated tissue to result in preventing 
experimentally induced cataracts and diabetic neuropathy.128  
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Chromane Ring 
Incorporation of the spirosuccinimidic ring into isoindole 7 and benzisothiazole 
8 resulted in marginal improvements for the inhibition.127 
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O O
 
 
The chromane ring of the sorbinil was also replaced by an isoquinoline-1,3- 
dione moiety . In this series were also operated further modification on the 
spirosuccinic ring: it was replaced by an azetidine 9, with an improvement of 
the orally activity, or  by a piridazine one 10 with a loss of inhibitory activity.127  
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Finally, N-substituted spirosuccinimides were synthesised and the orally 
potency is still retained in the N-acetamido derivative 11, while a loss of  the in 
vivo activity was observed for the N-sulfonamido derivative 12.129 
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3.2.3 Carboxilic Acid Derivatives 
Compounds with a flexible carboxylic moiety integrated with minimal 
structural requirements for the AR inhibition were developed in accordance 
with the observation that this structural function play an important role in the 
interaction with the enzyme, especially in physiological condition. 
Alrestatin 13 is the lead of the series and was stable when given orally and 
delayed the onset of diabetic complication in galactosemic rats as well as tested 
in diabetic patients suffering the neuropathy. 130 
NO O
COOH
13
 
A large number of acetic acid derivatives were also developed, including 
rhodanine acetic acid derivative 14, quinolineacetic 15 and phtalazinoacetic 
acids 16. 
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The clinical efficacy of epalrestat 14, a quinolinic acetic acid derivative, was 
evaluated in several patients with diabetic neuropathy and showed an 
improvement ratings of subjective symptoms and of nerve function tests in the 
diabetic patients.131 It showed also an antiproliferative antihypertophic effects 
on vascular smooth muscle cells induced by high glucose and suppressed 
intracellular NADH/NAD+ elevation and reduced the membrane-bound protein 
kinase C activation.132 
In order to develop more potent and orally active AR inhibitors, 
thionaphthostirylacetic acid derivatives 17 were synthesised. Although these 
compounds showed a good inhibitory activity both in vitro and in vivo,133 the 
naphtostyril moiety produced staining of animal tissue. The cleavage of the 
five-membered ring of the thionaphthostyrilacetic acid moiety and several 
modification  resulted in the tolrestat 18.127 
N
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Oxo and/or thioxo-3-benzothiazine (19) derivatives were also reported as potent 
acetic acid ARIs.134 Based on this findings and also from the structure of 
alrestatin and ponalrestat, novel ARIs having the 2,4-dioxo quinazoline ring 
system (20) were developed.135   
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The exchange of the acetic acid moiety with benzyl resulted in a drastic drop of 
activity. This may show that the flexible acid moiety might be placed in a 
position that could serve the interaction through the enzyme’s binding site. The 
inclusion of halogen atoms into the benzyl ring increased the overall potency 
either due to their hydrogen bonding properties or the increasing lipophilicity. 
Besides this, methoxy group at the same ring also served the raise in activity. It 
is reported that these compounds showed better activity than sorbinil.127 
Moreover, was noted that substitution of the benzyl ring greatly influenced the 
magnitude of the effectiveness in which electron-donating groups decreased the 
AR inhibition in comparison with those derivatives with electron-withdrawing 
group such as dihalogens. In particular, the 2-fluoro-4-bromobenzyl substitution 
seems to be preferred.127 
3.2.4 Phenolic Compounds 
In 1975, flavonoids were also reported as AR inhibitors in partially purified AR 
enzyme fron rat lens.136 One of the most studied flavonoids is quercetin (21), 
which decresed the lens sorbitol accumulation and therefore delayed the onset 
of cataract formation.137  
O
OOH
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21
 
One of the major problems with flavonoids is their water solubility, and, 
therefore, they may not be affective after oral administration.138 Since the 
linkage of a phenolic moiety to sugar or organic acids increase the water 
solubility and severely limits the passive diffusion, a number of flavonoids have 
been tested for their  AR inhibitory activities both from natural sources and 
synthetic compounds. 
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Akin to xanthone derivatives, benzophenone ring system were also considered 
in the thought of possible ARIs. 
The AR inhibitory activity of flavonoids and also benzophenones led to design 
benzopyran derivatives in search for active inhibitors for AR.139 Some of the 
benzopyran derivatives showed similar inhibitory activity to that of sorbinil 
with possessing of selectivity for aldehyde reductase.127 
3.2.5 Aryl Sulfonyl Nitromethanes 
Compound ICI 215918 (22), was able to inhibit both AR forms, the sensitive 
and the insensitive ones, exhibiting similar behaviour to spirohydantoines and 
acetic acids.  
SO2 CH2 NO2
22
 
 
Compound 22 and one representative of spirohydantoine and acetic acids class 
were used in order to investigate the interaction with the binding site of the 
enzyme. This studies indicated a kinetic competition between these compounds, 
suggesting that different ARIs overlapping binding sites.127  
3.2.6 Amino Acids 
In earlier studies were synthesised N-glycine and alanine derivatives as AR 
inhibitors. Successively were synthesised N-benzoyl aminoacids derivatives. 
Inhibition analyses  revealed that their kinetic mechanism of inhibition is 
similar, but significant differences in structure-inhibition relationship existed. 
For example, while the PS-alanine and the PS-2-phenylglycine showed 
enantioselective inhibition, no consistent pattern of enantioselectivity was 
observed for the isosteric N-benzoylalanines and phenylglycines. Also N-
methyland N-phenyl substitution of PS-aminoacids did not substantially alter 
the inhibitory activity, while similar substitution on the N-benzoyl series 
resulted in a significant increase of the inhibitory activity. Moreover, 
introduction of different substituents on to N-benzoyl group had no appreciable 
potentiating effects.127 
3.2.7 Other Compounds 
AR inhibitors from natural sources are usually involved, like the flavoids and 
vitamine C (23). Although a series of alkaloids including benzylisochinoline 
(24), papaverine(25) and berberine (26) heve been tested as ARIs, using rabbit 
lens, there were no satisfactory results.140 
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4 INTRODUCTION TO THE EXPERIMENATAL SECTION 
4.1 New mito-KATP channel openers  
KATP channel openers (KCOs) are chemically heterogeneous molecules, which 
are generally lacking of receptor and tissue selectivity in particular towards 
cardiac mitochondrial KATP channels. Despite the strong cardioprotective 
activity observed in experimental studies, their clinical use for the treatment of 
myocardial ischaemia is limited by several side-effects, such as vasodilation 
and hypotension, alteration of cardiac electrophysiological mechanism and 
hyperglycaemia, linked to the concomitant activation of sarcolemmal KATP 
channels in various tissues. Moreover, pharmacological evidence suggests the 
implication of KATP channels in the endogenous cardioprotective mechanism 
known as ischaemic preconditioning (IPC). In particular, the cardiac 
mitochondrial KATP channels (mito-KATP) have been identified as the main 
effectors of IPC.1,2 
In recent years, the research was addressed to the development of new KCOs in 
order to find new compounds with higher selectivity toward specific targets 
such as the KATP of pancreatic β-cells3 or the cardiac mito-KATP channels.4  
The benzopyran KCOs class is the most investigated and some studies have 
indicated that the structure-activity relationships for the antiischaemic and 
vasorelaxant potencies for the benzopyran-based KATP openers are distinct.5 
The two benzopyranyl-cyanoguanidine derivatives BMS-180448 and BMS-
191095 have been reported to possess high cardioprotective activity linked to 
the mitochondrial KATP channel activation and reduced vasorelaxing 
properties.6,7 
 
O
N
N
N
H
N
OH
BMS-191095
O
NH
OH
NH
NCN
N
Cl
BMS-180448
 
Despite the large number of chemical modifications on the benzopyran 
scaffold, only in a few cases have been reported at the C4 position 
conformational rigid substituents with respect to the heterocycle-benzopyran 
bond, although X-ray and NMR studies on cromakalim have indicated that the 
lactam ring possess a reduced conformational freedom and prefers, for steric 
reasons, an orthogonally relationship with the plane of the benzopyran. 
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Compound U96501,8 which incorporates a rigid, spirocyclic imidazolones at 
the benzopyran C4, shows a good activity towards KATP channels: in this 
molecule the spirocyclic ring fusion forces the plane of the heterocycle to be 
orthogonal to the benzopyran ring.  
O
N
OH
O
N
cromakalim
O
NH
N
N
+
O
-
O
O
NH
U96501
 
Starting from these observations, were previously synthesised new benzopyran-
type derivatives in which the substituent at the C4 is represented by a spiro-
morpholone (A) or a spiro-morpholine (B) ring in order to determine the effects 
of these structural modification on the cardioprotective properties and on the 
activity of these new compounds on vascular smooth muscle and blood 
pressure.9  
O
N
O
X
O
R
A
O
N
O
X R
B
 
In particular the anti-ischaemic activity of these previously synthesised 
compounds was evaluated through the recording of the functional (RPP) and 
morphological (Ai/Atot) parameters; moreover the potential role of the mito-
KATP channel in cardioprotective mechanisms was investigated and the effective 
compounds were tested in the presence of 5-hydroxydecanoic acid (5-HD), a 
selective blocker of this channel type. Finally, the vasorelaxing effects in vitro 
and in vivo were evaluated. (Table 4.1) 9 
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Table 4.1 Functional (RPP-120’) and morphological (% Ischemic Area vs Total Area) 
parameters recorded in hearts iolated from rats pretreated with the vehicle, with the synthesized 
compounds or with the reference drugs, in the absence or in the presence of the selective mito-
KATP blocker 5-hydroxydecanoic acid; parameters of vasorelaxing potency (pIC50) and efficacy 
(Emax) of the synthesised compounds and the references KATP openers recorded in isolated rat 
aortic rings. 
 
O
N
O
X
O
R
1a,b-2a,b
O
N
O
X R
3a,b-4a,b
 
 
 
Some of these compounds showed significant anti-ischaemic cardioprotective 
effect devoid of vasorelaxing activity, with a pharmacological profile 
qualitatively similar to those exhibited by BMS-180448 and BMS-191095.9  
With the aim to investigate more deeply this new class of KCOs, were also 
synthesised spiromorpholone- and spiromorpholine-benzopyran derivatives 
with a unsubstituted benzylic moiety (6a,b; 11a,b) or in which  the benzylic 
group is substituted by an electron-withdrawing group, such as CF3 (8a,b; 
13a,b), or an electron-donor substituent, such as amino (5a,b;10a,b), methyl 
(7a,b; 12a,b) or methoxy (9a,b;14a,b)10 (Figure 4.1). 
Compd X R RPP 120’ (%) 
heart 
Ai/Atot 
% 
pIC50 Emax%
vehicle 
diazoxide 
diazoxide + 5-HD 
(±)-cromakalim 
(±)-cromakalim + 5-
HD 
(±)-1a 
(±)-1a + 5-HD 
(±)-1b 
(±)-1b + 5-HD 
(±)-2b 
(±)-2b + 5-HD 
(±)-3a 
(±)-3a + 5-HD 
(±)-3b 
(±)-3b + 5-HD 
(±)-4b 
(±)-4b + 5-HD 
 
 
 
 
 
H 
 
Br 
 
Br 
 
H 
 
Br 
 
Br 
 
 
 
 
 
NHAc 
 
NHAc 
 
NHMs 
 
NHAc 
 
NHAc 
 
NHMs
23±6 
47±3 
6±3 
84±16 
18±1 
62±20 
27±11 
3 
 
57±19 
39±19 
17±5 
 
26±4 
 
77±19 
33±16 
35±7 
22±6 
52±5 
25±1 
38±3 
20±4 
49±5 
58±4 
 
13±3 
47±5 
50±2 
 
61±2 
 
14±2 
40±1 
 
4.72±0.04 
 
7.01±0.09 
 
4.60±0.03 
 
4.82±0.07 
 
5.14±0.03 
 
4.88±0.03 
 
5.62±0.03 
 
5.22±0.02 
 
97±2 
 
98±1 
 
57±3 
 
70±11 
 
87±3 
 
77±2 
 
99±1 
 
98±2 
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Among the previously synthesised compounds better results in terms of both 
cardioprotective activity and selectivity have been showed by compound 1a. 
O
N
O
X
O
R
5a,b-9a,b
O
N
O
X R
10a,b-14a,b  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Spiromorpholones and spiromorpholines previously synthesised. 
 
Aim of the work  
In this thesis the study on this class of 4-spiro-chromane derivatives has been 
extended, investigating: 
I. the influence of the position of the substituent on the benzylic group on 
the nitrogen atom;  
II. the replacement of the benzylic moiety and the modification of the 
heterocyclic core;  
III. the importance of the stereochemistry at the C4.  
 
Are also reported pharmacological data obtained by a more detailed 
pharmacological study on the selected compound 1a, which have shown a 
promising pharmacological profile. 
 
4.2 Influence of the position of the benzylic substituent 
Starting from the good pharmacological profile observed for some previously 
synthesised compound was first investigated the importance of the position of 
the substituent on the benzylic moiety linked to the nitrogen atom of the spiro-
morpholone and spiro-morpholine ring.  In particular, was selected the 
methoxy-substituent for the shifting from the para to the orto and meta position 
in both type of derivatives. 
Compd X R Compd X R 
5a 
5b 
6a 
6b 
7a 
7b 
8a 
8b 
9a 
9b 
H 
Br 
H 
Br 
H 
Br 
H 
Br 
H 
Br 
NH2 
NH2 
H 
H 
Me 
Me 
CF3 
CF3 
OMe 
OMe 
10a 
10b 
11a 
11b 
12a 
12b 
13a 
13b 
14a 
14b 
H 
Br 
H 
Br 
H 
Br 
H 
Br 
H 
Br 
NH2 
NH2 
H 
H 
Me 
Me 
CF3 
CF3 
OMe 
OMe 
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Moreover, in order to extend the series, were synthesised the spiromorpholone- 
and  spiromorpholine-derivatives in which the substituent in para-position of N-
benzyl ring is represented by a bromine atom. 
O
N
O
X
O
R
15a,b-17a,b
O
N
O
X
R
18a,b-20a,b  
 
 
 
 
 
 
 
. 
Synthesis 
Compounds 15a,b-20a,b were synthesised following the synthetic procedure 
illustrated in Scheme 4.1. Chromanones 48a,b, obtained from the appropriate 2-
hydroxyacetophenone,11 were subjected to nucloephilic addition with 
trimethylsilylcyanide (TMSC) in the presence of ZnI2 as the Lewis acid to give 
the corresponding trimethylsilyl cyanohydrins 49a,b. Aminoalcohols 50a,b are 
directly obtained by reduction in the presence of LiAlH4 in accordance with the 
procedure of Amundsen and Nelson.12 The subsequent reaction with 
chloroacetyl chloride in a heterogeneous phase yielded the corresponding 
chloroacetamides 51a,b. Base-catalyzed (t-BuOK) cyclization gave the 
spiromorpholones 52a,b. The subsequent reaction with the appropriate benzyl 
halide and NaH in DMF yielded the corresponding spiromorpholone derivatives 
15a,b-17a,b.13 Spiromorpholine derivatives 53a,b were obtained from 52a,b by 
reduction with LiAlH4 for 53a or with a borane-methyl sulfide complex for 
53b.14 This different synthetic pathway was used for 53b in order to prevent the 
halogen/metal exchange that occurs in the reaction conditions.  
Compounds 18a,b-20a,b were synthesised starting from the spiromorpholines 
51a,b with appropriate benzyl halide, in the presence of K2CO3. 
Compd X R Compd X R 
15a 
15b 
16a 
16b 
17a 
17b 
H 
Br 
H 
Br 
H 
Br 
o-OMe 
o-OMe 
m-OMe 
m-OMe 
p-Br 
p-Br 
18a 
18b 
19a 
19b 
20a 
20b 
H 
Br 
H 
Br 
H 
Br 
o-OMe 
o-OMe 
m-OMe 
m-OMe 
p-Br 
p-Br 
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Scheme 4. 1a  
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g or h
18a,b-20a,b
i
 
(a)Reagent and conditions:  (a) acetone, pyrrolidine; (b) TMSCN, ZnI2, CH2Cl2; (c) LiAlH4, 
THF; (d) chloroacetyl chloride, NaOH, H2O/CH2Cl2; (e) t-BuOK, toluene; (f) benzylhalide, 
NaH, DMF; (g) LiAlH4, THF or  (h) BH3·SMe2 , THF, mw; (i) K2CO3, CH3CN, benzylhalide. 
 
Pharmacological results  
The synthesised compound 15a,b-20a,b were tested as racemic mixtures at a 
dose of 40 mg Kg−1 ip on Langendorff perfused rat hearts subjected to 
ischemia/reperfusion cycles (120 min).Two well-known KATP channel openers, 
diazoxide and cromakalim, were also tested as reference drugs at doses of 40 or 
1 mg kg−1, respectively. Diazoxide is a benzothiadiazine derivative exhibiting a 
preferential activity towards mitochondrial channels (at the dose commonly 
used in this kind of experimental protocols), while cromakalim is a very potent 
KATP-channel activator of both sarcolemmal and mitochondrial channels, thus 
possessing anti-ischaemic effects associated with strong vasorelaxing and 
hypotensive properties.9,10 For each compound the ischaemic injury was 
evaluated by the recording of the functional and morphological parameters. 
 
Functional Parameter 
The ischaemic damage was determined through the recording of a functional 
post-ischaemic parameter (RPP%). In particular, the functional parameter of 
rate pressure product (RPP) recorded at the 120th min of reperfusion (RPP-
120’) has been expressed as a percentage of RPP value recorded at the last 
minute of the preischaemic period. This parameter was taken as indicator of the 
functional recovery of inotropism in the final stage of reperfusion. 
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Morphological Parameter 
At the end of reperfusion, the treatment of the heart with triphenyltetrazolium 
chloride (TTC) made it possible to carry out a morphological comparison of the 
necrotic and healthy areas of the left ventricular tissue, coloured white (or pale 
pink) and red, respectively, and then to calculate the ischemia-injured area 
(Ai/Atot) as a percentage of the total area. 
 
Table 4.2 Functional (RPP-120’) and morphological (% Ischemic Area vs Total Area) 
parameters recorded in hearts isolated from rats pretreated with the vehicle, with the synthesised 
compounds, or with the reference drugs. 
 
O
N
O
X
O
R
15a,b-17a,b
O
N
O
X
R
18a,b-20a,b
 
Compd X R RPP 
120’ 
(%) 
Ai/Atot 
(%) 
Compd X R RPP 
120’ 
(%) 
Ai/Atot 
(%)
vehicle 
cromakalim 
diazoxide 
1a9 
9a10 
9b10 
15a 
15b 
16a 
16b 
17a 
17b 
 
 
 
H 
H 
Br 
H 
Br 
H 
Br 
H 
Br 
 
 
 
p-NHAc 
p-OMe 
p-OMe 
o-OMe 
o-OMe 
m-OMe 
m-OMe 
p-Br 
p-Br 
31±4 
94±17 
47±9 
62±20 
27±6 
76±19 
36±19 
42±17 
29±16 
27±18 
80±12 
23±19 
37±4 
25±1 
28±8 
20±4 
29±4 
16±4 
25±5 
28±1 
41±5 
29±3 
23±5 
47±6 
vehicle 
cromakalim 
diazoxide 
1a9 
14a10 
14b10 
18a 
18b 
19a 
19b 
20a 
20b 
 
 
 
H 
H 
Br 
H 
Br 
H 
Br 
H 
Br
 
 
 
p-NHAc 
p-OMe 
p-OMe 
o-OMe 
o-OMe 
m-OMe 
m-OMe 
p-Br 
p-Br 
31±4 
94±17 
47±9 
62±20 
61±16 
60±7 
65±28 
59±25 
38±11 
42±22 
43±12 
53±10 
37±4 
25±1 
28±8 
20±4 
26±2 
10±2 
34±6 
30±3 
17±3 
29±5 
35±3 
16±6
 
Data reported in Table 4.2 indicate that among the spiromorpholone derivatives 
only compounds 9b and 17a exhibited a good pharmacological profile both in 
terms of functional and morphological parameters. As regards the 
spiromorpholine analogues, while that of  9b (14b) showed a good 
cardioprotective activity, that of 17a  (20a) showed a decrease of the 
pharmacological activity. 
 
Discussion 
As previously reported10, the pharmacological profile of the para-methoxy-
substituted spiromorpholones (9a) did not show any significant anti-ischemic 
activity. Change of substituent position (15a, 16a) did not affect the 
pharmacological profile. Conversely, insertion of a bromine atom in C4′ 
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position of N-benzyl ring (17a) led to an improvement of the pharmacological 
activity with inotropic recovery (RPP) better than that exhibited by 1a (RPP = 
80±12 vs 62±20) and the injured areas (Ai/Atot) almost comparable (Ai/Atot = 
23±5 vs 20±4), indicating that an electron-withdrawing group could be a 
positive requirement, while the methoxy group is detrimental for the 
cardioprotective activity. In the limited series of 6-bromine-substituted 
spiromorpholones were observed opposite results: the presence of an electron-
withdrawing group is detrimental, while insertion of a methoxy group in para-
position (9b) was favourable for the anti-ischaemic properties. The shifting of   
–OMe group in position ortho (15b) and meta (16b) of the N-benzyl ring 
showed a fall in the cardioprotective activity.  Also compound 17b showed a 
decrease of activity. 
The para-methoxy-substituted morpholines 14a,b showed a good 
cardioprotective activity slightly lower than that of 1a (RPP = 61±16 vs 62±20 
and 60±7 vs 62±20; Ai/Atot 26±2 vs 20±4 and 10±2 vs 20±4, respectively). In 
this case the shifting of the substituent did not afford a significant change in the 
pharmacological profile both in terms of RPP and Ai/Atot. For the 6-brominated 
derivative 20b the insertion of bromine-atom  in C4′ position of N-benzyl ring 
resulted in an improvement of the cardioprotective activity respect its 
spiromorpholone analogue 17b (RPP = 53±10 vs 23±19 and Ai/Atot 16±6 vs 
47±6), while compound 20a did not show any significant cardioprotective 
activity. 
 
4.3 Replacement of the benzylic moiety and modification of the 
heterocyclic core 
In order to extend the study of the structure-activity relationships of this new 
class of cardioprotective benzopyran-based mito-KATP openers, have been 
synthesised some derivatives in which the benzylic methylene directly linked to 
the nitrogen atom of the spiromorpholone-and spiromorpholine-ring was 
replaced by a carbonyl (C and E), thiocarbonyl (D), or sulfonyl group (G and 
H). The heterocyclic core was further modified and the carbonyl of the 
spiromorpholones is replaced by a thiocarbonyl to produce the thiomorpholone 
derivatives F (Figure 4.2). 
Compounds of type C still present the amidic function, but it is switched from 
the spirocyclic heterocycle to the nitrogen substituent. Compounds of type D  
and F present a thioamidic function obtained from the replacement of the 
carbonyl with its bioisoster thiocarbonyl. Both for the amidic derivatives C and 
for the thiomorpholones F were selected the benzylic substituents that have 
shown better cardiprotective activity. 
Compounds of type E present the imidic function instead of the amidic one: this 
kind of modification led to derivatives with increased acidity. Finally, 
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compounds of type G and H present the sulfonyl group as additional 
farmacophoric group.  
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 Figure 4.2 Modification of spiromorpholone and spiromorpholine scaffold. 
 
Synthesis 
Spiromorpholonone derivatives 6a,b and 7a, 9a , obtained as previously 
described, reacted in the presence of  Lawesson’s Reagent15 in chlorobenzene to 
give 21a,b and 22a, 23a. 
Compound 24a,b-25a,b were obtained by reaction of 6a,b with benzoylchloride 
(for 24a,b) or benzenesulfonyl chloride (for 25a,b) and n-BuLi in THF.16  
In order to prevent the halogen/metal exchange for 25b, particular attention 
during the work-up was required and the reaction mixture was quenched slowly 
with NH4Cl sat at -10 ˚C. 
The reaction of spiromorpholines 51a,b, obtained as previously described, with 
the appropriate 4-substituted benzoylchloride or benzenesulfonylchloride and 
triethylamine in CH2Cl2 yielded the corresponding N-benzoyl- or N- sulfonyl-
substituted compounds 26a,b and 27a-28a. Treatment of 26a with Lawesson’s 
Reagent in chlorobenzene yielded 29a. 
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Compound 30a was synthesised from 51a and p-aminobenzoic acid in the 
presence of N,N′-dicyclohexylcarbodiimide (DCC) and a catalytic amount of 4-
(dimethylamino) pyridine (DMAP). The subsequent reaction of 30a with acetic 
anhydride and methanesulfonylchloride yielded the acetamido- (31a) and 
methanesulfonamido- (32a) compounds, respectively.  
 
Scheme 4.2a 
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a Reagent and conditions: (a) benzyl bromide, NaH, DMF; (b) benzoylchloride, n-BuLi, THF, 
N2; (c) Lawesson’s Reagent, chlorobenzene; (d) benzensulfonylchloride, n-BuLi, THF, N2. 
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Scheme 4.3a 
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aReagent and conditions: (a) benzoylchloride, Et3N, CH2Cl2; (b) Lawesson’s Reagent, 
chlorobenzene; (c) PABA, DCC, DMAP, CH2Cl2; (e) Ac2O, acetone; (d) MeSO2Cl, pyridine, 
dioxane; (f) benzenesulfonylchloride Et3N, CH2Cl2. 
 
 
Pharmacological Results 
The synthesised compound 21a,b-33a were tested as racemic mixtures at a dose 
of 40mg Kg−1 ip on Langendorff perfused rat hearts subjected to 
ischemia/reperfusion cycles (120 min); two well-known KATP channel openers, 
diazoxide and cromakalim, were also tested as reference drugs at doses of 40 or 
1 mg kg−1, respectively. 
For each compound the ischaemic injury was evaluated by the recording of the 
functional (RPP) and morphological parameters (Ai/Atot) as previously 
described. 
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Table 4.3 Functional (RPP-120’) and morphological (% Ai/Atot) parameters recorded in hearts 
isolated from rats pretreated with the vehicle, with the synthesised compounds, or with the 
reference drugs. 
O
N
O
Z
X
Y
R
21a,b-33a,b
 
Compd X Y Z R RPP 120’ (%) heart Ai/Atot (%) 
vehicle 
cromakalim 
diazoxide 
1a 
21a 
21b 
22a 
23a 
24a 
24b 
25a 
25b 
26a 
26b 
27a 
28a 
29a 
30a 
31a 
32a 
33a 
33b 
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CH2 
CH2 
CH2 
CH2 
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CO 
CO 
SO2 
SO2 
CO 
CO 
CO 
CO 
CS 
CO 
CO 
CO 
SO2 
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NHAc 
H 
H 
Me 
Br 
H 
H 
H 
H 
H 
H 
Me 
F 
H 
NH2 
NHAc 
NHMs 
H 
H 
20±4 
85±9 
55±15 
62±20 
82±12 
- 
24±7 
60±10 
38±22 
nt 
36±12 
nt 
69±19 
44±8 
- 
23±7 
nt 
nt 
61±20 
59±6 
36 
nt 
37±4 
25±1 
28±8 
20±4 
24±4 
39±1 
33±6 
26±1 
42±4 
nt 
41±2 
nt 
43±9 
31±5 
30±1 
34±4 
nt 
nt 
16±3 
31±1 
42±4 
nt 
 
Preliminary data showed that, respect to the spiromorpholone scaffold, the 
replacement of the carbonyl group of the spiromorpholone with a thiocarbonyl 
one (21a,b-23a) did not improve the cardioprotective profile, with the 
exception of 21a, which exhibited a good pharmacological activity, with a 
marked improvement of the cardioprotective activity respect its analogue 6a 
(RPP 82±12 vs 35±9 and Ai/Atot 24±4 vs 33±3). Both the insertion of an 
additional carbonyl or sulfonyl group and the inversion of the amidic function 
(24a,b-33a) did not affect the cardioprotective activity. In these limited series, 
the only one compound endowed of cardioprotective activity is 31a, while 
compound 26a showed a controversial behaviour. In fact, even if the RPP value 
of 26a is comparable to diazoxide, the injured area (Ai/Atot) is greater than that 
of reference drug. Conversely, for the acetamido derivative 31a the value of the 
post-ischaemic functional recovery is comparable to that exhibited by 
diazoxide, while the necrotic area is clearly reduced. This result is completely 
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superimposable to this previously observed for the spiromorpholone analogue 
1a.  
 
Discussion 
Although the series of compounds is very limited, these results seems indicate 
that: (i) the insertion of an additional pharmacophoric group, as in compounds 
25a,b; 32a,b is detrimental; (ii) switching the amidic function, generally,  does 
not affect positively the pharmacological profile. 
 
4.4 Importance of the stereochemistry 
Whit the aim to understand the importance of the stereochemistry for the 
cardioprotective activity the 2,2-dimethyl-N-(4’-acetamido-benzyl)-4-spiro 
morpholone-chromane 1a, which showed cardioprotective activity when 
administered to male Wistar rats at a dose of 40 mg kg1- ip and  tested on 
Langendorff perfused rat hearts subjected to ischemia/reperfusion cycles (120 
min) was resynthesised.  
Anti-ischaemic properties of 1a could be summarized as an improvement of 
post-ischemic functional recovery and marked reduction of size of damaged 
tissue. Moreover, its cardioprotection was sensible to treatment with the 
selective mito-KATP inhibitor 5-HD, and this compound was devoid of 
significant effects on vascular smooth muscle and systolic blood pressure 9,10 
On the basis of this promising pharmacological profile exhibited in preliminary 
work, compound 1a was selected for (i) the enantiomeric resolution;17 (ii) a 
more detailed pharmacological study. 
4.4.1 Enantiomeric Resolution 
Compounds 1a,b and 2b were obtained following the synthetic Scheme 4.1 and 
4.4, as previously reported. The nitro derivatives 54a,b that were reduced to the 
corresponding  amines 5a,b with hydrazine hydrate in the presence of a 
catalytic amount of ferric chloride and activated carbon. Treatment of 5a,b with 
acetic anhydride afforded the corresponding acetamides 1a,b, while 
methanesulfonylation of 5a,b gave compound 2a,b. 
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Scheme 4.4a   
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(a)Reagent and conditions: (a) p-nitrobenzyl bromide, NaH, DMF; (b) NH2NH2.H2O, FeCl3, 
MeOH; (c) Ac2O, acetone; (d) MeSO2Cl, pyridine, dioxane. 
 
 
In order to verify if the anti-ischaemic activity of this new class of 4-spiro-
chromane derivatives may resides in only one or both enantiomers, the racemic 
mixtures of 1a was resolved, together with that of its methanesulfonamide-
analogue brominated in 6 position (2b), selected for comparative purposes in 
order to strengthen the data deriving from their racemic resolution and 
assignment of the absolute configurations to the single enantiomers. The direct 
enantioseparation of 1a and 2b was achieved by high performance liquid 
chromatography (HPLC) on chiral stationary phase (CSP). Single enantiomers, 
isolated at semipreparative scale, were submitted to comparative 
pharmacological and structural investigations. The absolute configuration 
assignment was accomplished by a combined strategy based on single-crystal 
X-ray diffraction and circular dichroism (CD) methods.   
The HPLC enantioseparation of compounds 1a and 2b was carried out on the 
amylose-based Chiralpak IA CSP using normal-phase conditions. Typical 
chromatograms of 1a with simultaneous UV and CD detection are showed in 
Figure 4.3. 
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Fig. 4.3 The stereochemical correspondences between the couples of the 
isolated enantiomers of 1a and 2b were established by CD analysis.  
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S(-)-2b       R(+)-2b 
 
Figure 4.4 ORTEP drawing of  (S)-(-)-2b and (R)-(+)-2b  
 
The structures and the absolute configurations of (+)-2b and (-)-2b, and 
therefore of (+)-1a and (-)-1a, was readily secured by X-ray crystallography 
(Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 CD spectra of enantiomers of 1a and 2b in ethanol. 
As illustrated in Figure 4.4, dextrorotatory and levorotatory enantiomers 
showed to have (R) and (S) configuration, respectively.  
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Pharmacological results 
The potential cardioprotective effects of the two enantiomers of  1a were 
evaluated at a dose of 40mg Kg−1 ip on Langendorff perfused rat hearts 
subjected to ischemia/reperfusion cycles (120 min); two well-known KATP 
channel openers, diazoxide and cromakalim, were also tested as reference drugs 
at doses of 40 or 1 mg kg−1, respectively. 
For each compound the ischaemic injury was evaluated by the recording of the 
functional (RPP) and morphological parameters (Ai/Atot) as previously 
described. 
 
Table 4.4 Functional (RPP-120’) and morphological (% Ischemic Area vs Total Area) 
parameters recorded in hearts isolated from rats pretreated with the vehicle, with the racemate 
(±)-1a, the two enantiomers (R)-(+)-1a and (S)-(-)-1a, or with the reference drugs. 
 
O
N
O
O
NH
O
1a
 
Compd RPP 120’ (%) Ai/Atot (%)
vehicle 
cromakalim 
diazoxide 
(±)-1a   
(R)-(+)-1a 
(S)-(-)-1a 
23±4 
86±12 
45±7 
59±13 
27±5 
64±20 
38±6 
23±3 
25±4 
22±5 
35±2 
16±6 
 
As shown in Table 4.4, the ischemia/reperfusion cycle induced a dramatic 
reduction of the post-ischaemic functional parameter (RPP-120’ = 21±4%) and 
a wide extension of the myocardial injured areas (Ai/Atot = 38±6%), in hearts 
isolated from vehicle-treated rats. As clearly observed in previous works, the 
reference drugs diazoxide and cromakalim gave myocardium an increased 
resistance against ischemia/reperfusion, resulting in an improved recovery of 
post-ischaemic cardiac functionality (RPP-120’ = 45±7% and 86±12%, 
respectively) and a marked reduction of the morphological evidence of tissue 
damage (Ai/Atot = 25±4% and 23±2%, respectively). When administered as 
racemic mixture, compound 1a confirmed its cardioprotective properties 
already emerged in the previous studies, with an overall amelioration of both 
the post-ischaemic indicators (RPP 120’ = 59±13% and  Ai/Atot = 22±5%).  
As concerns the two enantiomers of 1a, the (S)-(-)-1a  enantiomer showed 
significant cardioprotective effect, with a clear improvement of both the 
functional and the morphological markers (RPP-120’= 64±20%; Ai/Atot = 
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16±6%). Such an anti-ischaemic activity was almost comparable to that 
exhibited by the racemic mixture. On the contrary, the (R)-(+)-1a enantiomer 
was completely devoid of anti-ischaemic effects, since the post-ischaemic 
functional and morphological parameters recorded in hearts isolated from 
animals pre-treated with (R)-(+)-1a (RPP-120’= 27±5%; Ai/Atot = 35±2%) were 
almost superimposable to those observed in the vehicle-treated group.   
In order to investigate the potential role of the mito-KATP channel in 
cardioprotective mechanisms, the effective compound was tested in the 
presence of 5-HD. The cardioprotective effects of the S-(-)-1a enantiomer was 
almost completely abolished by 5-HD, suggesting that its antiischaemic 
properties may be due to the activation of the mito-KATP channels. 
 
Discussion 
It is demonstrated that the interaction of the new class of anti-ischaemic 
spirocyclic-benzopyran derivatives with their intracellular target is 
enantioselective and that the cardioprotective properties of the selected 
compound 1a resides in the levorotatory enantiomer while the dextrorotatory 
one is devoid of any activity. In addition, this result appears of particular 
interest because the peculiarity of such mito-KATP activators is the limited 
degree of conformational freedom which could let us to hypothesize a steric 
model for the interaction with the active site of the mito-KATP channel and 
therefore it could contribute to the rational design and development of a new 
innovative class of anti-ischaemic drugs, further improved in potency and 
selectivity for the cardiac target. This enantioselectivity in cardioprotection 
showed by this spirocyclic-benzopyran derivative is in accordance with the 
results obtained for the benzopyran cyanoguanidine BMS-180447,18 another 
well-characterised activator of mito-KATP channels.  
4.4.2 Pharmacological Study 
In order to extend the pharmacological study of 1a which have shown a good 
pharmacological profile as potential mito-KATP openers, was evaluated its anti-
ischaemic effect on an in vivo experimental model of myocardial infarction on 
anaesthetized rats; the probable involvement of mito-KATP channels in a model 
of anoxic condition on cultured cardiomyoblasts (H9c2 cells) and, finally, the 
induced mitochondrial swelling. 
 
Acute infarct 
Hearts of vehicle-treated animals submitted to left anterior descending coronary 
artery (LAD) occlusion showed clear evidence of ischemia-reperfusion (I/R) 
injury, with large size of damaged tissue (Ai/Avs = 35±3%). As expected, 
preconditioning protocol afforded significant cardioprotective effects, 
producing about a half-reduction of the damaged areas (Ai/Avs = 17±6%) and 
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pre-treatment with diazoxide led to almost equivalent anti-ischemic effects 
(Ai/Avs =21±2%). 
Pharmacological treatment with increasing doses (2, 10, 40 mg/Kg) of 1a, 
produced significant and dose-dependent cardioprotective responses (Ai/Avs = 
29±1%, 21±3% and 18±2% respectively).  
When tested on 5-HD (5 mg/Kg) pre-treated animals, compound 1a (40 mg/Kg) 
failed to exhibit any significant cardioprotective activity (Figure 4.6).  
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Figure 4.6 Infarct size, expressed as a percentage of the whole area of left ventricle (Ai/ALV%), 
after different in vivo treatments in a model of coronary occlusion-reperfusion on rat hearts. 
Bars represent the Ai/ALV% of the hearts of rats that 2 hours before the experimental procedures 
received vehicle or respectively an i.p. injection of: diazoxide 40 mg/Kg, compound 1a 2 
mg/Kg, compound 1a 10 mg/Kg, compound 1a 40 mg/Kg and 5-HD 5 mg/Kg plus compound 
1a 40 mg/Kg. The asterisks indicate a value significantly different from the vehicle (* = P< 
0.05; ** = P< 0.01). 
 
 
H9c2 cell viability 
The incubation in anoxic environment (95% N2 and 5% CO2) caused a drastic 
reduction of absorbance values taked as an index of H9c2 cell viability (Viab.% 
= 62 ± 5 ). Pre-treatment of cells with diazoxide (100 µM) and 1a (10 µM) 
conferred a strong resistance, producing a full preservation of cell viability 
(Viab.% = 108±4 and 106 ± 1, respectively). 5-HD (500µM) antagonised the 
protective effects of both diazoxide and 1a (Viab.% = 58 ± 5 and 63 ± 4, 
respectively) (Figure 4.7). 
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Figure 4.7. Cell viability normalised as percentage of the reference value, i.e. the non-ischemic 
vehicle-treated cells (N.I.). The bars represent the H9c2 viability after the indicated treatments. 
The symbol # indicates a value of viability significantly different from the reference value N.I. 
(## = P< 0.01). The symbol * means a value of viability significantly different from the vehicle-
treated ischemic cells (*** = P< 0.001). The symbol § means statistical differences from the 
corresponding value obtained in the absence of 5-HD (§§§ = P< 0.001). 
 
 
Mitochondrial swelling 
The spectrophotometrical evaluation of the influence of the tested compounds 
on matrix volume showed that both diazoxide and compound 1a evoked 
mitochondrial swelling. In particular, the decrease in absorbance at 520 nm 
recorded 15 min after the addition of diazoxide 100 µM or 1a 100 µM were 
0.110±0.013 and 0.123±0.014 (in absorbance arbitrary units), respectively 
(Figure 4.8). Compound 1a 10 µM did not produce any decrease of absorbance 
(data not shown). 
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Figure 4.8 Rat heart mitochondrial swelling represented by the decrease in absorbance at 
520nm recorded for 15 minutes after the addition (arrow) of  vehicle, diazoxide 100µM and 
compound 1a 100µM. 
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Discussion 
Compound 1a was tested in vivo, in an experimental model of acute infarct. In 
this model, more closely resembling the complex clinical pattern of the heart 
infarct, compound 1a showed cardioprotective effects almost comparable to 
those produced by the exogenous “self-defence” mechanism of IPC. Moreover, 
the anti-ischemic effects of 1a showed a dose-dependent fashion and were 
equivalent (or slightly superior) to those of the reference drug diazoxide. As 
already observed in the previous studieson isolated hearts,9 the cardioprotective 
effects of 1a were inhibited by 5-HD, selective blocker of mito-KATP channels. 
The probable involvement of mito-KATP channels clearly emerged also from the 
experimental protocols on cultured H9c2 cells. In this model of 
cardiomyoblasts, the anoxic condition caused a dramatic impact, leading to a 
high level of cell death. Both diazoxide and compound 1a (added of a 
concentration 10-fold lower than the reference benzothiadiazine) produced 
powerful protective effects, leading to a complete prevention of cell death 
induced by the incubation in the anoxic atmosphere. Again, the mito-KATP 
blocker 5-HD fully antagonised the protective effects.  
Given the strong indications by the above results about a mito-KATP activating 
mechanism of action, the studies were focused on the identification of 
“diagnostic” effects of compound 1a at the mitochondrial level, i.e. effects 
comparable to those produced by the reference mito-KATP activator diazoxide.  
Movements of K+ ions across the inner mitochondrial membrane, such as their 
influx into the matrix through electrogenic mechanisms (K+ channels and K+ 
leak) and their extrusion mainly due to K+/H+ exchanger, are fundamentally 
involved in the homeostatic control of matrix volume.19-21 In particular the 
opening of K+ channels leads to a K+ influx exceeding the K+ extrusion, which 
is compensated by increased H+ outward pumping and accumulation of 
phosphates in the matrix. This causes osmotic influx of water and mitochondrial 
swelling.21,22 In agreement with its pharmacodynamic feature of K+ channel 
activator, diazoxide caused mitochondrial swelling.  
A quantitatively and qualitatively similar effect was produced by compound 1a, 
but only at a concentration 10-fold higher (100 µM) than that exhibiting 
protective effects on H9c2 cells. 
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4.5 New aldose reductase inhibitors 
Aldose reductase (ALR2) and aldehyde reductase (ALR1) belong to the aldo-
keto reductase superfamily of enzymes whose members are responsible for a 
wide variety of biological functions. Aldose reductase has been identified as the 
first enzyme involved in the polyol pathway of glucose metabolism which 
converts glucose into sorbitol. Glucose over-utilization through the polyol 
pathway has been linked to tissue-based pathologies associated with diabetes 
complications, which make the development of potent aldose reductase 
inhibitors (ARIs) an obvious and attractive strategy to prevent or delay the 
onset and progression of the complications. Recently, it was demonstrated that 
inhibition of AR protects rat hearts from ischaemic injury and provide a 
foundation for evaluating aldose reductase inhibitors as potential therapeutic 
adjuncts in treating patients with myocardial infarction. 
ARIs are generically distinct in two main classes: spirohydantoines, such as 
sorbinil, and acetic acid derivatives, such as tolrestat, epalrestat, zopolrestat 
and ponalrestat.  
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N
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N
O
COOH
F
Br
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Both classes possess the structural requirements for the enzymatic interaction: 
an acidic group for the interaction with the anionic site and a lipophilic group 
for interaction with  the hydrophobic pocket, fundamental for the activity and 
selectivity of the enzyme. ARIs of the carboxylic class like zopolrestat are quite 
selective for aldose reductase vs aldehyde reductase and other enzymes. 
Howevever these carboxylic class of agent becomes highly protein bound in 
vivo thus limiting their efficacy in vivo. Hydantoin ARIs like sorbinil, on the 
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other hand, are relatively non-selective and inhibit aldehyde and aldose 
reductase with comparable efficacies.23  
The well known ARI sorbinil presents a benzopyran nucleus in which the C4 is 
involved in a spirohydantoine cycle. This compound has not therapeutic utility 
because of side-effect, such as hypersensitivity reaction, linked to hydantoinic 
core. Many chemical modifications have been reported in which the imidic 
cycle is bioisosterically replaced by  thiazolidindiones, oxazolidindiones and 
succinimides.  
 
N
H
NH
O
O
N
H
S
O
O
N
H
O
O
O
N
H O
O
thiazolindindiones
oxazolidindiones
succinimides
 
 
SAR  and computational studies have revealed that a flexible acidic group, such 
as an acetic chain, linked to an amidic function  is important for the interaction 
with the anionic site of the enzyme.  
NS COOH
MeO
CF3
Tolrestat
O
NH
N
H
O
O
F
Sorbinil
O
X
COOH
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Starting from the structural analogies existing between ARI sorbinil and the 
new 4-spiro-chromane derivatives synthesised potassium as mito-KATP channel 
openers (A), a part of this thesis focused on the development of new ARIs. 
O
N
O
O
X
O
NH
N
H
O
O
F
Sorbinil A
 
In particular, were synthesised compounds in which the spiroheterocycle is 
represented by a spiromorpholone- (34a,b), spiromorpholine- (35a,b) or a 
spirooxazolidinone (36a,b) ring respectively. The nitrogen atom of the 
spiroheterocycle core is substituted with an acetic chain; these derivatives still 
present the gem-methyl group in 2-position of the benzopyran.  
 
O
N
O
X
O
COOH
34a,b
a: X= H 
b: X=Br
O
X
O
N
COOHO
36a,b
O
N
O
X
COOH
35a,b
 
Synthesis 
Compounds 34a,b-36a,b were synthesised following the synthetic procedure 
illustrated in Scheme 4.5 Spiromorpholones 52a,b were obtained as previously 
described and their reaction with ethyl bromoacetate and NaH in DMF yielded 
compounds 55a,b. Spiromorpholines 53a,b, obtained as previously described, 
with ethylbromoacetate in the presence of K2CO3 yielded compounds 56a,b. 
The subsequent cleavage of ester 55a,b and 56a,b with KOH in MeOH yielded 
compounds 34a,b and 35a,b. The aminoalcohols 50a,b were obtained as 
previously described and their cyclization in the presence of N-N’-
carbonyldiimidazole (CDI) yielded the corresponding spiro-oxazolidinone 
derivatives 57a,b. Their reaction with ethyl bromoacetate and NaH in DMF 
yielded 58a,b and their saponification with methanolic KOH yielded 36a,b. 
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Scheme 4.5a  
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aReagent and Conditions: (a) NaH, ethylbromoacetate, DMF, N2; (b) KOH, MeOH; (I) K2CO3, 
ethylbromoacetate, CH3CN; (II) CDI, THF. 
 
Enzymatic Assays.  
Synthesised compounds were assayed in vitro for their ability to inhibit ALR1 
and ALR2. Rat lens, in which ALR2 is the predominant enzyme, and kidney, 
where ALR1 shows the highest concentration, were used for the isolation of 
ALR2 and ALR1, respectively. The activity of the two test enzymes was 
determined spectrophotometrically by monitoring the change in absorbance at 
340 nm, which is due to the oxidation of NADPH catalyzed by ALR2 and 
ALR1. In order to evaluate the selectivity towards aldose reductase, synthesised 
compounds were also assayed for the inhibitory activity against sorbitol 
dehydrogenase (SDH). 
 
Enzymatic Inhibition 
The inhibitory activity of the new synthesised compounds against ALR2 and 
ALR1 was assayed by adding 0.1 mL of the inhibitor solution to the reaction 
mixture described above (see exp section). The inhibitory effect of the new 
derivatives was routinely estimated at a concentration of 10-4 M. The 
determination of the IC50 values was performed by linear regression analysis of 
the log-dose response curve, which was generated using at least four 
concentrations of the inhibitor causing an inhibition between 20% and 80%, 
with two replicates at each concentration. The 95% confidence limits (95% CL) 
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were calculated from t values for n-2, where n is the total number of 
determinations. Results are reported in Table 4.5, together with the IC50 values 
of the two well known ARL2 inhibitors sorbinil and tolrestat. 
 
Table 4.5 ALR2 inhibition data of synthesised compounds and reference drugs. 
O
N
Z
O
X
COOH[ ]n
34a,b-36a,b
 
 
 
 
 
 
 
 
 
 
a IC50 (95% CL) values represent the concentration required to produce 50% enzyme inhibition.  
b n.a.: not active. Inhibition occurred at a concentration higher than 100 µM. 
 
Discussion  
The firstly synthesised compounds 34a,b-36a,b, presenting the gem-dimethyl 
group in 2-position of the chromanic scaffold, showed a quiet controversial 
inhibitory behaviour, in particular reducing the carbonyl group of the 
spiromorpholic ring led to a loss of inhibitory activity as regards compound 
devoid of substituent in the C6 of the benzopyran nucleus (34a vs 35a), while 
for the C6 brominated compounds was observed an opposite result (34b vs 
35b). As regards the introduction of a spirooxazolidinone moiety instead of a 
spiromorpholone one, also in this case was observed a reduction of the 
inhibitory activity for the C6-unsubsituted compound 36a, while this kind of 
structural modification ameliorates the activity for the C6-brominated 
compound (36b). 
  
Modification in 2-position: replacement of a methyl with a phenyl 
Furthermore, my work kept on with the synthesis of new derivatives, in order to 
evaluate the importance of the steric hindrance in 2-position for the interaction 
with the active site of the enzyme. In particular, the chemical manipulation in 
this position concerned the replacement of a methyl group with an aromatic 
moiety, aiming to increase the possible interaction with the binding site of the 
enzyme. At present, it is well known the existence of an additional hydrophobic 
pocket of the enzyme. As revealed from X-ray analysis,23 this novel subpocket 
is able to forms via the Trp 20 indole moiety a tight face-to-face π-π stacking 
Compd X Z n IC50 µM a
sorbinil 
tolrestat 
34a 
34b 
35a 
35b 
36a 
36b 
 
 
H 
Br 
H 
Br 
H 
Br
 
 
CO 
CO 
CH2 
CH2 
CO 
CO 
 
 
1 
1 
1 
1 
0 
0
0.65 
0.05 
2.0 
n.a. b 
n.a. b 
4.17 
42.3 
17.3 
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and the possibility to have the use of new structure of these possessing in 2-
position a lipophilic group able to interact with this pocket might increase the 
activity of the new synthesised compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Interaction between generic AR inhibitors and the active site of the enzyme. R1: 
acidic group for the interaction with the anionic site; R2: lipophilic group for interaction with 
the hydrophobic pocket; R3: additional lipophilic group for the interaction with the subpocket. 
 
On this base, were synthesised compounds of type B and C, structurally related 
to 34a,b and 36a,b, in which one of the methyl of the gem-methyl was replaced 
by a p-methoxy or a p-chlorophenyl group. 
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Synthesis 
Chromanones 59a,b and 60a,b were obtained from the appropriate 2-
hydroxyacetophenone and 4-methoxy or 4-chloro acetophenone respectively, 
and subjected to a nucleophilic addition with TMSC in the presence of ZnI2. 
Aminoalcohols 63a,b, 64a,b directly obtained by reduction of corresponding 
trimethylsilylcyanohydrines, were cyclizated in the presence of CDI to afford 
65a,b, 66a,b. Reaction of  65a,b, 66a,b with ethyl bromoacetate in the presence 
of n-BuLi led to the corresponding N-ethylacetate derivatives. The cleavage of 
the ester with KOH in MeOH yielded 37a,b-39a,b. Chloroacetamides 69a,b 
were obtained from aminoalcohols 63a,b and chloacetylchloride in 
heterogeneous phase and their base-catalized (tButOK) cyclization yielded the 
spiromorpholone derivatives 70a,b. The corresponding N-ethylacetate 
derivatives 71a,b were obtained by reaction with ethyl bromoacetate and NaH 
in DMF and the cleavage of the esthers with KOH in MeOH give compounds 
39a,b. 
New aldose reductase inhibitors 
 121
 
 
Scheme 4.6a 
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a Reagent and conditions: (a) pyrrolidine, CH3CN; (b) TMSCN, CH2Cl2,; (c) LiAlH4, THF; (d) 
CDI, THF; (e) n-BuLi, ethylbromoacetate, THF, -78ºC, N2; (f) KOH, MeOH; (g) 
chloroacetylchlori- de, NaOH, CH2Cl2/H2O; (h) tButOK, toluene; (i) NaH, ethylbromoacetate, 
DMF; (l) KOH, MeOH. 
Compd X R 
37a 
37b 
38a 
38b 
39a 
39b 
H 
Br 
H 
Br 
H 
Br
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Cl 
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Enzymatic Assays.  
Synthesised compounds were assayed in vitro for their ability to inhibit ALR1 
and ALR2 and SDH. Enzymatic inhibition was evaluated as previously 
reported. 
 
Tab. 4.5 ALR2 inhibition data of synthesised compounds and reference drugs. 
[ ]n
O
N
O
X
COOH
R
O
37a,b-39a,b
 
 
 
 
 
 
 
 
 
 
a IC50 (95% CL) values represent the concentration required to produce 50% enzyme inhibition.  
b n.a.: not active. Inhibition occurred at a concentration higher than 100 µM. 
 
Discussion 
The insertion of a lipophilic group (i. e. a phenyl substituted ring) instead of a 
gem-dimethyl substituent in 2-position, was generally favourable for the AR 
inhibition, with the only exception of 39a in which this kind of subsituent was 
detrimental for the activity. In particular, 37b showed a great improvement of 
the activity respect its analogous 36b (IC50 =17.3 vs 1.60) and for the 
spiromorpholone derivative 39b a satisfactory inhibitory behaviour was 
observed. 
 
Modification in 2-position: displacement  of the methyl group 
The methyl group of compounds 37a,b-38a,b was also removed, in order to 
evaluated if a reduced steric hindrance may improve the aminoacidic interaction 
of the new derivatives with the hydrophobic pocket, and were synthesised 
derivatives of type D, in which the substituents at 2-position are represented by 
an hydrogen atom and a p-methoxy or a p-chlorophenyl group. Moreover, was 
inserted a 2,4-di-halo-substituted phenyl ring in 2-position (E) accordingly with 
the observation that this kind of substituents could improve the activity, as 
observed for the Ponalrestat. 
 
Compd X n R IC50 µM a 
sorbinil 
tolrestat 
37a 
37b 
38a 
38b 
39a 
39b 
 
 
H 
Br 
H 
Br 
H 
Br 
 
 
0 
0 
0 
0 
1 
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Cl 
Cl 
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4.97 
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O
X
O
N
COOHO
R'
RD, E
a::X= H;
b :X= Br
R= Cl; F; Br
R'= Cl; F
 
Synthesis 
Compounds 40a,b-41a,b were synthesised starting from the appropriate 2-
hydroxyacetophenone and the appropriate benzaldehyde. The α-β insaturated 
compounds obtained were directly cyclizated with glacial AcOH to yield the 
corresponding chromanones 72a,b-73a,b24. Chromanones 72a,b, 73b and 74b 
were directly obtained from the appropriate  2-hydroxyacetophenone and the 
appropriate benzaldehyde in the presence of KOH. Compounds 74a,b-76a,b, 
77b and 78b were subjected to a nucleophilic addition with TMSC in the 
presence of ZnI2. Aminoalcohols 84a,b-86a,b,87b and 88b directly obtained by 
reduction of corresponding trimethylsilylcyanohydrines, were cyclizated in the 
presence of CDI to afford 89a,b-91a,b, 92b and 93b. Spirooxalidinones 89a,b-
91a,b, 92b and 93b, reacted with ethyl bromoacetate in the presence of n-BuLi 
to give the corresponding N-ethylacetate derivatives. The cleavage of the ester 
with KOH in MeOH yielded 40a,b-42a,b, 43b and 44b.  
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Scheme 4.7a 
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Cl 
Cl 
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a Reagent and conditions: (a) pyrrolidine, CH3CN; (b) KOH, MeOH;  (c) AcOH; (d) TMSCN, 
CH2Cl2; (e) LiAlH4, THF; (f) CDI, THF; (g) n-BuLi, ethylbromoacetate, THF, -78 ºC, N2; (h) 
KOH, MeOH. 
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Enzymatic Assays.  
Synthesised compounds were assayed in vitro for their ability to inhibit ALR1 
and ALR2 and SDH. Enzymatic inhibition was evaluated as previously 
reported. 
 
Table 4.6 ALR2 inhibition data of the synthesised compounds and the reference drugs. 
O
X
O
N
COOHO
R'
R
40a,b-44b
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a IC50 (95% CL) values represent the concentration required to produce 50% enzyme inhibition.  
 
Results and Discussion 
Displacement of the methyl group from compounds 37a,b-38a,b resulted in a 
further improvement of the inhibitory activity, with IC50 ranging from 0.58 µM 
(40a) and 13.7 µM (42b). Data reported in Table 2.6 indicate that both the 
mono- and the di-halo-substitution of the phenyl ring did not influence 
significantly the activity. The para-methoxy-subsituted derivative 40b showed 
the better result with an IC50 value comparable with that of the reference drug 
sorbinil. 
 
Experimental data of this limited series of synthesised compounds indicate 
some consideration: 1) the spirooxazolidinonic moiety is preferred to a 
spiromorpholone one; 2) a phenylic pendant  at 2-position of the benzopyran 
nucleus is a favourable features for the inhibitory activity; 3) insertion of a 
bromine atom at the C6 of the benzopyran nucleus is generally well-accepted. 
Compd X R’ R IC50 µM a 
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Further modification: replacement of the benzopyran scaffold 
Finally, starting from the observation that some compounds described in 
literature25 endowed of structural flexibility showed IC50 values in the 
micromolar range, were synthesised derivatives of type F, in which the spiro-
oxazolidinone moiety is still present and the benzopyran scaffold is replaced by 
a benzyloxy pendant.  
 
O
X
O
N
COOHO
R'
R
y
N
x
COOH
O
O
N
O COOH
R
[ ]n
R
D
n = 0;1
x,y = N; O; CH2
R = H; Me; OMe; NO2; 
F; Cl; Br; CF3
F
 
Compounds F present a 4-methoxy-subsituted benzyl ring (45a), 3,4-dimethoxy 
(46a) or 3,4,5-trimethoxy-subsituted benzyl ring (47a).  
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Synthesis 
Compounds 45a-47a were synthesised starting from 2-hydroxyacetophenone 
and the appropriate benzylchorides. Benzyloxyphenylethanones 102a-104a 
were subject to a nucleophilic addition with TMSCN in the presence of ZnI2 to 
give the corresponding trimethylsilylcyanohydrins 105a-107a. Aminoalcohols 
108a-110a, directly obtained by reduction of 105a-107a, were cyclizated in the 
presence of CDI. Spirooxalidinones 111a-113a reacted with ethyl bromoacetate 
in the presence of n-BuLi to give the corresponding N-ethylacetate derivatives. 
The cleavage of the ester with KOH in MeOH yielded 45a-47a (Scheme 2.8). 
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CDI, THF; (e) n-BuLi, ethylbromoacetate, THF, -78 ºC, N2; (f) KOH, MeOH; 
 
 
 
 
 
Chapter 4 
 128 
Enzymatic Assays.  
Synthesised compounds were assayed in vitro for their ability to inhibit ALR1 
and ALR2 and SDH. Enzymatic inhibition was evaluated as previously 
reported. 
 
Table 4.7 ALR2 inhibition data of synthesised compounds and the reference drugs. 
O
O
N
O COOH
R"
R'
R45a-47a
 
 
 
 
 
 
 
a IC50 (95% CL) values represent the concentration required to produce 50% enzyme inhibition.  
 
Results 
Data reported in Table 4.7. seems to indicate that also the replacement of the 
benzopyran scaffold with a more flexible nucleus is a well tolerated chemical 
manipulation that could led to new compounds endowed of AR inhibitory 
activity. To establish if this nucleus enhance  the affinity and selectivity of these 
compounds towards AR, other analogous variously substituted might be 
synthesised. 
Compd R R’ R” IC50 µM a
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5 EXPERIMENTAL SECTION 
5.1 Chemistry 
Melting points were determined on a Kofler hot-stage apparatus and are 
uncorrected. NMR spectra were obtained with a Varian Gemini 200 MHz 
spectrometer. Chemical shifts (δ) are reported in parts per million downfield 
from tetramethylsilane and referenced from solvent references. The elemental 
compositions of the compounds agreed to within (0.4% of the calculated value. 
Chromatographic separation was performed on silica gel columns by flash 
(Kieselgel 40, 0.040-0.063 mm; Merck) or gravity column (Kieselgel 60, 0.063-
0.200 mm; Merck) chromatography. Reactions were followed by thin-layer 
chromatography (TLC) on Merck aluminum silica gel (60 F254) sheets that were 
visualized under a UV lamp. Evaporation was performed in vacuo (rotating 
evaporator). Sodium sulfate was always used as the drying agent. The 
microwave-assisted procedures were carried out with a CEM Discover 
LabMate Microwave. Commercially available chemicals were purchased from 
Sigma-Aldrich. 
 
4′-(2-methoxybenzyl)-2,2-dimethyl-2,3-dihydro-52H-spiro-[chromene-4,2′ 
[1,4]oxazinan]-52-one 15a.  
To a stirred solution of NaH (0.07 g, 3.00 mmol, 60% dispersion in mineral oil) 
in dry DMF (10 mL) was added 52a (0.9 g, 4.00 mmol) under N2 atmosphere. 
After 30 min, the reaction mixture was cooled at 0 °C and 2-methoxybenzyl 
bromide (0.78 g, 5.00 mmol) was added. The reaction mixture was allowed to 
warm at 25 °C and stirred for 1 h before being quenched with water and 
extracted with EtOAc. The combined organic layers were dried, filtered, and 
concentrated under vacuum. The crude product was purified by flash column 
chromatography eluting Hexane/EtOAc (1/1) to give 15a (0.44 g, 1.20 mmol, 
30% yield) as an oil.  
1H-NMR (CDCl3) δ: 1.15 (s, 3H, Me); 1.33 (s, 3H, Me); 1.77 (d, 1H, J = 14.5 
Hz, CH2); 2.25 (d, 1H, J = 14.5 Hz, CH2); 3.11 (d, 1H, J = 12.6 Hz, CH2); 3.79 
(s, 3H, OMe); 3.82 (d, 1H, J = 12.6 Hz, CH2); 4.26 (d, 1H, J = 17.4 Hz, CH2); 
4.38 (d, 1H, J = 17.4 Hz, CH2); 4.48 (d, 1H, J = 14.2 Hz, CH2N); 4.94 (d, 1H, J 
= 14.2 Hz, CH2N); 6.78-6.98 (m, 4H, Ar); 7.17-7.41 (m, 4H, Ar) ppm. 13C 
NMR (CDCl3) δ: 166.49, 157.79, 153.67, 131.04, 130.16, 129.42, 127.43, 
123.97, 121.86, 120.86, 120.75, 118.15, 110.55, 74.26, 69.17, 63.72, 55.42, 
53.56, 44.08, 39.61, 28.60, 26.27. MS m/z: 367 (M+ 22%). Anal. (C22H25NO4) 
C, H, N. 
 
4′-(2-methoxybenzyl)-6-bromo-2,2-dimethyl-2,3-dihydro-52Hspiro[ 
chromene-4,2′-[1,4]oxazinan]-52-one 15b.  
Compound 15b was synthesized from 52b (1.30 g, 4.00 mmol) and 2-
methoxybenzyl bromide (0.78 g, 5.00 mmol) following the same procedure 
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described above for 15a. The crude product was purified by flash column 
chromatography eluting with Hexane/EtOAc (1/1) to afford 15b (0.37 g, 0.84 
mmol, 21% yield): mp 48-50 °C. 1H-NMR (CDCl3) δ: 1.11 (s, 3H, Me); 1.30 (s, 
3H, Me); 1.74 (d, 1H, J = 14.6 Hz, CH2); 2.22 (d, 1H, J = 14.6 Hz, CH2); 3.10 
(d, 1H, J = 12.8 Hz, CH2); 3.72-3.84 (m, 1H, CH2); 3.80 (s, 3H, OMe); 4.25 (d, 
1H, J = 17.4 Hz, CH2); 4.38 (d, 1H, J = 17.4 Hz, CH2); 4.47 (d, 1H, J = 14.3 
Hz, CH2N); 4.93 (d, 1H, J = 14.3 Hz, CH2N); 6.69 (d, 1H, J = 8.6 Hz, Ar); 
6.85-7.00 (m, 2H, Ar); 7.24-7.35 (m, 3H, Ar); 7.50 (d, 1H, J = 2.4 Hz, Ar) ppm. 
13C NMR (CDCl3) δ: 166.41, 157.63, 152.33, 133.07, 131.00, 129.87, 129.56, 
127.87, 123.46, 120.54, 120.19, 112.50, 110.21, 74.68, 68.99, 63.63, 55.78, 
53.21, 44.33, 39.57, 28.80, 25.97. MS m/z: 446 (M+ 38%). Anal. 
(C22H24BrNO4) C, H, N. 
 
4′-(3-methoxybenzyl)-2,2-dimethyl-2,3-dihydro-52H-spiro-[chromene-4,2′-
[1,4]oxazinan]-52-one 16a.  
Compound 16a was synthesized from 52a (0.9 g, 4.00 mmol) and 3-
methoxybenzyl chloride (0.78 g, 5.00 mmol) following the same procedure 
described above for 15a. The crude product was purified by flash column 
chromatography eluting Hexane/EtOAc (7/3) to give 16a (0.79 g, 2.16 mmol, 
54% yield) as an oil. 1H-NMR (CDCl3) δ:  1.14 (s, 3H, Me); 1.33 (s, 3H, Me); 
1.76 (d, 1H, J = 14.5 Hz, CH2); 2.26 (d, 1H, J = 14.5 Hz, CH2); 3.08 (d, 1H, J = 
12.4 Hz, CH2); 3.79 (d, 1H, J = 12.4 Hz, CH2); 3.80 (s, 3H, OMe); 4.24 (d, 1H, 
J = 14.3 Hz, CH2N); 4.29 (d, 1H, J = 17.4 Hz, CH2); 4.41 (d, 1H, J = 17.4 Hz, 
CH2); 4.99 (d, 1H, J = 14.3 Hz, CH2N); 6.79-6.94 (m, 5H, Ar); 7.17-7.30 (m, 
2H, Ar); 7.37 (dd, 1H, J = 1.6, 7.9 Hz, Ar) ppm. 13C NMR (CDCl3) δ: 166.51, 
160.03, 153.67, 131.48, 130.29, 129.89, 127.34, 121.66, 121.19, 120.80, 
118.24, 114.43, 113.58, 74.25, 69.15, 63.69, 55.40, 55.20, 49.74, 39.69, 28.65, 
26.21. MS m/z: 367 (M+ 45%). Anal. (C22H25NO4) C, H, N. 
 
4′-(3-methoxybenzyl)-6-bromo-2,2-dimethyl-2,3-dihydro-52Hspiro[ 
chromene-4,22-[1,4]oxazinan]-52-one 16b.  
Compound 16b was synthesized from 52b (1.30 g, 4.00 mmol) and 3-
methoxybenzyl bromide (0.78 g, 5.00 mmol) following the same procedure 
described above for 15a. The crude product was purified by flash column 
chromatography eluting with Hexane/EtOAc (7/3) to obtain 16b (0.57 g, 1.28 
mmol, 32% yield) as an oil. 1H-NMR (CDCl3) δ: 1.11 (s, 3H, Me); 1.31 (s, 3H, 
Me); 1.74 (d, 1H, J = 14.6 Hz, CH2); 2.23 (d, 1H, J = 14.6 Hz, CH2); 3.06 (d, 
1H, 12.4 Hz, CH2); 3.72-3.80 (m, 1H, CH2); 3.80 (s, 3H, OMe); 4.23 (d, 1H, J 
= 14.2 Hz, CH2N); 4.28 (d, 1H, J = 17.4 Hz, CH2); 4.41 (d, 1H, J = 17.4 Hz, 
CH2); 4.97 (d, 1H, J = 14.2 Hz, CH2N); 6.69 (d, 1H, J = 8.8 Hz, Ar); 6.83-6.88 
(m, 3H, Ar); 7.22-7.32 (m, 2H, Ar); 7.49 (d, 1H, J =2.4 Hz, Ar) ppm. 13C NMR 
(CDCl3) δ: 166.52, 160.12, 152.45, 133.26, 131.09, 130.41, 129.68, 127.64, 
120.55, 120.23, 114.16, 113.88, 112.49, 74.50, 69.04, 63.53, 55.30, 55.21, 
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49.60, 39.81, 28.55, 25.14. MS m/z: 446 (M+ 51%). Anal. (C22H24BrNO4) C, H, 
N. 
 
4'-(4-bromobenzyl)-2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4] oxazinan]-5'-one 17a.  
Compound 17a was synthesized from 52a (0.9 g, 4.00 mmol) and 4-bromo-
benzyl bromide (1.30 g, 5.00 mmol) following the same procedure described 
above for 15a. The crude product was purified by trituration with Et2O to give 
17a (0.63 g, 1.52 mmol, 38 % yield): mp 134-136 °C. 1H-NMR (CDCl3) δ: 1.20 
(s, 3H, Me); 1.33 (s, 3H, Me); 1.72 (d, 1H, J  = 14.6 Hz, CH2); 2.27 (d, 1H, J  
=14.6 Hz, CH2); 3.04 (d, 1H, J  = 12.4 Hz, CH2); 3.79 (d, 1H, J  = 12.4 Hz, 
CH2); 4.29-4.44 (m, 3H, CH2, CH2); 4.87 (d, 1H, J  = 14.4 Hz, CH2); 6.80-6.95 
(m, 2H, Ar); 7.16-7.22 (m, 3H, Ar); 7.35(dd, 1H J = 1.5, 7.9 Hz, Ar); 7.48 (d, 
2H, J = 8.4 Hz, Ar) ppm. 13C-NMR (CDCl3) δ: 166.69, 153.78, 135.16, 132.03, 
130.55, 130.30, 127.20, 122.19, 121.74, 120.79, 118.35, 74.21, 69.23, 63.67, 
55.73, 49.47, 40.16, 29.13, 26.04. MS (m/z): 416 (M+ 46%). Anal. 
(C21H22BrNO3) C, H, N. 
 
4'-(4-bromobenzyl)-6-bromo-2,2-dimethyl-2,3-dihydro-5'H-
spiro[chromene-4,2'-[1,4]oxazinan]-5'-one 17b.  
Compound 17b was synthesized from 52b (1.30 g, 4.00 mmol) and 4-bromo-
benzyl chloride (1.25 g, 5.00 mmol) following the same procedure described 
above for 15a. The crude product was purified by trituration with Et2O/Hex to 
give 17b (0.51 g, 1.04 mmol, 26 % yield): mp 83-85 °C. 1H-NMR (CDCl3) δ: 
1.18 (s, 3H, Me); 1.31 (s, 3H, Me); 1.69 (d, 1H, J  = 14.6 Hz, CH2); 2.24 (d, 
1H, J  = 14.6 Hz, CH2); 3.04 (d, 1H, J  =12.4 Hz, CH2); 3.74 (d, 1H, J  = 12.4 
Hz, CH2); 4.23-4.49 (m, 3H, CH2); 4.83 (d, 1H, J  = 14.5 Hz, CH2); 6.70 (d,1H, 
J  = 8.8 Hz, Ar); 7.16-7.34 (m, 4H, Ar); 7.45-7.50 (m, 2H, Ar) ppm. 13CNMR 
(CDCl3) δ: 166.29, 152.88, 133.54, 133.26, 132.31, 130.23, 127.58, 125.62, 
123.41, 120.50, 112.90, 74.11, 69.30, 63.54, 55.65, 49.40, 39.89, 29.05, 26.12. 
MS (m/z): 495 (M+ 36%). Anal. (C21H21Br2NO3) C, H, N. 
 
4′-(2-methoxybenzyl)-2,2-dimethyl-2,3-dihydrospiro[chromene-4,2′-[1,4] 
oxazinane] 18a.  
To a solution of 53a (0.13 g, 0.57 mmol) in MeCN (5 mL) was added K2CO3 
(0.09 g, 0.64 mmol) and 2-methoxy-benzylchloride (0.09 g, 0.57 mmol). The 
resulting mixture was refluxed for 12 h, then, after cooling, was filtered and the 
solvent evaporated. The crude product was transformed into the hydrochloride 
salt and crystallized from i-PrOH to give 18a (0.29 g, 0.76 mmol, 37% yield): 
mp 185-187 °C. 1H-NMR (CDCl3) δ: 1.27 (s, 3H, Me); 1.36 (s, 3H, Me); 2.13 
(d, 1H, J = 14.6 Hz, CH2); 2.33-2.59 (m, 4H, CH2, CH2); 2.30 (d, 1H, J = 12.7 
Hz, CH2); 2.70-2.75 (m, 1H, CH2); 3.53 (d, 1H, J = 12.7 Hz, CH2); 3.72-4.01 
(m, 2H, CH2); 3.79 (s, 3H, OMe); 6.76-6.95 (m, 4H, Ar); 7.12-7.26 (m, 3H, 
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Ar); 7.62 (d, 1H, J = 7.7 Hz, Ar) ppm. 13C NMR (CDCl3) δ: 158.28, 153.98, 
134.21, 132.15, 130.60, 126.85, 121.68, 121.41, 120.73, 118.64, 115.69, 
111.14, 74.61, 69.99, 61.70, 57.88, 55.76, 55.00, 51.54, 39.45, 28.47, 26.27. 
MS (m/z): 353 (M+ 58%). Anal. (C22H27NO3·HCl) C, H, N. 
 
4′-(2-methoxybenzyl)-6-bromo-2,2-dimethyl-2,3-dihydrospiro[chromene-
4,2′ [1,4]oxazinane] 18b.  
Compound 18b was synthesized from 53b (0.18 g, 0.57 mmol) and 2-methoxy-
benzylchloride (0.09 g, 0.57 mmol) following the same procedure described 
above for the preparation of 18a. The crude residue was transformed into the 
hydrochloride salt and crystallized from i-PrOH to yield 18b (0.1 g, 0.21 mmol, 
26% yield): mp 158-160 °C. 1H-NMR (CDCl3) δ: 1.33 (s, 3H, Me); 1.36 (s, 3H, 
Me); 2.61(d, 1H, J = 15.0 Hz, CH2); 2.85 (d, 1H, J = 15.0 Hz, CH2); 2.95-3.15 
(m, 2H, CH2); 3.58-4.03 (m, 4H, CH2); 3.85 (s, 3H, OMe); 4.35-4.60 (m, 2H, 
CH2); 6.72 (d, 1H, J = 8.8 Hz, Ar); 6.94 (d, 1H, J = 8.2 Hz, Ar); 7.03-7.11 (m, 
1H, Ar); 7.29-7.47(m, 3H, Ar); 7.86-7.90 (m, 1H, Ar). 13C NMR (CDCl3) δ: 
157.95, 152.81, 132.15, 131.13, 130.42, 128.31, 126.94, 125.98, 120.37, 
119.60, 112.36, 110.61, 75.21, 70.06, 63.47, 61.32, 56.40, 55.60, 53.69, 40.74, 
29.13, 27.00. MS (m/z): 432 (M+, 31%). Anal. (C22H26BrNO3·HCl) C, H, N. 
 
4′-(3-methoxybenzyl)-2,2-dimethyl-2,3-dihydrospiro[chromene-4,2′-[1,4] 
oxazinane] 19a.  
Compound 19a was synthesized from 53a (0.08 g, 0.34 mmol) and 3-methoxy-
benzylbromide (0.07 g, 0.34 mmol) following the same procedure described 
above for the preparation of 18a. The crude product was transformed to the 
hydrochloride salt and crystallized from i-PrOH to yield 19a (0.3 g, 0.83 mmol, 
40% yield): mp 141-143 °C. 1H-NMR (CDCl3) δ: 1.32 (s, 3H, Me); 1.35 (s, 3H, 
Me); 2.63 (d, 1H, J = 15.0 Hz, CH2); 2.83 (d, 1H, J = 15.0 Hz, CH2); 2.94-3.08 
(m, 2H, CH2); 3.65-3.99 (m, 4H, CH2, CH2); 3.84 (s, 3H, OMe); 4.55-4.69 (m, 
2H, CH2); 6.82 (d, 1H, J = 8.1 Hz, Ar); 6.90-6.98 (m, 2H, Ar); 7.14-7.35 (m, 
4H, Ar); 7.43-7.56 (m, 1H, Ar). 13C NMR (CDCl3) δ: 160.19, 153.89, 130.67, 
130.44, 128.93, 127.05, 123.32, 121.28, 120.79, 118.58, 116.58, 116.25, 74.57, 
70.04, 61.85, 58.44, 57.82, 55.71, 52.58, 39.54, 28.23, 26.63. MS (m/z): 353 
(M+ 58%). Anal. (C22H27NO3·HCl) C, H, N. 
 
4′-(3-methoxybenzyl)-6-bromo-2,2-dimethyl-2,3-dihydrospiro[chromene-
4,2′ [1,4]oxazinane] 19b.  
Compound 19b was synthesized from 53b (0.13 g, 0.43 mmol) and 3-methoxy-
benzylbromide (0.07 g, 0.43 mmol) following the same procedure described 
above for the preparation of 18a The crude residue was transformed to the 
hydrochloride salt to give 19b (0.07 g, 0.14 mmol, 41% yield): mp 141-143 °C. 
1H-NMR (CDCl3) δ: 1.28 (s, 3H, Me); 1.33 (s, 3H, Me); 2.64-3.09 (m, 4H, 
CH2); 3.66-3.99 (m, 4H, CH2); 3.84 (s, 3H, OMe); 4.53-4.68 (m, 2H, CH2); 
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6.70 (d, 1H, J = 8.8 Hz, Ar); 6.96 (dd, 1H, J = 1.5, 8.2 Hz, Ar); 7.16-7.36 (m, 
3H, Ar); 7.45-7.48 (m, 2H, Ar) ppm 13C NMR (CDCl3) δ: 160.10, 153.21, 
133.25, 131.35, 129.89, 129.75, 123.52, 121.23, 120.16, 114.36, 113.20, 
112.79, 75.28, 69.73, 61.95, 58.30, 57.97, 55.46, 52.50, 39.49, 28.05, 26.88. 
MS (m/z): 432 (M+ 31%). Anal. (C22H26BrNO3·HCl) C, H, N. 
 
4′-(4-bromobenzyl)-2,2-dimethyl-2,3-dihydrospiro[chromene-4,2′-[1,4] 
oxazinane] 20a.  
Compound 20a was synthesized from 53a (0.15 g, 0.64 mmol) and 4-bromo-
benzylbromide (0.16 g, 0.64 mmol) following the same procedure described 
above for the preparation of 18a. The crude product was transformed into the 
hydrochloride salt to give 20a (0.08 g, 0.19 mmol, 30% yield): mp 182-184 °C. 
1H-NMR (CDCl3) δ: 1.33 (s, 6H, Me); 2.51 (d, 1H, J = 15.2 Hz, CH2); 2.86 (d, 
1H, J = 15.2 Hz, CH2);  2.95-3.03 (m, 2H, CH2); 3.65-3.98 (m, 4H, CH2); 4.51-
4.65 (m, 2H, CH2); 6.80-6.98 (m, 2H, Ar); 7.19-7.35 (m, 2H, Ar); 7.54 (d, 2H, J 
= 8.4 Hz, Ar); 7.63 (d, 2H, J = 8.4 Hz, Ar) ppm. 13C NMR (CDCl3) δ: 153.93, 
148.23, 147.19, 146.04, 133.15, 132.71, 130.76, 127.00, 120.82, 118.69, 74.54, 
70.09, 61.12, 58.20, 57.80, 52.16, 39.56, 28.49, 26.36. MS (m/z): 402 (M+ 
34%). Anal. (C21H24BrNO2·HCl) C, H, N. 
 
4′-(4-bromobenzyl)-6-bromo-2,2-dimethyl-2,3-dihydrospiro[chromene-4,2′ 
[1,4]oxazinane] 20b.  
Compound 20b was synthesized from 53b (0.21 g, 0.76 mmol) and 4-bromo-
benzylbromide (0.19 g, 0.76 mmol) following the same procedure described 
above for the preparation of 18a. The crude residue was transformed into the 
hydrochloride salt and crystallized from iPrOH to give 20b (0.5 g, 0.93 mmol, 
45% yield): mp 168-170 °C. 1H-NMR (CDCl3) δ: 1.30 (s, 3H, Me); 1.32 (s, 3H, 
Me); 2.56 (d, 1H, J = 15.2 Hz, CH2); 2.80 (d, 1H, J = 15.2 Hz, CH2); 2.89-3.04 
(m, 2H, CH2); 3.66-3.99 (m, 4H, CH2); 4.50-4.67 (m, 2H, CH2); 6.70 (d, 1H, J 
= 8.8 Hz, Ar); 7.31 (dd, 1H, J = 2.3, 8.8 Hz, Ar); 7.46 (d, 1H, J = 2.3 Hz, Ar); 
7.56 (d, 2H, J = 8.4 Hz, Ar); 7.67 (d, 2H, J = 8.4 Hz, Ar). 13C NMR (CDCl3) δ: 
153.14, 133.70, 133.22, 132.79, 129.91, 126.45, 125.21, 123.32, 120.66, 
112.76, 75.16, 69.99, 61.19, 58.44, 57.88, 52.67, 39.40, 28.33, 26.49. MS 
(m/z): 481 (M+ 57%). Anal. (C21H23Br2NO2·HCl) C, H, N. 
 
4'-benzyl-2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinane]-5'-thione 21a. 
To a stirred solution of 6a (0.1 g, 0.3 mmol) in chlorobenzene Lawesson’s 
Reagent (0.17 mmol) was added. The reaction mixture was refluxed for 2h and 
then the solvent was evaporated. The crude residue was crystallized from EtOH 
to give 21a (0.06 g, 0.17 mmol, yield 57%): mp 154-158 ˚C. 1H-NMR (CDCl3) 
δ:1.04 (s, 3H, Me); 1.30 (s, 3H, Me); 1.59 (d, 1H, J = 14.5 Hz, CH2); 2.15 (d, 
1H, J = 14.5 Hz, CH2); 3.25 (d, 1H, J = 13.4 Hz, CH2); 3.78 (d, 1H, J = 13.4 
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Hz, CH2); 4.59-4.92 (m, 3H, CH2); 5.99 (d, 1H, J = 13.9 Hz, CH2); 6.79 (d, 1H, 
J = 8 Hz, Ar); 6.88-6.96 (m, 1H, Ar); 7.18-7.43 (m, 7H, Ar) ppm. 13C NMR 
(CDCl3) δ: 195.76, 153.80, 134.74, 130.70, 129.21, 128.84, 127.55, 121.36, 
121.16, 118.46, 74.36, 70.32, 69.36, 56.79, 56.72, 39.60, 28.33, 26.46. Anal. 
(C21H23NO2S) C, H, N. 
 
4'-benzyl-6-bromo-2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinane]-5'-thione 21b.  
Compound 21b was synthesized from 6b following the same procedure 
described above for 21a. The crude product was purified by flash column 
chromatography eluted with Hex/EtOAc to give 21b (yield 61%) mp170-172 C. 
1H-NMR (CDCl3) δ: 1.00 (s, 3H, Me); 1.28 (s, 3H, Me); 1.56 (d, 1H, Ј = 14.5 
Hz, CH2); 2.12 (d, 1H, Ј = 14.5 Hz, CH2); 3.24 (d, 1H, Ј = 13.5 Hz, CH2); 3.74 
(d, 1H, Ј = 13.5 Hz, CH2); 4.58–4.92 (m, 3H, CH2); 5.98 (d, 1H, Ј = 14.1 Hz, 
CH2); 6.68 (d, 1H, Ј = 8.8 Hz, Ar); 7.26–7.46 (m, 7H, Ar) ppm. Anal. 
(C21H22BrNO2S) C, H, N. 
 
4'-(4-methylbenzyl)-2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinane]-5'-thione 22a. 
Compound 22a was synthesized from 7a (0.4 g, 1.14 mmol) and Lawesson’s 
Reagent (0.28 g, 0.68mmol) following the same procedure described above for 
21a. The crude product was purified by flash column chromatography eluted 
with Hex/EtOAc (95/5) to give 22a (0.18 g, 0.49 mmol, yield 43%). 1H-NMR 
(CDCl3) δ:1.07 (s, 3H, Me); 1.29 (s, 3H, Me); 1.57 (d, 1H, Ј = 14.5 Hz, CH2); 
2.14 (d, 1H, Ј = 14.5 Hz, CH2); 2.38 (s, 3H, Me); 3.21 (d, 1H, Ј = 13.5 Hz, 
CH2); 3.74 (d, 1H, Ј = 13.5 Hz, CH2); 4.63 (d, 1H, J = 13.9 Hz, CH2); 4.69 (d, 
1H, J = 18.9 Hz, CH2); 4.84 (d, 1H, J = 18.9 Hz, CH2); 5.87 (d, 1H, Ј = 13.9 
Hz, CH2); 6.79 (d, 1H, Ј = 8.2 Hz, Ar); 6.87-6.94 (m, 1H, Ar); 7.11–7.32 (m, 
6H, Ar) ppm.  13C NMR (CDCl3): δ 195.61, 153.82, 138.66, 131.63, 130.65, 
129.79, 127.53, 121.45, 121.12, 118.46, 74.36, 70.32, 69.37, 56.77, 56.54, 
39.71, 28.55, 26.24, 21.51. Anal. (C22H25NO2S) C, H, N. 
 
4'-(4-bromobenzyl)-2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinane]-5'-thione 23a. 
Compound 23a was synthesized from 9a (0.22 g, 0.53 mmol) and Lawesson’s 
Reagent (0.26 g, 0.63 mmol). The reaction mixture was refluxed overnight. The 
solvent was evaporated under vaccum and the crude product was purified by 
trituration with CH2Cl2, to give 23a (0.07 g, 0.16 mmol, yield 30%).  
1H-NMR (CDCl3) δ :  1.16 (s, 3H, Me); 1.32 (s, 3H, Me); 1.60 (d, 1H, Ј = 14.6 
Hz, CH2); 2.18 (d, 1H, Ј = 14.6 Hz, CH2); 3.20 (d, 1H, Ј = 13.4 Hz, CH2); 3.77 
(d, 1H, Ј = 13.4 Hz, CH2); 4.70 (d, 1H, J = 19.1 Hz, CH2); 4.75 (d, 1H, J = 14.2 
Hz, CH2); 4.85 (d, 1H, J = 19.1 Hz, CH2); 5.76 (d, 1H, Ј = 14.2 Hz, CH2); 6.82 
(dd, 1H, Ј = 1.1, 8.2 Hz, Ar); 6.88-6.96 (m, 1H, Ar); 7.18–7.32 (m, 4H, Ar); 
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7.49 (d, 2H, J = 8.4 Hz, Ar)  ppm.  13C NMR (CDCl3): δ 196.19, 153.82, 
133.72, 132.30, 130.79, 127.44, 122.87, 121.25, 121.18, 118.55, 74.33, 70.28, 
69.37, 57.23, 56.19, 39.84, 28.93, 26.02. Anal. (C21H22BrNO2S) C, H, N. 
 
2,2-dimethyl-4'-(phenylcarbonyl)-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinan]-5'-one 24a.  
A solution of 52a (0.2 g, 0.8 mmol) in dry THF was added dropwise, at -78 ˚C, 
under N2 atmosphere to a solution of n-BuLi (0.850mL, 1.6 M in Hexane). The 
reaction mixtures were stirred for 1h and then benzoyl chloride (0.11 g, 0.8 
mmol) was added dropwise at -78 ˚C and the resulting mixtures were allowed 
to warm to rt and stirred overnight. The mixtures were quenched with NH4Clsat 
and then the solvent was evaporated. The residues were extracted with EtOAc, 
the combined organic layers were dried and concentrated under vacuum. The 
crude product was purified by trituration with Et2O to give 24a (0.08 g, 0.24 
mmol, yield 30%): mp 151-155 ˚C. 1H-NMR (CDCl3) δ: 1.43 (s, 3H, Me); 1.47 
(s, 3H, Me); 2.11 (d, 1H, J = 14.5 Hz, CH2); 2.43 (d, 1H, J = 14.5 Hz, CH2); 
4.01 (d, 1H, J = 13.7 Hz, CH2); 4.24 (d, 1H, J = 13.7 Hz, CH2); 4.35 (d, 1H, J = 
17.7 Hz, CH2); 4.47 (d, 1H, J = 17.7 Hz, CH2); 6.87-7.03 (m, 2H, Ar); 7.23-
7.32 (m, 1H, Ar); 7.41-7.57 (m, 5H, Ar); 7.64-7.69 (m, 1H, Ar) ppm. 13C NMR 
(CDCl3) δ: 172.56, 170.01, 153.71, 135.16, 132.70, 130.70, 128.68, 128.55, 
127.09, 122.38, 121.30, 118.66, 74.51, 70.43, 64.73, 53.28, 41.12, 29.81, 25.97. 
Anal. (C21H21NO4) C, H, N. 
 
6-bromo-2,2-dimethyl-4'-(phenylcarbonyl)-2,3-dihydro-5'H-
spiro[chromene-4,2'-[1,4]oxazinan]-5'-one 24b. 
Compound 24b was synthesized from 52b (0.2 g, 0.6 mmol) following the 
same procedure described above for 24a. The crude product was purified by 
crystallization from EtOH to give 24b (0.05 g, 0.12 mmol, yield 20%). mp180-
185 ˚C. 1H-NMR (CDCl3) δ: 1.40 (s, 3H, Me); 1.46 (s, 3H, Me); 2.09 (d, 1H, J 
= 14.7 Hz, CH2); 2.39 (d, 1H, J = 14.7 Hz, CH2); 4.02 (d, 1H, J = 13.7 Hz, 
CH2); 4.16 (d, 1H, J = 13.7 Hz, CH2); 4.33 (d, 1H, J = 17.7 Hz, CH2); 4.48 (d, 
1H, J = 17.7 Hz, CH2); 6.78 (d, 1H, J = 8.7 Hz, Ar); 7.36 (dd, 1H, J = 2.4, 8.7; 
Ar); 7.42-7.69 (m, 6H, Ar) ppm. Anal. (C21H20BrNO4) C, H, N. 
 
2,2-dimethyl-4'-(phenylsulfonyl)-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinan]-5'-one 25a. 
Compound 25a was synthesized from 52a  (0.2 g, 0.8 mmol) and 
benzenesulfonyl chloride (0.14 g, 0.8 mmol) following the same procedure 
described above for 24a. The crude product was purified by trituration with 
Hexane to give 25a (0.03 g, 0.08 mmol, yield 10%). mp162-167 ˚C. 1H-NMR 
(CDCl3) δ:  1.36 (s, 3H, Me); 1.44 (s, 3H, Me); 2.04 (d, 1H, J = 14.6 Hz, CH2); 
2.24 (d, 1H, J = 14.6 Hz, CH2); 4.08 (d, 1H, J = 12.9 Hz, CH2); 4.17 (d, 1H, J = 
12.9 Hz, CH2); 4.20 (d, 1H, J = 18 Hz, CH2); 4.32 (d, 1H, J = 18 Hz, CH2); 
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6.87-6.98 (m, 2H, Ar); 7.23-7.36 (m, 2H, Ar); 7.55-7.75 (m, 3H, Ar); 8.06–8.10 
(m, 2H, Ar) ppm. 13C NMR (CDCl3) δ: 166.80, 153.69, 137.99, 134.50, 130.75, 
129.09, 128.91, 126.92, 121.00, 118.58, 74.36, 70.24, 64.47, 54.69, 40.01, 
29.31, 25.94. Anal. (C20H21NO5S) C, H, N. 
 
6-bromo-2,2-dimethyl-4'-(phenylsulfonyl)-2,3-dihydro-5'H-
spiro[chromene-4,2'-[1,4]oxazinan]-5'-one 25b. 
Compound 25b was synthesized from 49b  (0.2 g, 0.61 mmol) and 
benzenesulfonyl chloride (0.11 g, 0.61 mmol) following the same procedure 
described above for 24a. The crude product was purified by flash column 
chromatography eluted by Hex/EtOAc (4/1) to give 25b (0.11 g, 0.23 mmol, 
yield 38%). 1H-NMR (CDCl3) δ: 1.35 (s, 3H, Me); 1.44 (s, 3H, Me); 2.05 (d, 
1H, J = 14.6 Hz, CH2); 2.24 (d, 1H, J = 14.6 Hz, CH2); 3.99 (d, 1H, J = 13.0 
Hz, CH2); 4.16-4.37 (m, 3H, CH2); 6.78 (d, 1H, J = 8.8 Hz, Ar); 7.33-7.38 (m, 
1H, Ar); 7.47 (d, 1H, J = 2.38, Ar); 7.55-7.71 (m, 3H, Ar); 8.06–8.10 (m, 2H, 
Ar) ppm. 13C NMR (CDCl3) δ: 166.62, 152.99, 137.95, 134.74, 133.78, 129.92, 
129.33, 129.24, 129.04, 120.59, 113.13, 75.07, 70.27, 64.60, 54.57, 39.75, 
29.24, 26.00. Anal. (C20H20BrNO5S) C, H, N. 
 
(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-4'-yl) 
(phenyl)methanone 26a.  
To a solution of  53a (0.3 g, 1.29 mmol) in CH2Cl2 was added triethylamine 
(0.15 g, 1.55 mmol) and benzoyl chloride (0.18 g, 1.29 mmol). The resulting 
mixture was stirred rt overnight and then CH2Cl2 was added and the organic 
phase was washed with HCl 1N, NaHCO3, brine. The organic layer was dried, 
filtered and evaporated under vacuum. The crude product was purified by 
precipitation from iPr2O/Hex  to give 26a (0.21 g, 0.63 mmol, yield 49%): 
mp110-116˚C. 1H-NMR (CD3)2CO δ: 1.33 (br s, 7H, CH2, Me); 2.47 (d, 1H, J 
= 14.5 Hz, CH2); 3.21–3.88 (m, 5H, CH2); 3.97 (dt, 1H, J = 3, 11.9 Hz, CH2); 
6.58–6.83 (m, 1H, Ar); 6.90-6.97 (m, 1H, Ar); 7.16-7.23 (m, 1H, Ar); 7.32–
7.72 (m, 6H, Ar) ppm. 13C NMR (CD3)2CO δ: 168.94, 153.00, 135.38, 128.93, 
128.81, 127.75, 127.40, 126.60, 123.18, 119.56, 116.86, 73.73, 69.27, 59.11, 
41.48, 27.04, 25.42. Anal. (C21H23NO3) C, H, N. 
 
(6-bromo-2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-
[1,4]oxazinan]-4'-yl)(phenyl)methanone 26b.  
Compound 26b was synthesized from 53b (0.37 g, 1.18 mmol) and benzoyl 
chloride (0.15g, 1.07 mmol) following the same procedure described above for 
26a. The crude product was purified by flash column chromatography eluted 
with Hex/Ac 4/1 to give 26b (0.12 g, 0.29 mmol, yield 25%) mp 99-101 ºC. 1H-
NMR (CD3OD) δ: 1.27–1.47 (m, 6H, Me); 2.04–2.45 (m, 2H, CH2); 3.48–3.95 
(m, 5H, CH2); 4.47–4.53 (m, 1H, CH2); 6.71–6.78 (m, 1H, Ar) 7.34–7.73 (m, 
7H, Ar) ppm. 
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13C NMR (CD3)2CO δ: 168.94, 152.35, 135.25, 131.68, 130.15, 128.99, 127.77, 
126.62, 119.14, 111.11, 74.45, 69.25, 59.25, 37.46, 26.79, 25.53. Anal. 
(C21H22BrNO3) C, H, N. 
 
(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-4'-yl)(4-
methylphenyl)methanone 27a. 
Compound 27a was synthesized from 53a (0.2 g, 0.858 mmol) and p-toluoyl 
chloride (0.12g, 0.77 mmol) following the same procedure described above for 
26a. The crude product was purified by flash column chromatography eluted 
with Hex/EtOAc (4/1) to give 27a (0.1 g, 0.28 mmol, yield 33%). 1H-NMR 
(CD3)2CO δ: 1.33 ( br s, 7H, CH2, Me); 2.34 (s, 3H, Me); 2.46 (d, 1H, J = 14.8 
Hz, CH2); 3.21–3.88 (m, 5H, CH2); 3.97 (dt, 1H, J = 12, 2.9 Hz, CH2); 6.75 (d, 
1H, J = 8.42 Hz, Ar); 6.89-6.97 (m, 1H, Ar); 7.16-7.20 (m, 1H, Ar); 7.25 (d, 
2H, J = 7.87 Hz, Ar); 7.37 (d, 2H, J = 7.87 Hz, Ar); 7.59 (d, 1H, J = 7.14 Hz, 
Ar) ppm. 13C NMR (CDCl3) δ: 160.25, 153.75, 140.55, 132.32, 130.15, 129.48, 
127.51, 120.94, 118.26, 74.67, 70.36, 64.99, 59.87, 57.83, 38.75, 28.55, 26.06, 
21.74. Anal. (C22H25NO3) C, H, N. 
 
(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-4'-yl)(4-
fluorophenyl)methanone 28a. 
To a solution of 53a (0.2 g; 0.86 mmol) in THF was added 4-fluorobenzoic acid 
(0.12 g; 0.86 mmol); N,N′-dicyclohexylcarbodiimide (0.21 g; 1.03 mmol) and 
catalytic amount of 4-(dimethylamino)pyridine. The reaction mixture was 
stirred rt for 1h and then the solvent was evaporated under vacuum. The crude 
product was purified by flash column chromatography eluted by Hex/EtOAc 
(1/1) to give 28a (0.19g, 0.55 mmol, yield 64%). 1H-NMR (CD3)2CO δ: 1.33 
(br s, 7H, CH2, Me); 2.46 (d, 1H, J = 14.6 Hz, CH2); 3.30–3.80 (m, 5H, CH2); 
3.97 (dt, 1H, J = 2.9, 11.9 Hz, CH2); 6.76 (d, 1H, J = 8.06 Hz, Ar); 6.89-6.97 
(m, 1H, Ar); 7.16-7.25 (m, 3H, Ar); 7.53-7.60 (m, 3H, Ar); ppm. 13C-NMR 
(CDCl3) δ: 170.06, 153.74, 130.04, 129.74, 129.58, 127.40, 123.23, 120.79, 
118.24, 116.11, 115.67, 74.54, 70.37, 60.03, 40.47, 40.40, 39.03, 28.47, 25.10. 
Anal. (C21H22FNO3) C, H, N.  
 
(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-4'-yl) 
(phenyl)methanethione 29a. 
Compound 29a was synthesized from 26a  (0.21 g, 0.62 mmol) and Lawesson’s 
Reagent (0.15 g, 0.37 mmol) following the same procedure described above for 
21a. The crude product was purified by flash column chromatography eluted by 
Hex/EtOAc (4/1) to give 32a (0.05 g, 0.15 mmol, yield 24%). mp 132-137 ºC. 
1H-NMR (CDCl3) δ: 1.19 (s, 3H, CH3); 1.30 (s, 3H, CH3); 1.58-1.61 (m, 1H, 
CH2); 2.36 (d, 1H, J = 19.9 Hz, CH2); 3.43-4.12 (m, 6H, CH2); 6.77 (d, 1H, J  = 
7.9 Hz, Ar); 6.86-6.94 (m, 1H, Ar); 6.99-7.03 (m, 1H, Ar); 7.17-7.55 (m, 6H, 
Ar) ppm. Anal. (C21H23NO2S) C, H, N. 
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(4-aminophenyl)(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4] 
oxazinan]-4'-yl)methanone 30a. 
Compound 30a was synthesised from 51a (0.33 g; 1.43 mmol) and p-
aminobenzoic acid (0.19 g; 1.43 mmol) and N,N′-dicyclohexylcarbodiimide 
(0.35 g; 1.7 mmol) and catalytic amount of 4-(dimethylamino)pyridine. The 
reaction mixture was stirred overnight and then the solvent was evaporated 
under vacuum. The crude product was purified by flash column 
chromatography eluted by Hex/EtOAc (1/1) to give 30a (0.17 g, 0.47 mmol, 
yield 33%). 1H-NMR (CD3)2CO δ: 1.32 (br s, 6H, Me); 1.95 (d, 1H, J = 14.6 
Hz, CH2); 2.39 (d, 1H, J = 14.6 Hz, CH2); 3.30–3.44 (m, 1H, CH2); 3.56 (d, 1H, 
J = 13.0 Hz, CH2); 3.69 (dd, 1H, J = 2.6, 11.9 Hz, CH2); 3.87-4.15 (m, 3H, 
CH2) 5.05 (br s, 2H, CH2); 6.66 (d, 2H, J = 8.5 Hz, Ar); 6.72–6.77 (m, 1H, Ar); 
6.89-6.97 (m, 1H, Ar); 7.15-7.19 (m, 1H, Ar); 7.24 (d, 2H, J = 8.5 Hz, Ar); 7.59 
(dd, 1H, J = 1.6, 7.8 Hz, Ar) ppm. 13C NMR (CD3)2CO δ: 169.76, 153.00, 
149.76, 128.79, 128.71, 127.44, 123.42, 122.23, 119.54, 116.82, 112.51, 73.74, 
69.32, 59.09, 37.86, 26.95, 25.38. Anal. (C21H24N2O3) C, H, N. 
 
N-{4-[(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-
4'-yl)carbonyl]phenyl}acetamide 31a. 
To a solution of 30a (0.22 g; 0.61 mmol) in acetone (5mL) was added K2CO3 
(0.13 g, 0.91 mmol) and acetic anhydride (0.06 g, 0.61 mmol) and then the 
reaction mixture was stirred rt overnight. The solvent was evaporated and the 
residue was dissolved in EtOAc, washed with water and brine. The organic 
layer was dried and concentrated under vacuum. Th crude product was purified 
by flash column chromatography eluted by Hex/EtOAc (3/7) to give 31a 
(0.12g, 0.3 mmol, yield 50%).  1H-NMR (CDCl3) δ : 1.34 1.32 (br s, 7H, CH2, 
Me); 2.18 (s, 3H, Me); 2.33 (d, 1H, J = 14.5 Hz, CH2); 3.37 (br s, 2H, CH2 ); 
3.79 (br s, 4H, CH2); 6.80 (d, 1H, J = 8.5 Hz, Ar); 6.92–6.99 (m, 1H, Ar); 7.17-
7.21 (m, 1H, Ar); 7.36-755 (m, 5H, Ar) ppm. 13C NMR (CD3)2CO δ: 168.86, 
167.46, 153.06, 140.31, 129.70, 128.68, 127.55, 127.29, 123.38, 119.50, 
117.86, 116.86, 73.71, 69.36, 59.07, 38.11, 25.29, 22.80. Anal. (C23H26N2O4) C, 
H, N. 
 
N-{4-[(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-
4'-yl)carbonyl]phenyl}methanesulfonamide 32a. 
To a solution of 30a (0.22 g; 0.61 mmol) in dioxane (5mL) was added K2CO3 
(0.13 g, 0.91 mmol) and acetic anhydride (0.06 g, 0.61 mmol) and then the 
reaction mixture was stirred rt overnight. The solvent was evaporated and the 
residue was dissolved in EtOAc, washed with water and brine. The organic 
layer was dried and concentrated under vacuum. The crude product was 
purified by flash column chromatography eluted by Hex/EtOAc (3/7) to give 
32a (0.12g, 0.3 mmol, yield 50%).1H-NMR (CD3)2CO δ: 1.33 ( br s, 7H, CH2, 
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Me); 2.44 (d, 1H, J = 14.6 Hz, CH2); 3.02 (s, 3H, Me); 3.21–3.74(m, 5H, CH2); 
3.97 (dt, 1H, J = 2.8, 11.9 Hz, CH2); 6.76 (d, 1H, J = 8.06 Hz, Ar); 6.89-6.97 
(m, 1H, Ar); 7.15-7.24 (m, 1H, Ar); 7.38 (d, 2H, J = 8.5 Hz, Ar); 7.50 (d, 2H, J 
= 8.5 Hz, Ar); 7.59 (dd, 1H, J = 7.7, 1.5 Hz, Ar) ppm. 13C-NMR (CDCl3) δ: 
170.36, 153.82, 139.31, 131.28, 130.15, 129.13, 127.51, 120.90, 119.72, 
118.39, 118.30, 74.67, 70.47, 65.66, 60.05, 39.97, 39.60, 39.08, 34.09, 28.64. 
Anal. (C22H26NO2S) C, H, N.  
 
2,2-dimethyl-4'-(phenylsulfonyl)-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinan]-5'-one 33a.  
Compound 33a was obtained from 51a (0.3 g, 1.28mmol) and benzenesulfonyl 
chloride (0.22 g, 1.28 mmol) following the same procedure described above for 
26a. The crude product was purified by crystallization from iPr2O to give 33a 
(0.05 g, 0.12 mmol, yield 10%) mp135-140 C. 1H-NMR (CDCl3) δ: 1.39 (s, 3H, 
Me); 1.44 (s, 3H, Me); 2.32 (d, 1H, J = 14.7 Hz, CH2); 2.41 (d, 1H, J = 14.7 Hz, 
CH2); 2.55–2.69 (m, 2H, CH2); 3.54–3.67 (m, 2H, CH2); 3.76–3.83 (m, 1H, 
CH2); 4.02 (dt, 1H, J  = 2.8, 11.9 Hz, CH2); 6.82-6.92 (m, 2H, Ar); 7.17–7.33 
(m, 2H, Ar); 7.52–7.75 (m, 5H, Ar) ppm.  13C-NMR (CDCl3) δ: 153.95, 136.16, 
133.21, 130.06, 129.41, 127.86, 127.44, 123.34, 120.69, 118.32, 74.95, 70.16, 
60.22, 55.59, 46.09, 39.51, 28.50, 27.70.  Anal. (C20H23NO4S) C, H, N. 
 
6-bromo-2,2-dimethyl-4'-(phenylsulfonyl)-2,3-dihydrospiro[chromene-4,2'-
[1,4]oxazinane] 33b 
Compound 33b was obtained from 51b (0.15g, 0.48 mmol) and 
benzenesulfonyl chloride (0.08 g, 0.48 mmol) following the same procedure 
described above for 26a. The crude product was purified by flash column 
chromatography eluted by Hex/EtOAc (4/1) to give 33b (0.03g, 0.06 mmol, 
yield 14%).1H-NMR (CDCl3) δ : 1.38 (s, 3H, Me); 1.43 (s, 3H, Me); 2.28 (d, 
1H, J = 14.5 Hz, CH2); 2.44 (d, 1H, J = 14.5 Hz, CH2); 2.53–2.67 (m, 2H, 
CH2); 3.58–3.83 (m, 3H, CH2); 3.96–4.07 (m, 1H, CH2); 6.72 (d, 1H, J = 8.6 
Hz, Ar); 7.26–7.31 (m, 1H, Ar); 7.39 (d, 1H, J = 2.5 Hz, Ar); 7.55–7.75 (m, 5H, 
Ar) ppm. 13C-NMR (CDCl3) δ : 153.04, 135.69, 133.56, 133.08, 130.28, 
129.66, 127.82, 125.33, 120.25, 112.80, 75.60, 70.07, 60.34, 55.46, 46.01, 
38.91, 28.17, 27.86. Anal. (C20H22BrNO4S) C, H, N. 
 
(2,2-dimethyl-5'-oxo-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-
4'-yl)acetic acid 34a.  
To a stirred solution of 55a (0.26 g, 0.77 mmol) in MeOH (3  mL) was added 
KOH 50% (0.005 mL) and the resulting mixture was refluxed for 2h. The 
solvent was evaporated under vacuum and then HCl 1N was added (pH =3). 
The precipitate was filtered and dried to give 34a (0.14 g, .0.46 mmol, 60% 
yield). mp 163-165˚C. 1H-NMR (CDCl3) δ : 1.41 (s, 6H, Me); 2.19 (d, 1H, J = 
14.6 Hz, CH2); 2.42 (d, 1H, J = 14.6 Hz, CH2); 3.26 (d,1H, J = 12.08 Hz, CH2); 
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4.02- 4.10 (m, 2H, CH2); 4.35- 4.46 (m, 3H, CH2); 6.84- 7.0 (m, 2H, Ar); 7.22- 
7.29 (m, 1H, Ar); 7.46- 7.47 (m, 1H, Ar) ppm. Anal. (C16H19NO5) C, H, N. 
 
(6-bromo-2,2-dimethyl-5'-oxo-2,3-dihydro-4'H-spiro[chromene-4,2'-
[1,4]oxazinan]-4'-yl)acetic acid 34b.  
Compound 34b was obtained from 55b (0.39 g, 0.96 mmol) following the same 
procedure descrided for 34a. The crude product was collected without further 
purification to yield 34b (0.12 g, 0.32 mmol, 34%yield). mp 132-134˚C. 1H-
NMR (DMSO) δ : 1.32 (s, 3H, Me); 1.35 (s, 3H, Me); 2.14 (d, 1H, J = 15 Hz, 
CH2); 2.42- 2.52 (m, 1H, CH2); 3.96- 4.24 (m, 6H, CH2); 6.79 (d, 1H, J = 8.6 
Hz, Ar); 7.4 (dd, 1H, J = 2.5, 8.7 Hz, Ar); 7.6 (d, 1H, J = 2.4 Hz, Ar) ppm. 
Anal. (C16H18BrNO5) C, H, N. 
 
(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-4'-
yl)acetic acid 35a. 
Compound 35a was obtained from 56a (0.55 g, 1.90 mmol) following the same 
procedure descrided for 34a. The crude product was collected and purified by 
precipitation from CHCl3/Hex to yield 35a (0.01 g, 0.04 mmol, yield 2%). 1H-
NMR (CD3OD) δ : 1.35 (s, 3H, Me); 1.45 (s, 3H, Me); 2.20 (d, 1H, J = 14.8 
Hz, CH2); 2.65 (d, 1H, J = 14.8 Hz, CH2); 3.26-3.40 (m, 2H, CH2); 3.70-4.01 
(m, 3H, CH2); 4.07-4.24 (m, 1H, CH2); 4.90 (s, 2H, CH2); 6.78- 6.83 (m, 1H, 
Ar); 6.93- 7.00 (m, 1H, Ar); 7.20- 7.28 (m, 1H, Ar); 7.55 (dd, 1H, J = 1.5, 7.9 
Hz, Ar) ppm. Anal. (C16H21NO4) C, H, N. 
 
(6-bromo-2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-
[1,4]oxazinan]-4'-yl)acetic acid 35b.  
Compound 35b was obtained from 53b (0.03 g, 0.11 mmol) and chloroacetic 
acid (0.01 g, 0.11 mmol) following the same procedure described above for 
18a. compound 35b was obtained without further purification. 35b (0.005 g, 
0.07 mmol, yield 67%). 1H-NMR (CDCl3) δ : 1.33 (s, 3H, Me); 1.40 (s, 3H, 
Me); 2.14 (d, 1H, J = 14.5 Hz, CH2); 2.54 (d, 1H, J = 14.5 Hz, CH2); 2.70-3.00 
(m, 4H, CH2); 3.19-3.42 (m, 2H, CH2); 3.78-3.84 (m, 1H, CH2); 3.99-4.10 (m, 
1H, CH2); 6.71 (d, 1H, J = 8.8 Hz, Ar); 7.29 (dd, 1H, J = 2.4, 8.8 Hz, Ar); 7.64 
(d, 1H, J = 2.4 Hz, Ar) ppm. Anal. (C16H20BrNO4) C, H, N. 
 
(2,2-dimethyl-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-[1,3]oxazolidin]-
3'-yl)acetic acid 36a.  
Compound 36a was obtained from 55a (0.23 g, 0.56 mmol) following the same 
procedure descrided for 34a without further purification. 36a (0.04 g, 0.16 
mmol, yield 29%). mp 160-165˚C. 1H-NMR (DMSO) δ : 1.32 (s, 3H, Me); 1.36 
(s, 3H, Me); 2.27 (d, 1H, J = 14.8 Hz, CH2); 2.37 (d, 1H, J = 14.8 Hz, CH2); 
3.68 (d, 1H, J = 9.1 Hz, CH2); 3.87 (d, 1H, J = 9.1 Hz, CH2); 3.95 (d, 1H, J = 
17.7 Hz, CH2); 4.08 (d, 1H, J = 17.7 Hz, CH2); 6.8 (d, 1H, J = 8.7 Hz, Ar); 6.98  
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(m, 1H, Ar); 7.26 (m, 1H, Ar); 7.58 (d, 1H, J = 7.7 Hz, Ar) ppm. Anal. 
(C15H17NO5) C, H, N. 
 
(6-bromo-2,2-dimethyl-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-3'-yl)acetic acid 36b.  
Compound 36b was obtained from 55b (0.33 g, 0.67 mmol) following the same 
procedure descrided for 34a  without further purification. 36b (0.12 g, 0.35 
mmol, 53%yield). mp165-170°C 1H-NMR (DMSO) δ : 1.32 (s, 3H, Me); 1.36 
(s , 3H, Me) ; 2.27 (d , 1H , J = 15.0 Hz, CH2) ; 2.37 (d, 1H , J = 15.0 Hz, CH2); 
3.68 (d, 1H, J = 9.2 Hz, CH2); 3.88 (d, 1H, J = 9.2 Hz, CH2); 3.90 (d, 1H, J = 
18.1 Hz, CH2); 4.0 (d, 1H, J = 18.1 Hz, CH2); 6.79 (d, 1H, J = 8.7 Hz, Ar); 7.43 
(dd, 1H, J = 2.3, 8.7 Hz, Ar); 7.85 (d, 1H, J  = 2.3 Hz, Ar) ppm. Anal. 
(C15H16BrNO5) C, H, N. 
 
[2-(4-methoxyphenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-3'-yl]acetic acid 37a.  
Compound 37a was obtained from 64a (0.03 g, 0.07 mmol) following the same 
procedure descrided for 34a without further purification. 37a (0.006 g, 0.01 
mmol, yield 22%). 1H-NMR (CD3OD) δ : 1.68 (s, 3H, Me); 2.25 (d, 1H, J = 
12.6 Hz, CH2); 2.41 (d, 1H, J = 14.3 Hz, CH2); 2.83 (d, 1H, J = 14.3 Hz, CH2); 
2.96 (d, 1H, J = 12.6 Hz, CH2); 3.11-3.31 (m, 2H, CH2); 3.76 (s, 3H, OMe); 
6.817- 7.04 (m, 4H, Ar);7.263- 7.40 (m, 3H, Ar); 7,46- 7.51 (m, 1H, Ar) ppm. 
Anal. (C21H21NO6) C, H, N. 
 
[6-bromo-2-(4-methoxyphenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-
spiro[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetic acid 37b.  
Compound 37b was obtained from 64b (0.25 g, 0.51 mmol) following the same 
procedure descrided for 34a without further purification. 37b (0.1 g, 0.23 
mmol, 45%yield). mp78-80°C 1H-NMR (DMSO) δ :1.63 (s, 3H, Me); 2.69 (d, 
2H, J = 17 Hz, CH2); 3.30-3.40 (m, 2H); 3.73 (s, 3H, OMe); 3.86 (d, 1H, J = 
17.9 Hz, CH2); 4.00 (d, 1H, J = 17.9 Hz, CH2); 6.90 (d, 2H, J = 8.7 Hz, Ar); 
6.99- 7.06( m, 1H, Ar); 7.26- 7.38 (m, 2H, Ar); 7.5 (dd, 1H, J = 2.4; 8.7 Hz, 
Ar); 7.76 (d, 1H, J = 2.4 Hz, Ar) ppm. Anal. (C21H20BrNO6) C, H, N. 
 
[2-(4-chlorophenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-3'-yl]acetic acid 38a.  
Compound 38a was obtained from 65a (0.39 g, 0.95 mmol) following the same 
procedure descrided for 34a. The crude product was collected and purified by 
precipitation from EtOAC/Hex to yield 38a (0.2 g, 0.52 mmol, yield 55%): mp 
85-87°C. 1H-NMR (CDCl3) δ : 1.72 (s, 3H, Me); 2.58 (d, 1H, J = 14.5 Hz, 
CH2); 2.72 (d, 1H, J = 14.5 Hz, CH2); 3.26 (d, 1H, J = 8.8 Hz, CH2); 3.50 (d, 
1H, J = 8.8 Hz, CH2); 4.05 (s, 2H, CH2); 6.96-7.05 (m, 2H, Ar); 7.27-7.51 (m, 
6H, Ar) ppm. Anal. (C20H18ClNO5) C, H, N. 
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[6-bromo-2-(4-chlorophenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-
spiro[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetic acid 38b.  
Compound 38b was obtained from 65b (0.47 g, 0.95 mmol) following the same 
procedure descrided for 34a. The crude product was collected and purified by 
precipitation from EtOAC/Hex to yield 38b (0.27 g, 0.59 mmol, yield 62%): 
mp103-106°C. 1H-NMR (CDCl3) δ : 1.71 (s, 3H, Me); 2.56 (d, 1H, J = 14.5 Hz, 
CH2); 2.70 (d, 1H, J = 14.5 Hz, CH2); 3.18-3.52 (m, 2H, CH2); 3.95-4.17 (m, 
2H, CH2);  6.89-7.04 (m, 1H, Ar); 7.26-7.52 (m, 5H, Ar); 7.69 (d, 1H, J = 2.0 
Hz, Ar) ppm. Anal. (C20H17BrClNO5) C, H, N. 
 
2-(4-methoxyphenyl)-2-methyl-5'-oxo-2,3-dihydro-4'H-spiro[chromene-
4,2'-[1,4]oxazinan]-4'-yl)acetic acid 39a.  
Compound 39a was obtained from 68a (0.47 g, 1.10 mmol) following the same 
procedure descrided for 34a without further purification. 39a (0.09 g, 0.23 
mmol, yield 21%). mp175-178°C 1H-NMR (DMSO) δ : 1.63 (s, 1H, Me); 2.30 
(d, 1H, J = 12.6 Hz, CH2); 2.42 (d, 1H, J = 14.3 Hz, CH2); 2.92 (d, 1H, J = 14.3 
Hz, CH2); 3.25 (d, 1H, J = 17.2 Hz, CH2); 3.62 (d, 1H, J = 12.6 Hz, CH2); 3.71 
(s, 3H, OMe); 4.16 (d, 1H, J = 17.3 Hz, CH2); 4.22 (d, 1H, J = 17.2 Hz, CH2); 
4.35 (d, 1H, J = 17.2 Hz, CH2); 6.88 (d, 2H, J = 8.7 Hz, Ar); 6.94-7.04 (m, 2H, 
Ar); 7.26-7.42 (m, 4H, Ar) ppm. Anal. (C22H23NO6) C, H, N. 
 
[6-bromo-2-(4-methoxyphenyl)-2-methyl-5'-oxo-2,3-dihydro-4'H-
spiro[chromene-4,2'-[1,4]oxazinan]-4'-yl)acetic acid 39b.  
Compound 39b was obtained from 68b (0.2 g, 0.4 mmol) following the same 
procedure descrided above for 34a. The crude product was purified by 
crystallization from (iPr)2O  to give 39b (0.03 g, 0.07 mmol, yield 18%) 1H-
NMR (DMSO) δ : 1.64 (s, 1H, Me); 2.30-2.39 (m, 1H, CH2); 2.92 (d, 1H, J = 
14.6 Hz, CH2); 2.92 (d, 1H, J = 14.3 Hz, CH2); 3.25-3.38 (m, 2H, CH2); 3.54-
3.65 (m, 1H, CH2); 3.72 (s, 3H, OMe); 4.08-4.40 (m, 3H, CH2); 6.89 (d, 2H, J = 
8.8 Hz, Ar); 7.03 (d, 1H, J = 8.6 Hz, Ar); 7.29-7.35 (m, 2H, Ar); 7.45-7.50 (m, 
1H, Ar); 7.55 (d, 1H, J = 2.4 Hz, Ar) ppm. Anal. (C22H22BrNO6) C, H, N. 
[2-(4-methoxyphenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-3'-yl]acetic acid 40a.  
Compound 40a was obtained from 91a (0.03g, 0.07 mmol) following the same 
procedure descrided above for 34a.   40a (0.02 g, 0.05 mmol, yield 72%) 1H-
NMR (CDCl3) δ : 2.45-2.65 (m, 2H, CH2); 3.70-3.93 (m, 5H, CH2, OMe); 4.12 
(s, 2H, CH2); 4.98-5.04 (m, 1H, CH); 6.88-7.03 (m, 4H, Ar); 7.22--7.27 (m, 1H, 
Ar);  7.37 (d, 2H, J = 8.0 Hz, Ar); 7.46-7.49 (m, 1H, Ar) ppm. Anal. 
(C20H19NO6) C, H, N. 
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[6-bromo-2-(4-methoxyphenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-3'-yl]acetic acid 40b.  
Compound 40b was obtained from 91b (0.17 g, 0.37 mmol) following the same 
procedure descrided for 34a. 40b (0.1 g, 0.22 mmol, 60 %yield). 1H-NMR 
(CD3OD) δ : 2.30-2.60 (m, 2H, CH2); 3.81 (s, 3H, OMe); 3.90 (d, 1H, J = 9.5 
Hz, CH2); 3.99 (d, 1H, J = 9.5 Hz, CH2); 4.04 (d, 1H, J = 18 Hz, CH2); 4.14 (d, 
1H, J = 18 Hz, CH2); 5.15 (dd, 1H, J = 2.2, 11.7 Hz, CH); 6.82 (d, 1H, J = 8.8 
Hz, Ar); 6.96 (d, 2H, J = 8.8 Hz, Ar);  7.36-7.44 (m, 3H, Ar); 7.63 (d, 1H, J = 
2.4 Hz, Ar) ppm. Anal. (C20H18BrNO6) C, H, N. 
  
[2-(4-chlorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-3'-yl]acetic acid 41a.  
Compound 41a was obtained from 92a (0.05 g, 0.11 mmol) following the same 
procedure descrided for 34a. 41a (0.04 g, 0.10 mmol, 99 %yield). 1H-NMR 
(CD3OD) δ : 2.40-2.65 (m, 2H, CH2); 3.90-4.23 (m, 4H, CH2); 4.88 (s, 2H, 
CH2); 5.19-5.25 (m, 1H, CH); 6.89-7.08 (m, 2H, Ar); 7.24-7.33 (m, 1H, Ar);  
7.40-7.54 (m, 5H, Ar) ppm. Anal. (C19H16ClNO5) C, H, N. 
 
[6-bromo-2-(4-chlorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-3'-yl]acetic acid 41b  
Compound 41b was obtained from 92b (0.32 g, 0.68 mmol) following the same 
procedure described for 34a.The crude product was purified by trituration with 
Hexane to give 41b (0.1 g, 0.23 mmol, yield 34%): mp153-155 °C. 1H-NMR 
(CDCl3) δ : 2.45-2.52 (m, 2H, CH2); 3.79-3.92 (m, 2H, CH2); 4.11 (s, 2H, 
CH2); 4.98-5.08 (m, 1H, CH); 6.79 (d, 1H, J = 9.0 Hz, Ar); 6.89-7.05 (m, 1H, 
Ar);  7.30-7.49 (m, 4H, Ar); 7.59 (d, 1H, J = 2.2 Hz, Ar) ppm. Anal. 
(C19H15BrClNO5) C, H, N. 
  
[2-(2,4-dichlorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-3'-yl]acetic acid 42a  
Compound 42a was obtained from 93a (0.05 g, 0.11 mmol) following the same 
procedure descrided for 34a. The crude product was collected and purified by 
crystallization from iPrOH to yield 42a (0.008 g, 0.02 mmol, yield 19%). 
mp128-130 ˚C. 1H-NMR (CDCl3) δ : 2.17-2.37 (m, 1H, CH2); 2.62-2.71 (m, 
1H, CH2); 3.55-4.17 (m, 4H, CH2); 5.38-5.50 (m, 1H, CH); 6.93-7.10 (m, 1H, 
Ar); 7.24-7.74 (m, 5H, Ar) ppm. Anal. (C19H15Cl2NO5) C, H, N. 
 
[6-bromo-2-(2,4-dichlorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-3'-yl]acetic acid 42b  
Compound 42b was obtained from 93b (0.38 g, 0.73 mmol) following the same 
procedure descrided for 34a. The crude product was collected and purified by 
precipitation from EtOAC/Hex to yield 42b (0.16 g, 0.33 mmol, yield 36%). 
mp190-192 ˚C. 1H-NMR (DMSO) δ : 2.28- 2.41 (m, 1H, CH2); 2.58 (d, 1H, J = 
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13.2 Hz, CH2); 3.75-3.97 (m, 2H, CH2); 4.01 (d, 2H, J = 2.8 Hz, CH2); 5.58 (d, 
1H, J = 11.5 Hz, CH); 6.96 (dd, 1H, J = 1.1, 8.8 Hz, Ar); 7.47-7.77 (m, 5H, Ar) 
ppm. Anal. (C19H14BrCl2NO5) C, H, N. 
 
[6-bromo-2-(2,4-difluorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-3'-yl]acetic acid 43b.  
Compound 43b was obtained from 94b (0.09 g, 0.18 mmol) following the same 
procedure descrided for 34a. The crude product was collected and purified by 
trituration with Hexane to yield 43b (0.05 g, 0.11 mmol, 63% yield): mp118-
120 ˚C. 1H-NMR (CDCl3) δ : 2.39-2.58 (m, 2H, CH2); 3.84 (d, 1H, J  = 8.5 Hz, 
CH2); 3.91 (d, 1H, J  = 8.5 Hz, CH2); 4.16 (s, 2H, CH2); 5.31-5.37 (m, 1H, CH); 
6.81 (d, 1H, J  = 8.8 Hz, Ar); 6.86-7.01 (m, 2H, Ar); 7.37 (dd, 1H, J  = 8.8, 2.4 
Hz, Ar); 7.51-7.59 (m, 1H, Ar); 7.62 (d, 1H, J  = 2.4 Hz, Ar) ppm. Anal. 
(C19H14BrF2NO5) C, H, N. 
 
[6-bromo-2-(4-bromo-2-fluorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro 
[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetic acid 44b.  
Compound 44b was obtained from 95b (0.38 g, 0.7 mmol) following the same 
procedure descrided for 34a without further purification. 44b (g, 0.21mmol, 
30%yield). mp 178-180 ˚C. 1H-NMR (CDCl3) δ : 2.37-2.59 (m, 2H, CH2); 3.81 
(s, 2H, CH2); 3.87 (d, 1H, J = 4.1 Hz; CH2); 4.13 (d, 1H, J  = 4.1 Hz, CH2 ); 
5.33 (d, 1H, J = 10.6 Hz, CH); 6.82 (d, 1H, J  = 8.6 Hz, Ar); 7.26-7.53 (m, 4H, 
Ar); 7.61-7.62 (m, 1H, Ar) ppm. Anal. (C19H14Br2FNO5) C, H, N. 
 
(5-{2-[(4-methoxybenzyl)oxy]phenyl}-5-methyl-2-oxo-1,3-oxazolidin-3-
yl)acetic acid 45a 
Compound 45a was obtained from 114a (0.05 g, 0.12 mmol) following the 
same procedure descrided for 34a. The crude product was collected and 
purified by precipitation from EtOAc/Hex to yield 45a (0.02 g, 0.06 mmol, 
49% yield): mp117-119 ˚C. 1H-NMR (CDCl3) δ : 1.75 (s, 3H, Me); 3.67-3.79 
(m, 2H, CH2); 3.83 (s, 3H, OMe); 4.02-4.11 (m, 2H, CH2); 5.00 (s, 2H, CH2); 
6.91-7.02 (m, 4H, Ar); 7.24-7.32 (m, 3H, Ar); 7.58 (dd, 1H, J = 1.8, 8.1 Hz, 
Ar) ppm. Anal. (C20H21NO6) C, H, N. 
 
(5-{2-[(3,4-dimethoxybenzyl)oxy]phenyl}-5-methyl-2-oxo-1,3-oxazolidin-3-
yl)acetic acid 46a 
Compound 46a was obtained from 115a (0.05 g, 0.12 mmol) following the 
same procedure descrided for 34a without further purification. 46a (0.04 g, 0.11 
mmol, 90% yield): mp118-120 ˚C. 1H-NMR (CDCl3) δ : 1.79 (s, 3H, Me); 
3.65-3.90 (m, 8H, CH2, OMe); 4.03-4.17 (m, 2H, CH2); 4.94-5.08 (m, 2H, 
CH2); 6.83-7.04 (m, 5H, Ar); 7.26-7.33 (m, 1H, Ar); 7.59-7.63 (m, 1H, Ar) 
ppm. Anal. (C21H23NO7) C, H, N. 
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(5-{2-[(3,4,5-trimethoxybenzyl)oxy]phenyl}-5-methyl-2-oxo-1,3-oxazolidin-
3-yl)acetic acid 47a 
Compound 47a was obtained from 116a (0.54g, 1.18 mmol) following the same 
procedure descrided for 34a. The crude product was dissolved in EtOAc and 
washed with NaHCO3 and then exctracted with CH2Cl2. The organic layers 
were dried and concentrated under vacuum to give 47a (0.07 g, 0.15 mmol, 13 
% yield): 1H-NMR (CDCl3) δ : 1.83 (s, 3H, Me); 3.57-4.18 (m, 11H, CH2, 
OMe); 5.02(s, 2H, CH2); 6.61 (s, 2H, Ar); 6.95-7.05 (m, 2H, Ar); 7.26-7.34 (m, 
1H, Ar); 7.59-7.63 (m, 1H, Ar) ppm. Anal. (C22H25NO8) C, H, N. 
 
2,2-dimethyl-2,3-dihydro-4H-chromen-4-one 48a. 
To a solution of  2-hydroxy acetophenone (3.00 g, 22.00 mmol) in CH3CN (20 
mL) was added acetone (7.66 g, 132.00 mmoli) and pyrrolidine (3.72 g, 52.35 
mmol). The mixture was stirred at rt for 1h, then refluxed for 8 h. The solvent 
was removed under reduced pressure and the residue diluted with EtOAc and 
washed with HCl 1N, NaOH 1N and water. The organic layers were dried and 
evaporated The crude product was directly used in the next step without further 
purification. 48a (2.51 g, 14.3 mmol, yield 65%): 1H-NMR (CDCl3) δ : 1.46 (s, 
6H, Me); 2.72 (s, 2H, CH2); 6.95 (m, 2H, Ar); 7.46 (m, 1H, Ar); 7.85 (m, 1H, 
Ar).  MS (m/z): 177 (M+, 100%).  
 
6-bromo-2,2-dimethyl-2,3-dihydro-4H-chromen-4-one 48b.   
Compound 48b was obtained from 5-bromo-2-hydroxy acetophenone (3.00 g, 
13.95 mmol) following the procedure described for 48a. The crude product was 
directly used in the next step without further purification. 48b (2.88 g, 11.3 
mmol, yield 81%): 1H-NMR (CDCl3) δ : 1.45 (s, 6H, Me); 2.71 (s, 2H, CH2); 
6.82 (d,1H, J = 8.8 Hz, Ar);  7.53 (dd, 1H, J = 8.8; 2.5 Hz, Ar); 7.95 (d, 1H, J = 
2.5 Hz, Ar) ppm.  
 
3,4-dihydro-2,2-dimethyl-4-[(trimethylsilyl)oxy]-2H-1-benzopyran-4-
carbonitrile 49a. 
To a solution of 48a  (1.23 g, 7 mmol) in CH2Cl2 was added 
trimethylsilylcyanide (TMSCN) (1.4 mL, 10.5 mmol) and ZnI2 (0.33 g, 1.05 
mmol). The mixture was stirred at r.t. for 4 h, then CH2Cl2 was added and the 
solution was washed with water. The organic layer was dried and evaporated, to 
give 49a. (1.89 g, 6.86 mmol, yield 98%): 1H-NMR (CDCl3) δ: 0.27 (s, 9H, 
Me); 1.44 (s, 3H, Me); 1.48 (s, 3H, Me); 2.35 (d, 1H, J = 14 Hz, CH2); 2.47 (d, 
1H, J = 14 Hz, CH2); 6.82-6.86 (m, 1H, Ar); 6.97-7.05 (m, 1H, Ar); 7.24-7.32 
(m, 1H, Ar); 7.54-7.58 (m, 1H, Ar) ppm.  
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6-bromo-3,4-dihydro-2,2-dimethyl-4-[(trimethylsilyl)oxy]-2H-1-
benzopyran-4-carbonitrile 49b.  
Compound 49b (2.55 g, 10 mmol) was obtained from 48b following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 49b (3.26 g, 9.20 mmol, yield 92%): 1H-NMR 
(CDCl3) δ : 0.28 (s, 9H, Me); 1.41 (s, 3H, Me); 1.45 (s, 3H, Me); 3.28 (d, 1H, J 
= 14.1 Hz, CH2); 2.43 (d, 1H, J = 14.1 Hz, CH2); 6.71 (d, 1H, J = 8.8 Hz, Ar); 
7.35 (dd, 1H, J = 8.8; 2.4 Hz, Ar); 7.61 (d, 1H, J = 2.4 Hz, Ar). MS (m/z): 353 
(M+, 61%); 284 (M+- Si(CH3)3 100%).  
 
4-(aminomethyl)-2,2-dimethylchroman-4-ol  50a.  
A solution of 49a (1.38 g, 5.00 mmol) in THF was added dropwise at 0°C to a 
solution of LiAlH4 (1M in THF, 10 mmol) The reaction mixture was stirred at 
rt for 1h, then quenched with water and NaOH. The resulting lithium salts were 
filtered and the solution was evaporated to give 50a that was used without 
further purification (0.92 g, 4.40 mmol, yield 88%): 1H-NMR (CDCl3) δ: 1.36 
(s, 3H, Me); 1.42 (s, 3H, Me); 2.01 (s, 2H, CH2); 2.77 (d, 1H, J = 13 Hz, CH2); 
2.98 (d, 1H, J = 13 Hz, CH2); 6.80-6.84 (m, 1H, Ar); 6.88-6.96 (m, 1H, Ar); 
7.13-7.21 (m, 1H, Ar); 7.36-7.40 (m, 1H, Ar). MS (m/z): 207 (M+, 25%); 177 
(M+-CH2NH2, 100%).  
 
6-bromo-4-(aminomethyl)-2,2-dimethylchroman-4-ol 50b.  
A solution of 49b (1.77 g, 5.00 mmol) ) in THF was added dropwise at -10°C to 
a solution of LiAlH4 (1M in THF, 10 mmol) The reaction mixture was stirred at 
-10°C for 1h, then quenched with water and NaOH. The resulting lithium salts 
were filtered and the solution was evaporated to give 50b that was used without 
further purification (1.07 g, 3.75 mmol, yield 75%): 1H-NMR (CDCl3) δ: 1.35 
(s, 3H, Me); 1.42 (s, 3H, Me); 1.98 (s, 2H, CH2); 2.78 (d, 1H, J = 12.8 Hz,  
CH2); 2.96 (d, 1H, J = 12.8 Hz, CH2); 6.71 (d, 1H, J = 8.8 Hz, Ar); 7.26 (dd, 
1H, J = 8.8; 2.4 Hz, Ar); 7.53 (d, 1H, J = 2.4 Hz, Ar). MS (m/z): 286 (M+, 
16%); 255 (M+- CH2NH2, 100%).  
 
2-chloro-N-[(4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-
yl)methyl] acetamide 51a.  
A solution of NaOH (0.19 g, 4.75 mmol) in H2O (8,5 mL) was added to a 
solution of  50a (0.83 g, 4.00 mmol) in CH2Cl2 (12 mL). The mixture was 
stirred, cooled to 0° C and treated dropwise with chloroacetyl chloride (0.73 g, 
6.5 mmol). At the end of the addiction, the mixture was stirred vigorously at r.t. 
for 1 h. The layers were separated and the CH2Cl2 solution was washed with 
diluted HCl and H2O, dried and evaporated to give 51a (0.88 g, 3.13 mmol, 
yield 66%): 1H-NMR (CDCl3) δ: 1.36 (s, 3H, Me); 1.42 (s, 3H, Me); 2.02 (s, 
2H, CH2); 3.56 (dd, 1H, J = 13.7; 7.2 Hz, CH2); 3.73 (dd, 1H, J = 13.7; 5 Hz, 
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CH2); 4.08 (s, 2H, CH2); 6.82-6.87 (m, 1H, Ar); 6.92-7.0 (m, 1H, Ar); 7.18-7.25 
(m, 1H, Ar); 7.41-7.46 (m, 1H, Ar).  
 
N-[(6-bromo-4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-
yl)methyl]-2-chloroacetamide 51b.  
Compound 51b was obtained from 50b ((1.68 g, 5.87 mmol)  and chloroacetyl 
chloride (1.07 g, 9.5 mmol).following the procedure described for 50a.The 
crude product was directly used in the next step without further purification. 
51b (1.36g, 3.76 mmol, yield 64%): 1H-NMR (CDCl3) δ: 1.34 (s, 3H, Me); 1.42 
(s, 3H, Me); 1.95 (d, 1H, J = 14.6 Hz, CH2); 2.04 (d, 1H, J = 14.6 Hz, CH2); 
3.52 (dd, 1H, J = 13.9; 7.1 Hz, CH2); 3.70 (dd, 1H, J = 13.9; 5.1 Hz, CH2); 4.11 
(s, 2H, CH2); 6.74 (d, 1H, J = 8.8 Hz, Ar); 7.30 (dd, 1H, J =  8.8; 2.4 Hz, Ar); 
7.57 (d, 1H, J = 2.4 Hz, Ar).  
 
2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-4,2'-[1,4]oxazinan]-5'-one 
52a. tert-BuOK (1.45 g, 13 mmol) was added portionwise over 1 h to a stirred 
solution of 51a (2.5 mmol) in toluene (20 mL). The reaction mixture was stirred 
at rt for 2 h, then the solvent was evaporated. The residue was diluted with 
EtOAc and the organic layer washed with water, dried and evaporated to give 
corresponding compounds 52a (0.45 g, 1.80 mmol, yield 72%): 1H-NMR 
(CDCl3) δ: 1.40 (s, 3H, Me); 1.43 (s, 3H, Me); 2.04 (d, 1H, J = 14.6 Hz, CH2); 
2.42 (d, 1H, J = 14.6 Hz, CH2); 3.25 (dd, 1H, J = 12.4; 4.3 Hz, CH2); 3.93 (d, 
1H, J = 12.4 Hz, CH2); 4.22 (d, 1H, J = 17.5 Hz, CH2); 4.34 (d, 1H, J = 17.5 
Hz,); 6.84-6.99 (m, 2H, Ar); 7.21-7.29 (m, 1H, Ar); 7.45 (dd, 1H, J = 7.86; 1.47 
Hz, Ar). MS (m/z): 248 (M+, 20%).  
 
6-bromo-2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinan]-5'-one 52b.  
Compound 52b was obtained from 51b (0.75 g, 2.07 mmol) following the 
procedure described for 52a.The crude product was directly used in the next 
step without further purification. 52b (0.54 g, 1.65 mmol, yield 80%):  1H-
NMR (CDCl3) δ: 1.38 (s, 3H, Me); 1.41 (s, 3H, Me); 2.03 (d, 1H, J = 14.6 Hz, 
CH2); 2.41 (d, 1H, J = 14.6 Hz, CH2); 3.23 (dd, 1H, J = 12.4; 4.5 Hz, CH2); 
3.88 (d, 1H, J = 12.4 Hz, CH2); 4.23 (d, 1H, J = 17.7 Hz, CH2); 4.36 (d, 1H, J = 
17.7 Hz, CH2); 6.75 (d, 1H, J = 8.8 Hz, Ar); 7.33 (dd, 1H, J = 8.8; 2.4 Hz, Ar);  
7.57 (d, 1H, J = 2.4 Hz, Ar). MS (m/z) : 327 (M+, 48%).  
 
2,2-dimethyl-2,3-dihydrospiro[chromene-4,22-[1,4]oxazinane] 53a.  
A solution of 52a  (0.7 g, 2.83 mmol)) in THF (3 mL) was added to a solution 
of LiAlH4 (1 M in THF, 8.30 mmol) cooled at 0 °C. The mixture was refluxed 
for 1 h, then water  and NaOH 1 M was added, and the resulting suspension was 
filtered. The solvent was evaporated, and the crude product was used without 
further purification.53a (0.35 g, 1.5 mmol, 53% yield): 1H-NMR (CDCl3) δ : 
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1.37 (s, 3H, Me); 1.41 (s, 3H, Me); 2.11 (d, 1H, J  = 14.7 Hz, CH2); 2.58 (d, 
1H, J  = 14.7 Hz, CH2); 2.78 (d, 1H, J  =12.2 Hz, CH2); 2.86-3.12 (m, 2H 
CH2); 3.23 (d, 1H, J  = 12.2 Hz, CH2); 3.65-3.73 (m, 1H, CH2); 3.85-3.98 (m, 
1H, CH2); 6.82 (d, 1H, J = 8.1 Hz, Ar); 6.90-6.98 (m, 1H, Ar); 7.15-7.23 (m, 
1H, Ar); 7.57 (dd, 1H, J  = 1.7, 7.8 Hz, Ar).  
 
6-bromo-2,2-dimethyl-2,3-dihydrospiro[chromene-4,22-[1,4]oxazinane] 
53b.  
A solution of 52b (0.22 g, 0.67 mmol) in THF (3 mL) was added to a solution 
of BH3 ·SMe2 (2 M in THF 2.70 mmol). The resulting mixture was heated for 
30 min by microwave irradiation at 100 °C and with a power of 150 W, and 
then water was added and the solvent evaporated. The aqueous phase was 
acidified with HCl 1 N, neutralized with NaOH 1 N and extracted with EtOAc. 
The organic layer was dried, and the solvent was evaporated. The crude product 
was transformed into the hydrochloride salt to give 53b (0.54 g, 1.55 mmol, 
88% yield): 1H-NMR (CDCl3) δ: 1.37 (s, 3H, Me); 1.45 (s, 3H, Me); 2.45 (d, 
1H, J  =14.7 Hz, CH2); 2.63 (d, 1H, J  = 14.7 Hz, CH2); 3.20-3.42 (m, 4H, 
CH2); 3.92 (d, 1H, J  = 13.2 Hz, CH2); 4.16-4.30 (m, 1H, CH2); 6.74 (d, 1H, J 
=  8.6 Hz, Ar); 7.34 (dd, 1H, J  = 2.3, 8.6 Hz, Ar); 7.51 (d, 1H, J  = 2.3 Hz, 
Ar).  
 
2,2-dimethyl-4'-(4-nitrobenzyl)-2,3-dihydro-5'H-spiro[chromene-4,2'-[1,4]- 
oxazinan]-5'-one 54a. 
Compound 54a was synthesised from 52a (0. 62 g, 2.5 mmol). and 4-
nitrobenzyl bromide (0.65 g, 3 mmol) following the procedure described for 
15a. The crude product was purified by chromatography eluting with 
Hexane/EtOAc (1:1) 54a (0.39 g, 1.03 mmol, yield 41%): 1H-NMR (CDCl3) δ: 
1.24 (s, 3H, Me); 1.33 (s, 3H, Me); 1.74 (d, 1H, J = 14.6 Hz, CH2); 2.31 (d, 1H, 
J = 14.6 Hz, CH2); 3.06 (d, 1H, J = 12.4 Hz, CH2); 3.83 (d, 1H, J = 12.4 Hz, 
CH2); 4.31 (d, 1H, J = 11 Hz, CH2); 4.40 (d, 1H, J = 11 Hz, CH2); 4.53 (d, 1H, 
J = 14.8 Hz, CH2); 4.90 (d, 1H, J = 14.8 Hz, CH2); 6.78-6.95 (m, 2H, Ar); 7.16-
7.24 (m, 1H, Ar); 7.31-7.36 (m, 1H, Ar); 7.47 (d, 2H, J = 8.8 Hz, Ar); 8.20 (d, 
2H, J = 8.8 Hz, Ar). MS (m/z): 382 (M+, 60%). Anal. (C21H22N2O5) C, H, N. 
 
6-bromo-2,2-dimethyl-4'-(4-nitrobenzyl)-2,3-dihydro-5'H-spiro[chromene-
4,2'-[1,4]oxazinan]-5'-one 54b.  
Compound 54b was synthesised from 49b (0.8 g, 2.44 mmol) following the 
same procedure described above for the preparation of 15a. The crude product 
was purified by chromatography eluting with Hexane/EtOAc (1:1) to give 54b 
(0.6 g, 1.32 mmol, yield 54%): 1H-NMR (CDCl3) δ: 1.22 (s, 3H, Me); 1.31 (s, 
3H, Me); 1.71 (d, 1H, J = 14.6 Hz,); 2.28 (d, 1H, J = 14.6 Hz, CH2); 3.06 (d, 
1H, J = 12.4 Hz, CH2); 3.77 (d, 1H, J = 12.4 Hz, CH2); 4.26 (d, 1H, J = 17.7 H 
CH2); 4.40 (d, 1H, J = 17.7 Hz, CH2); 4.60 (d, 1H, J = 14.6 Hz, CH2); 4.81 (d, 
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1H, J = 14.6 Hz, CH2); 6.69 (d, 1H, J = 8.8 Hz, Ar); 7.28 (dd, 1H, J = 8.8; 2.4 
Hz, Ar); 7.42 (d, 1H, J = 2.4 Hz, Ar); 7.48 (d, 2H, J = 8.8 Hz, Ar); 8.2 (d, 2H, J 
= 8.8 Hz, Ar). MS (m/z) : 462 (M+, 18%). Anal. (C21H21BrN2O5) C, H, N. 
 
4'-(4-aminobenzyl)-2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-4,2'-
[1,4]oxazinan]-5'-one 5a: To a solution of compound 54a (1.5 g, 4 mmol) in 
MeOH (50 mL) was added carbon (0.216 g) and FeCl3. The reaction mixture 
was warmed to 60 °C, then hydrazine monohydrate was added dropwise (3.22 
mL, 66 mmol). The mixture was refluxed overnight then filtered on a celite pad. 
Methanol was concentrated, the residue diluted with CHCl3, dried over Na2SO4 
and evaporated to give 5a (1.19 g, 3.4 mmol, 85%).1H-NMR (CDCl3) δ: 1.14 
(s, 3H); 1.31 (s, 3H); 1.71 (d, 1H, J = 14.6 Hz); 2.22 (d, 1H, J = 14.6 Hz); 3.06 
(d, 1H, J = 12.6 Hz); 3.74 (d, 1H, J = 12.6 Hz); 4.11 (d, 1H, J = 14 Hz); 4.25 (d, 
1H, J = 17.5 Hz); 4.35 (d, 1H, J = 17.5 Hz); 4.90 (d, 1H, J = 14 Hz); 6.63 (d, 
2H, J = 8.4 Hz); 6.77-6.95 (m, 2H); 7.07 (d, 2H, J = 8.4 Hz); 7.16-7.21 (m, 
1H); 7.34-7.38 (m, 1H). MS (m/z): 352 (M+, 29%). Anal. (C21H24N2O3) C, H, 
N. 
 
4'-(4-aminobenzyl)-6-bromo-2,2-dimethyl-2,3-dihydro-5'H-
spiro[chromene-4,2'-[1,4]oxazinan]-5'-one 5b: Compound 5b was 
synthesized from 54b (0.14 g, 0.3 mmol) following the same procedure 
described above for the preparation of 5a. 5b (yield 87%, 0.11 g, 0.26 mmol): 
1H-NMR (DMSO) δ: 1.10 (s, 3H); 1.23 (s, 3H); 1.64 (d, 1H, J = 14.6 Hz); 2.30 
(d, 1H, J = 14.6 Hz); 3.03 (d, 1H, J = 12.6 Hz); 3.78 (d, 1H, J = 12.8 Hz); 4.08 
(d, 1H, J = 14 Hz); 4.22 (s, 2H); 4.63 (d, 1H, J = 14 Hz); 6.52 (d, 2H, J = 8.2 
Hz); 6.80-6.87 (m, 1H); 6.95 (d, 2H, J = 8 Hz); 7.36 (dd, 1H, J = 8.4; 2,4 Hz); 
7.57 (d, 1H, J = 2.4 Hz). MS (m/z): 432 (M+, 15%). Anal. (C21H23BrN2O3) C, 
H, N. 
 
4'-(N-(4-acetamidobenzyl))-2,2-dimethyl-2,3-dihydro-5'H-spiro[chromene-
4,2'-[1,4]oxazinan]-5'-one 1a: Compound 1a was obtained from 5a (0.18 g, 
0.514 mmol) in acetone (5 mL) and K2CO3 ( 0.106 g, 0.76 mmol) and acetic 
anhydride (0.04 mL, 0.514 mmol) following the same procedure described 
above for 31a. The crude product was purified by tritration with Et2O to yield 
1a (0.17 g, 0.45 mmol, 88%)  mp: 85-88 °C; 1H-NMR (CDCl3) δ: 1.18 (s, 3H); 
1.32 (s, 3H); 1.73 (d, 1H, J = 14.6 Hz); 2.17 (s, 3H, COCH3); 2.26 (d, 1H, J = 
14.6 Hz); 3.06 (d, 1H, J = 12.6 Hz); 3.78 (d, 1H, J = 12.6 Hz); 4.23-4.44 (m, 
3H); 4.88 (d, 1H, J = 14.2 Hz); 6.78-6.94 (m, 2H); 7.16-7.26 (m, 3H); 7.33-7.37 
(m, 1H); 7.48 (d, 2H, J = 8.42 Hz). 13C-NMR (CDCl3) δ : 168.50; 154.86; 
136.47; 130.42; 130.18; 127.42; 120.92; 120.21; 118.39;  74.26; 69.22; 65.64; 
63.78; 55.62; 45.10; 40.60; 39.60; 29.22; 28.10. MS (m/z): 394 (M+, 32%). 
Anal. (C23H26N2O4) C, H, N. 
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4'-(N-(4-methansolfonamido)benzyl)-6-bromo-2,2-dimethyl-2,3-dihydro-
5'H-spiro[chromene-4,2'-[1,4]oxazinan]-5'-one 2b: Compound 2b was 
obtained from 5b (0.5 g, 1.15 mmol) and methanesulfonyl chloride (0.115 mL, 
1.5 mmol) following the same procedure described for 32a. The crude product 
was purified by was purified by cromathography eluting with Hexane/EtOAc 
(3:7) to give 2b (0.275 g , 0.54 mmol, 47%).: mp.: 68-70°C; 1H-NMR (DMSO) 
δ: 1.13 (s, 3H); 1.24 (s, 3H); 1.68 (d, 1H, J = 14.6 Hz); 2.35 (d, 1H, J = 14.6 
Hz); 2.96 (s, 3H); 3.09 (d, 1H, J = 12.8 Hz); 3.90 (d, 1H, J = 12.8 Hz); 4.25 (s, 
2H); 4.32 (d, 1H, J = 14.6 Hz); 4.67 (d, 1H, J = 14.6 Hz); 6.74 (d, 1H, J = 8.8 
Hz); 7.17 (d, 2H, J = 8.4 Hz); 7.29 (d, 2H, J = 8.4 Hz); 7.36 (dd, 1H, J = 8.8; 
2.4 Hz); 7.59 (d, 1H, J = 2.4 Hz). 13C-NMR (CDCl3) δ: 218.54; 205.47; 165.94; 
152.30; 136.28; 132.67; 132.33; 129.63; 129.45; 123.20; 120.35; 119.62; 
112.22; 74.19; 68.45; 63.03; 54.92; 48.82; 39.92; 28.41; 25.44. MS (m/z): 510 
(M+, 35%). Anal. (C22H25BrN2O5S) C, H, N. 
 
ethyl(2,2-dimethyl-5'-oxo-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4] 
oxazinan] -4'-yl) acetate 55a. 
Compound 55a was obtained from 52a (0.6 g, 2.42 mmol) and ethyl 
bromoacetate (0.48 g, 2.90 mmol) following the same procedure described for 
15a. The crude product was used for the next step without further purification. 
55a (0.26 g, 0.77 mmol, yield 32%): 1H-NMR (CDCl3) δ : 1.21- 1.41 (m, 9H, 
Me); 2.21 (d, 1H, J = 14.7 Hz, CH2); 2.42 (d, 1H, J = 14.7 Hz, CH2); 3.22 (d, 
1H, J = 12.08 Hz, CH2); 3.93- 4.41 (m, 7H); 6.84 (dd, 1H, J = 1.1; 8.2 Hz, Ar); 
6.90- 6.98 (m, 1H, Ar); 7.19- 7.28 (m, 1H, Ar); 7.49 (dd, 1H, J = 1.6; 7.8 Hz, 
Ar) ppm.  
 
ethyl(6-bromo-2,2-dimethyl-5'-oxo-2,3-dihydro-4'H-spiro[chromene-4,2'-
[1,4] oxazinan]-4'-yl)acetate 55b. 
Compound 55b was obtained from 52b (0.33 g, 1.00 mmol) and ethyl 
bromoacetate (0.20 g, 1.20 mmol) following the same procedure described for 
15a. The crude product was used for the next step without further purification. 
55b (0.18 g, 0.44 mmol, yield 44%) 1H-NMR (CDCl3) δ : 1.20- 1.41 (m, 9H, 
Me); 2.20-2.45 (m, 2H CH2); 3.20 (d, 1H, J = 12.2 Hz, CH2); 3.90- 4.44 (m, 7H 
CH2); 6.73 (d, 1H, J = 8.6 Hz, Ar); 7.32 (dd, 1H, J = 2.4, 8.8 Hz, Ar); 7.61 (d, 
1H, J = 2.6 Hz, Ar) ppm.  
 
ethyl(2,2-dimethyl-2,3-dihydro-4'H-spiro[chromene-4,2'-[1,4]oxazinan]-4'-
yl)acetate 56a. 
Compound 56a was obtained from 53a (0.45 g, 1.92 mmol) and ethyl 
bromoacetate (0.32 g, 1.92 mmol) following the same procedure described for 
18a. The crude product was used for the next step without further purification.  
56a (0.55 g, 1.90 mmol, yield 99%): 1H-NMR (CDCl3) δ : 1.22- 1.33 (m, 3H, 
Me); 1.36 (s, 3H, Me); 1.41 (s, 3H, Me); 2.28 (d, 1H, J = 14.8 Hz, CH2); 2.56 
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(d, 1H, J = 14.8 Hz, CH2); 2.65-2.90 (m, 2H, CH2); 3.19 (d, 1H, J = 16.7 Hz, 
CH2); 3.37 (d, 1H, J = 16.7 Hz, CH2); 3.73-3.82 (m, 3H, CH2); 4.01-4.28 (m, 
3H, CH2); 6.78-6.96 (m, 2H, Ar); 7.14-7.23 (m, 1H, Ar); 7.56 (dd, 1H, J =  1.5, 
7.8 Hz, Ar) ppm.  
 
2,2-dimethyl-2,3-dihydro-2'H-spiro[chromene-4,5'-[1,3]oxazolidin]-2'-one 
57a. 
A solution of 50a (1.31 g, 6.33 mmol) in THF was added dropwise to a solution 
of N-N’-carbonyl diimidazole (CDI) (1.02 g, 6.33 mmol) in THF at 0 ˚C. The 
reaction mixtures were stirred rt for 5h. The solvent was evaporated under 
vacuum and the residue diluted with EtOAc and washed with HCl 1N and 
K2CO3sat. The organic layers were dried and concentrated under vacuum. The 
crude product was directly used for the next reaction without further 
purification. 57a (1.6 g, 4.93 mmol, yield 78%): 1H-NMR (CDCl3) δ : 1.42 (s, 
6H, Me); 2.17 (d, 1H, J = 14.6 Hz, CH2); 2.46 (d, 1H, J = 14.6 Hz, CH2); 3.63 
(d, 1H, J = 8.8 Hz, CH2); 3.89 (d, 1H, J = 8.9 Hz, CH2); 6.83 (d, 1H, J = 8.2 Hz, 
Ar); 6.93-7.01 (m, 1H, Ar); 7.22-7.29 (m, 1H, Ar); 7.49 (dd, 1H, J = 1.3, 7.8 
Hz, Ar) ppm. 
 
6-bromo-2,2-dimethyl-2,3-dihydro-2'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-2'-one 57b. 
Compound 57b was obtained from 50b (1.81 g, 6.33 mmol) following the 
procedure described for 57a.The crude product was was directly used for the 
next reaction without further purification. 57b (2.15 g, 5.31 mmol, yield 84%): 
1H-NMR (CDCl3) δ : 1.41 (s, 6H, Me); 2.14 (d, 1H, J =14.6 Hz, CH2); 2.42 (d, 
1H, J =14.6 Hz, CH2); 3.64 (d, 1H, J = 9.0 Hz, CH2); 3.86 (d, 1H, J  = 8.9 Hz, 
CH2); 6.72 (d, 1H, J =8.8 Hz, Ar); 7.33 (dd, 1H, J =8.8, 2.4 Hz, Ar); 7.58 
(d,1H, J =2.4 Hz, Ar) ppm. 
 
ethyl(2,2-dimethyl-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-[1,3] 
oxazolidin]-3'-yl)acetate 58a. 
Compound 58a was obtained from 57a (0.44 g, 1.37 mmol) and ethyl 
bromoacetate (0.23g, 1.37 mmol) following the same procedure described for 
15a. The crude product was directly used for the next reaction without further 
purification. 58a (0.23 g, 0.56 mmol, yield 41%): 1H-NMR ( CDCl3 ) δ : 1.33 
(t, 3H, J =7.1 Hz, Me); 1.42 (s, 6H, Me); 2.17 (d, 1H, J =14.6  Hz, CH2); 2.46 
(d, 1H, J =14.6 Hz, CH2);  3.64 (d, 1H, J =8.4 Hz, CH2); 3.98 (d, 1H, J =8.4 Hz, 
CH2); 4.02 (d, 1H, J =18.0 Hz, CH2); 4.20 (d, 1H, J =18.0 Hz, CH2); 4.25 (q, 
2H, J =7.1 Hz, CH2); 6.82 (d, 1H, J =8.2 Hz, Ar); 6.94-7.02 (m, 1H, Ar); 7.20-
7.29 (m, 1H, Ar); 7.58 (dd, 1H, J =1.6, 7.8 Hz, Ar) ppm. 
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ethyl(6-bromo-2,2-dimethyl-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3] oxazolidin]-3'-yl)acetate 58b. 
Compound 58b was obtained from 57b (0.55 g, 1.37 mmol) and ethyl 
bromoacetate (0.23g, 1.37 mmol) following the same procedure described for 
15a. The crude product was directly used for the next reaction without further 
purification. 58b (0.33 g, 0.67 mmol, yield 49%): 1H-NMR ( CDCl3 ) δ : 1.32 
(t, 3H, J = 7.1 Hz, Me); 1.41 (s, 6H, Me); 2.16 (d, 1H, J = 14.7 Hz, CH2); 2.45 
(d, 1H, J = 14.7 Hz, CH2); 3.67 (d, 1H , J = 8.7 Hz, CH2); 3.93 (d, 1H, J = 8.7 
Hz, CH2); 4.01-4.33 (m, 4H, CH2); 6.7 (d, 1H, J = 8.7 Hz, Ar); 7.33 (dd , 1H, J 
= 2.4, 8.7 Hz, Ar); 7.68 (d, 1H, J = 2.38 Hz, Ar) ppm. 
 
2-(4-methoxyphenyl)-2-methyl-2,3-dihydro-4H-chromen-4-one 59a. 
To a solution of  2-hydroxy acetophenone ( 1.00 g, 7.35 mmol) in CH3CN (10 
mL) was added  4-methoxy-acetophenone (1.1 g, 7.35 mmoli) and pirrolidine 
(0.49 g; 7.35 mmoli). The mixture was stirred at rt for 1h, then refluxed for 48 
h. The solvent was removed under reduced pressure and the residue diluted 
with EtOAc and washed with HCl 1N, NaOH 1N and water. The organic layers 
were dried and evaporated. The crude product was purified by flash column 
chromatography eluted with Hex/EtOAc 7/3 to give 59a (0.37 g, 1.4 mmol, 
yield 19%)  
1H-NMR (CDCl3) δ : 1.74 (s, 3H, Me ); 3.08 (d, 1H, J  = 16.4 Hz, CH2); 3.31 
(d, 1H, J = 16.4 Hz, CH2); 3,74 (s, OMe); 6.8 (d, 2H, J = 8.7 Hz, Ar); 6.88 - 
6.95(m, 1H, Ar); 7.03 (d, 1H, J = 8.2 Hz, Ar) 7.32 (d, 2H, J = 8.7 Hz, Ar); 7.41-
7.49 (m, 1H, Ar); 7.76 (dd, 1H, J = 1.6, 7.7 Hz, Ar) ppm. 
 
6-bromo-2-(4-methoxyphenyl)-2-methyl-2,3-dihydro-4H-chromen-4-one 
59b. 
Compound 59b was obtained from 5-bromo-2-hydroxy acetophenone (1.58 g, 
7.35 mmol) and 4-methoxy-acetophenone (1.1 g, 7.35 mmoli) following the 
procedure described for 59a. The crude product was purified by flash column 
chromatography eluted with Hex/EtOAc 7/3 to give 59b (0.56 g, 1.62 mmol, 
yield 22%): 1H-NMR (CDCl3) δ : 1.74 (s, 3H, Me); 3.04 (d, 1H, J = 16.5 Hz, 
CH2); 3.3 (d, 1H, J = 16.5 Hz, CH2); 3.75 (s, OMe); 6.81 (d, 2H, J = 8.8 Hz, 
Ar); 6.92 (d, 1H, J = 8.8 Hz,; Ar); 7.3 (d, 2H, J = 8.8 Hz, Ar); 7.51 (dd, 1H, J = 
2.6; 8.8 Hz, Ar); 7.85 (d, 1H, J = 2.6 Hz, Ar) ppm. 
 
2-(4-chlorophenyl)-2-methyl-2,3-dihydro-4H-chromen-4-one 60a. 
Compound 60a was obtained from 2-hydroxy acetophenone (5.00 g, 36.72 
mmol)  and 4-chloro-acetophenone (5.68 g, 36.72 mmol) following the 
procedure described for 59a. The crude product was purified by flash column 
chromatography eluted with Hex/EtOAc (95:5) to give 60a (4.00 g, 14.66 
mmol, yield 40%): mp 82-85°C. 1H-NMR (CDCl3) δ : 1.74 (s, 3H, Me); 3.08 
(d, 1H, J = 16.5 Hz, CH2); 3.27 (d, 1H, J = 16.5 Hz, CH2); 6.91-6.99 (m, 1H, 
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Ar); 7.05 (d, 1H, J = 8.2 Hz, Ar); 7.26 (d, 2H, J = 8.8 Hz, Ar); 7.35 (d, 2H, J = 
8.8 Hz, Ar); 7.44-7.52 (m, 1H, Ar); 7.76 (dd, 1H, J = 1.6, 7.9 Hz, Ar) ppm. 
 
6-bromo-2-(4-chlorophenyl)-2-methyl-2,3-dihydro-4H-chromen-4-one 60b. 
Compound 60b was obtained from 5-bromo-2-hydroxy acetophenone (7.89 g, 
36.72 mmol) and 4-chloro-acetophenone (5.68 g, 36.72 mmol)  following the 
procedure described for 59a. The crude product was used for the next step 
without further purification. 60b ( 5.81 g, 16.52 mmol, yield 45 %): mp 90-
92°C. 1H-NMR (CDCl3) δ : 1.74 (s, 3H, Me); 3.07 (d, 1H, J = 16.6 Hz, CH2); 
3.28 (d, 1H, J = 16.6 Hz, CH2); 6.95 (d, 1H, J = 8.8 Hz, Ar); 7.24-7.34 (m, 4H, 
Ar); 7.54 (dd, 1H, J = 2.6, 8.8 Hz, Ar); 7.86 (d, 1H, J = 2.6 Hz, Ar) ppm. 
 
4-[(trimethylsilyl)oxy]-2-(4-methoxyphenyl)-2-methyl-3,4-dihydro-2H-
chromene-4-carbonitrile 61a. 
Compound 61a was obtained from 59a (0.9 g, 3.35 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 61a (0.97 g, 2.65 mmol, yield 79%): 1H-NMR 
(CDCl3) δ : 0.27 (s, 9H, Me);  1.71 (s, 3H, Me); 2.56 (d, 1H, J = 14.3 Hz, CH2); 
2.79 (d, 1H, J = 14.3 Hz, CH2); 3.78 (s, OMe); 6.87 (d, 2H, J = 8.7 Hz, Ar); 
6.97 - 7.04 (m, 2H, Ar); 7.25 - 7.36 (m, 3H, Ar); 7.52 (dd, 1H, J = 1.8, 8.0 Hz, 
Ar) ppm. 
 
6-bromo-4-[(trimethylsilyl)oxy]-2-(4-methoxyphenyl)-2-methyl-3,4-
dihydro-2H-chromene-4-carbonitrile 61b.  
Compound 61b was obtained from 59b (1.1 g, 3.35 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 61b (1.34 g, 3.01 mmol, yield 90%): 1H-NMR 
(CDCl3) δ : 0.28 ( m, 9H, Me); 1.70 ( s, 3H, Me); 2.53 ( d, 1H, J = 14.1 Hz, 
CH2); 2.81 ( d, 1H, J = 14.1 Hz, CH2); 3.79 ( s, OMe); 6.852- 6.93 ( m, 3H, Ar); 
7.252-7.30 ( m, 3H, Ar ); 7.38- 7.44 ( m, 1H, Ar); 7.58- 7.59 ( m, 1H, Ar) ppm.  
 
4-[(trimethylsilyl)oxy]-2-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-
chromene -4-carbonitrile 62a. 
Compound 62a was obtained from 60a (0.53 g, 1.95 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 62a (0.27g, 0.72 mmol, yield 37 %): 1H-NMR 
(CDCl3) δ : 0.28 (s, 9H, Me); 1.72 (s, 3H, Me); 2.61 (d, 1H, J = 14.1 Hz, CH2); 
2.77 (d, 1H, J = 14.1 Hz, CH2); 6.99-7.07 (m, 2H, Ar); 7.27-7.39 (m, 5H, Ar); 
7.52 (dd, 1H, J = 1.6, 8.1 Hz, Ar) ppm. 
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6-bromo-4-[(trimethylsilyl)oxy] -2-(4-chlorophenyl)-2-methyl-3,4-dihydro-
2H-chromene-4-carbonitrile 62b.  
Compound 62b was obtained from 60b (0.68 g, 1.95 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification.62b (0.74 g, 1.64 mmol, yield 84 %) mp 81-
84°C: 1H-NMR (CDCl3) δ :  0.30 (s, 9H, Me); 1.70(s, 3H, Me); 2.55 (d, 1H, J = 
14.3 Hz, CH2); 2.78 (d, 1H, J = 14.3 Hz, CH2); 6.92 (d, 1H, J = 8.8 Hz, Ar); 
7.28-7.36 (m, 4H, Ar); 7.42 (dd, 1H, J = 2.1, 8.8 Hz, Ar); 7.59 (d, 1H, J = 2.1 
Hz, Ar) ppm. 
 
4-(aminomethyl)-2-(4-methoxyphenyl)-2-methyl-3,4-dihydro-2H-chromen-
4-ol 63a.  
Compound 63a was obtained from 61a (0.97 g, 2.65 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 63a (0.75 g, 2.5 mmol, yield 94% ): 1H-NMR 
(CDCl3) δ : 1.68 (s, 3H, Me); 2.10 (d, 1H, J = 13.3 Hz, CH2); 2.24 (d, 1H, J = 
14.1 Hz, CH2); 2.49 (d, 1H, J = 13.3 Hz, CH2); 2.56 (d, 1H, J = 14.1 Hz, CH2); 
3.78 (s, OMe); 6.81 - 7.03 (m, 4H, Ar); 7.19 - 7.41 (m, 4H, Ar) ppm. 
 
4-(aminomethyl)-6-bromo-2-(4-methoxyphenyl)-2-methyl-3,4-dihydro-2H-
chromen-4-ol 63b. 
Compound 63b was obtained from 61b (1.34 g, 3.01 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 63b (0.85 g, 2.26 mmol, yield 75%): 1H-NMR 
(CDCl3) δ : 1.64 ( s, 3H, Me); 2.02 (d, 1H, J = 13.2 Hz, CH2); 2.19 (d, 1H, J = 
14.2 Hz, CH2); 2.38 (d, 1H, J = 13.2 Hz, CH2); 2.53 (d, 1H, J = 14.2 Hz, CH2); 
3.76 (s, OMe); 6.80- 6.90 (m, 3H, Ar); 7.21- 7.32 (m, 3H, Ar); 7.48 (d, 1H, J = 
2.4 Hz, Ar) ppm. 
 
4-(aminomethyl)-2-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-chromen-4-
ol 64a.  
Compound 64a was obtained from 62a (0.26 g, 0.71 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 64a (0.21 g, 0.71 mmol, yield 100%): 1H-
NMR (CDCl3) δ : 1.67 (s, 3H, Me); 2.13 (d, 1H, J = 13.2 Hz, CH2); 2.27 (d, 
1H, J = 14.1 Hz, CH2); 2.41-2.57 (m, 2H, CH2); 6.92-7.07 (m, 2H, Ar); 7.22-
7.41 (m, 6H, Ar) ppm. 
 
4-(aminomethyl)-6-bromo-2-(4-chlorophenyl)-2-methyl-3,4-dihydro-2H-
chromen-4-ol 64b. 
Compound 64b was obtained from 62b (0.32 g, 0.71 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 64b (0.24 g, 0.64 mmol, yield 90%): 1H-NMR 
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(CDCl3) δ : 1.66 (s, 3H, Me); 2.11 (d, 1H, J = 13.2 Hz, CH2 ); 2.25 (d, 1H, J = 
14.3 Hz, CH2 ); 2.46 (d, 1H, J = 13.2 Hz, CH2 ); 2.51 (d, 1H, J = 14.3 Hz, CH2 
); 6.89 (d, 1H, J = 8.7 Hz, Ar); 7.25-7.37 (m, 5H, Ar); 7.51 (d, 1H, J = 2.2 Hz, 
Ar) ppm. 
 
2-(4-methoxyphenyl)-2-methyl-2,3-dihydro-2'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-2'-one 65a.  
Compound 65a was obtained from 63a (0.23 g, 0.78 mmol) following the 
procedure described for 57a.The crude product was directly used in the next 
step without further purification. 65a (0.06 g, 0.19 mmol, yield 25%): 1H-NMR 
(CDCl3) δ : 1.65 (s, 3H, Me); 2.37 (Br-d, 2H, J = 14.5 Hz, CH2); 2,69-2.94 (m, 
2H, CH2); 3.75 (s, 3H, OMe); 6.73- 7.07 (m, 4H, Ar); 7.213- 7.42 (m, 4H, Ar) 
ppm.  
 
6-bromo-2-(4-methoxyphenyl)-2-methyl-2,3-dihydro-2'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-2'-one 65b.  
Compound 65b was obtained from 63b (0.29 g, 0.78 mmol) following the 
procedure described for 57a.The crude product was directly used in the next 
step without further purification. 65b (0.23 g, 0.58 mmol, yield 75%): 1H-NMR 
(CDCl3) δ : 1.73 (s, 3H, Me); 2.63- 2.65 (m, 2H, CH2); 3.06- 3.20 (m, 2H, 
CH2); 3.79 (s, 3H, OMe); 6.85 (d, 2H, J = 8.9 Hz, Ar); 6.901-6.95 (m, 1H, Ar); 
7.21-7.26 (m, 3H, Ar); 7.4 (dd, 1H, J = 2.4; 8.8 Hz, Ar); 7.51- 7.52 (m, 1H, Ar) 
ppm.  
 
2-(4-chlorophenyl)-2-methyl-2,3-dihydro-2'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-2'-one 66a. 
Compound 66a was obtained from 64a (0.21 g, 0.71 mmol) following the 
procedure described for 57a.The crude product was directly used in the next 
step without further purification. 66a (0.23 g, 0.71 mmol, yield 100 %): 1H-
NMR (CDCl3) δ: 1.73 (s, 3H, Me); 2.55 (d, 1H, J = 14.3 Hz, CH2); 2.72 (d, 1H, 
J = 14.3 Hz, CH2); 3.18 (d, 1H, J = 9.2 Hz, CH2); 3.36 (d, 1H, J = 9.2 Hz, 
CH2); 6.92-7.46 (m, 8H, Ar) ppm. 
 
6-bromo-2-(4-chlorophenyl)-2-methyl-2,3-dihydro-2'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-2'-one 66b. 
Compound 66b was obtained from 64b (0.24 g, 0.64 mmol) following the 
procedure described for 57a.The crude product was directly used in the next 
step without further purification. 66b (0.23 g, 0.56 mmol, yield 88 %): mp 45-
48°C. 1H-NMR (CDCl3) δ : 1.72 (s, 3H, Me); 2.54 (d, 1H, J = 14.5 Hz, CH2); 
2.69 (d, 1H, J = 14.5 Hz, CH2); 3.16 (d, 1H, J = 9.2 Hz, CH2); 3.31 (d, 1H, J = 
9.2 Hz, CH2); 6.92 (d, 1H, J = 8.8 Hz, Ar); 7.25-7.44 (m, 5H, Ar); 7.53 (d, 1H, 
J = 2.2 Hz, Ar) ppm. 
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ethyl[2-(4-methoxyphenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-spiro 
[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetate 67a. 
Compound 67a was obtained from 65a (0.06 g, 0.19 mmol) following the 
procedure described for 58a.The crude product was directly used in the next 
step without further purification. 67a (0.03 g, 0.07 mmol, yield 38%): 1H-NMR 
(CDCl3) δ : 1.20- 1.32 (m, 3H, Me); 1.66 (s, 3H, Me); 2.04- 2.32 (m, 2H, CH2); 
2.51-2.83 (m, 2H CH2); 3.77 (s, OMe); 4.08-4.24 (m, 2H, CH2); 6.75- 7.05 (m, 
4H, Ar); 7.19-7.43 (m, 4H, Ar) ppm.  
 
ethyl[6-bromo-2-(4-methoxyphenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-spiro 
[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetate 67b. 
Compound 67b was obtained from 65b (0.23 g, 0.58 mmol) following the 
procedure described for 58a.The crude product was directly used in the next 
step without further purification. 67b (0.25 g, 0.51 mmol, yield 88 %): 1H-
NMR (CDCl3) δ : 1.21- 1.35 (m, 3H, Me); 1.72 (s, 3H, Me); 2.67 (s, 2H, CH2); 
3.16 (d, 1H, J = 9 Hz, CH2); 3.29 (d, 1H, J = 9 Hz, CH2); 3.79 (s, 3H, OMe); 
3.97 (s, 2H, CH2); 4.18-4.29 (m, 2H, CH2); 6.82- 6.94 (m, 3H, Ar); 7.22- 7.26 
(m, 3H); 7.4 (dd, 1H, J = 2.4; 8.6 Hz, Ar); 7.58 (d, 1H, J = 2.4 Hz, Ar) ppm. 
 
ethyl[2-(4-chlorophenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-3'-yl]acetate 68a. 
A solution of 66a (0.49 g, 1.50 mmol)  in dry THF was added dropwise, at -78 
˚C, under N2 atmosphere to a solution of n-BuLi (1.05 ml, 1.70 mmol, 1.6 M in 
Hexane) and the reaction mixtures were stirred for 1h. Ethyl bromoacetate (0.25 
g, 1.50 mmol) was added dropwise at -78 ˚C and the resulting mixtures were 
allowed to warm to rt and stirred overnight. The mixtures were quenched with 
NH4Clsat and then the solvent was evaporated. The residues were extracted with 
EtOAc, the combined organic layers were dried and concentrated under 
vacuum.The crude product was directly used in the next step without further 
purification. 68a (0.39 g, 0.94 mmol, yield 63 %): 1H-NMR (CDCl3) δ : 1.20-
1.37 (m, 3H, Me); 1.73 (s, 3H, Me); 2.61 (d, 1H, J = 14.5 Hz, CH2); 2.73 (d, 
1H, J = 14.5 Hz, CH2); 3.24 (d, 1H, J = 8.9 Hz, CH2); 3.49 (d, 1H, J = 8.9 Hz, 
CH2); 4.01 (d, 2H, J = 2.4 Hz, CH2); 4.22 (q, 2H, J = 7.2 Hz, CH2); 6.99-7.06 
(m, 2H, Ar); 7.27-7.39 (m, 5H, Ar); 7.50-7.55 (m, 1H, Ar) ppm. 
 
ethyl[6-bromo-2-(4-chlorophenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-spiro 
[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetate 68b. 
Compound 68b was obtained from 66b (0.61 g, 1.50 mmol) following the 
procedure described for 66a.The crude product was directly used in the next 
step without further purification. 68b (0.56 g, 1.14 mmol, yield 76 %): 1H-
NMR (CDCl3) δ : 1.21-1.34 (m, 3H, Me); 1.73 (s, 3H, CH3); 2.40-2.73 (m, 2H, 
CH2); 3.12-3.52 (m, 2H, CH2); 4.01 (s, 2H, CH2); 4.10-4.30 (m, 2H, CH2); 
6.90-7.05 (m, 1H, Ar); 7.25-7.45 (m, 5H, Ar); 7.54 (d, 1H, J = 2.4 Hz, Ar) ppm. 
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{[4-hydroxy-2-(4-methoxyphenyl)-2-methyl-3,4-dihydro-2H-chromen-4-yl] 
methyl}carbamic chloride 69a. 
Compound 69a was obtained from 63a (1.6 g, 5.35 mmol) and chloroacetyl 
chloride (0.86 g, 7.49 mmol) following the procedure described for 51a.The 
crude product was directly used in the next step without further purification. 
69a (1.30 g, 3.47 mmol, yield 65 %): 1H-NMR (CDCl3) δ : 1.67 (s, 3H, Me); 
2.29 (d, 1H, J = 14.2 Hz, CH2); 2.63 (d, 1H, J = 14.2 Hz, CH2); 3.45 (dd, 1H, J  
= 5.8, 14.4 Hz, CH2); 3.74 (d, 1H, J = 14.6 Hz, CH2); 3.75 (s,OMe); 3.99 (d,1H, 
J  = 15.5 Hz, CH2); 4.09 (d, 1H, J  = 15.5 Hz, CH2); 6.79-6.90 (m, 3H, Ar); 
6.94-7.021 (m,1H, Ar); 7.18 -7.36 (m, 3H, Ar); 7.45 (d, 1H, J = 7.6 Hz, Ar) 
ppm. 
 
{[6-bromo-4-hydroxy-2-(4-methoxyphenyl)-2-methyl-3,4-dihydro-2H-
chromen -4-yl]methyl}carbamic chloride 69b. 
Compound 69b was obtained from 63b (0.8 g, 2.11 mmol) and chloroacetyl 
chloride (0.34 g, 2.954 mmol) following the procedure described for 51a.The 
crude product was directly used in the next step without further purification. 
69b (0.8 g, 1.76 mmol, yield 47%). 1H-NMR (CDCl3) δ : 1.69 (s, 3H, Me); 
2.24-2.36 (m, 2H, CH2); 2.66 (d, 1H, J = 14.2 Hz, CH2); 3.38-3.48 (m, 1H, 
CH2); 3.78 (s, 3H, OMe); 4.03 (d,1H, J  = 15.7 Hz, CH2); 4.13 (d, 1H, J  = 15.7 
Hz, CH2); 6.80-6.94 (m, 3H, Ar); 7.24-7.38 (m, 3H, Ar); 7.61 (d, 1H, J = 2.6 
Hz, Ar) ppm. 
 
2-(4-methoxyphenyl)-2-methyl-2,3-dihydro-2'H-spiro[chromene-4,5'-[1,3] 
oxazinan]-2'-one 70a. 
Compound 70a was obtained from 69a (1.30 g, 3.47 mmol) following the 
procedure described for 52a.The crude product was directly used in the next 
step without further purification. 70a (0.73 g, 2.16 mmol, yield 63 %). 1H-NMR 
(CDCl3) δ : 1.72 (s, 3H, Me); 2.24 (d, 1H, J = 12.8 Hz, CH2); 2.33 (d, 1H, J = 
13.7 Hz, CH2); 3.01 (d, 1H, J = 13.7 Hz, CH2); 3.33 (d, 1H, J = 12.8 Hz, CH2); 
3.76 (s, OMe); 4.38 (s, 2H CH2); 6.80 (d, 2H, J = 7.6 Hz, Ar); 6.92 – 6.99 (m, 
1H, Ar); 7.03 - 7.07 (m, 1H, Ar); 7.15 -7.39 (m, 5H, Ar) ppm. 
 
6-bromo-2-(4-methoxyphenyl)-2-methyl-2,3-dihydro-2'H-spiro[chromene-
4,5'-[1,3]oxazinan]-2'-one 70b.  
Compound 70b was obtained from 69b (0.8 g, 1.76 mmol) following the 
procedure described for 52a.The crude product was directly used in the next 
step without further purification. 70b (0.63 g, 1.5 mmol, yield 85%). 1H-NMR 
(CDCl3) δ: 1.74 (s, 3H, Me); 2.29 (d, 1H, J = 12.8 Hz, CH2); 2.35 (d, 1H, J = 
13.7 Hz, CH2); 3.05 (d, 1H, J = 13.7 Hz, CH2); 3.40 (d, 1H, J = 12.8 Hz, CH2); 
3.78 (s, OMe); 4.40 (s, 2H CH2); 6.82 (d, 2H, J = 8.8 Hz, Ar); 7.03 (d, 1H, J = 
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8.6 Hz, Ar); 7.29-7.35 (m, 2H, Ar); 7.45-7.50 (m, 1H, Ar); 7.55 (d, 1H, J = 2.4 
Hz, Ar) ppm. 
 
ethyl(2,-(4-methoxyphenyl)-2-methyl-2'-oxo-2,3-dihydro-3'H-
spiro[chromene-4,5'-[1,3]oxazinan]-3'-yl)acetate 71a. 
Compound 71a was obtained from 70a (0.73 g, 2.16 mmol) and 
ethylbromoacetate (0.78 g, 2.16 mmol) following the procedure described for 
15a.The crude product was directly used in the next step without further 
purification. 71a (0.47 g, 1.10 mmol, yield 51 %): 1H-NMR ( CDCl3) δ: 1.26 (t, 
3H, J = 7.1 Hz, Me); 1.73 (s, 3H); 2.21 (d, 1H, J = 12.4 Hz, CH2); 2.39 (d, 1H, 
J = 13.5 Hz, CH2); 3.04 (d, 1H, J = 13.5 Hz, CH2); 3.18 (d, 1H, J = 17.3 Hz, 
CH2); 3.64 (d, 1H, J  = 12.6 Hz, CH2); 3.78 (s, OMe); 4.16 (q, 2H, J = 7.1 Hz, 
CH2); 4.34 (d, 1H, J = 17.3 Hz, CH2); 4.41 (s, 2H CH2); 6.82 (d, 2H, J = 8.7 
Hz, Ar); 6.93 - 7.08 (m, 2H, Ar); 7.21 – 7.36 (m, 3H, Ar); 7.44 (dd, 1H, J = 7.7, 
1.4 Hz, Ar) ppm. 
 
ethyl(6-bromo-2-(4-methoxyphenyl)-2-methyl -2'-oxo-2,3-dihydro-3'H-
spiro [chromene-4,5'-[1,3]oxazolidin]-3'-yl)acetate 71b.  
Compound 71b was obtained from 70b (0.3 g, 0.72 mmol) and 
ethylbromoacetate (0.12 g, 0.72 mmol) following the procedure described for 
15a.The crude product was directly used in the next step without further 
purification. 71b (0.22 g, 0.4 mmol, yield 55%).  
 
(2E)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one 72a. 
To a solution of  4-methoxybenzaldehyde (1.51 g, 11.09 mmol) in absolute 
EtOH (20 mL) was added 2-hydroxyacetophenone (1.50 g, 11.09 mmol). The 
reaction mixture was stirred for 5 min and then NaOH  (1.33 g, 33.29 mmol) 
was added. The resulting mixture was stirred for 5h rt and then HCl 1N was 
added. The precipitate was filtered to give 72a directly used in the next reaction 
without further purification. 72a (2.75 g, 10.87 mmol, yield 99%) 1H-NMR 
(CDCl3) δ : 3.87 (s, 3H, OMe); 6.90-7.05 (m, 2H, Ar); 6.96 (d, 2H, J = 8.8 Hz, 
CH); 7.45-7.54 (m, 1H, Ar); 7.54 (d, 1H, J = 15.3 Hz, CH); 7.64 (d, 2H, J = 8.8 
Hz, Ar); 7.87-7.94 (m, 1H, CH); 7.91 (d, 1H, J = 15.3 Hz, CH) ppm. 
 
(2E)-1-(5-bromo-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one 
72b. 
Compound 72b was obtained from 5-bromo-2-hydroxyacetophenone (1.50 g, 
6.97 mmol) and 4-methoxybenzaldehyde (0.95 g, 6.97 mmol) following the 
same procedure described for 72a. The crude product was directly used in the 
next reaction without further purification. 72b (2.3 g, 6.9 mmol, yield 99%) 1H-
NMR (CDCl3) δ: 3.87 (s, 3H, OMe); 6.89-6.90 (m, 3H, Ar); 7.43 (d, 1H, J = 
15.3 Hz, CH); 7.55 (dd, 1H, J = 2.4, 8.8 Hz, Ar); 7.60 (d, 2H, J = 8.8 Hz, Ar); 
7.90 (d, 1H,   J = 15.3 Hz, CH); 8.00 (d, 1H, J = 2.4 Hz, Ar) ppm. 
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(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 73a. 
Compound 73a was obtained from 2-hydroxyacetophenone (0.63 g, 4.65 mmol) 
and 4-chlorobenzaldehyde (0.65 g, 4.65 mmol) following the same procedure 
described for 72a and used for the next reaction without further purification. 
73a (1.18 g, 4.56 mmol, yield 98%): 1H-NMR (CDCl3) δ: 6.91-7.05 (m, 2H, 
Ar); 7.40 (d, 2H, J  = 8.6 Hz, Ar); 7.47-7.65 (m, 4H, Ar, CH); 7.82-7.92 (m, 
2H, Ar, CH) ppm. 
 
(2E)-1-(5-bromo-2-hydroxyphenyl)-3-(4-chlorophenyl)prop-2-en-1-one 
73b. 
Compound 73b was obtained from 5-bromo-2-hydroxyacetophenone (1.00 g, 
4.65) and 4-chlorobenzaldehyde (0.65 g, 4.65 mmol) following the same 
procedure described for 72a and used for the next reaction without further 
purification. 73b (1.38 g, 4.09 mmol, yield 88%):  1H-NMR (CDCl3) δ : 6.95 
(d, 1H, J  = 9.0 Hz, Ar); 7.41-7.49 (m, 2H, Ar); 7.55-7.65 (m, 4H, Ar, CH); 
7.89 (d, 1H, J  = 15.6 Hz, CH); 7.99 (d, 1H, J  = 2.4 Hz, Ar) ppm. 
 
2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one 74a. 
The solution of 72a (2.75 g, 10.87 mmol) in  glacial AcOH (20 mL) was 
refluxed for 72h. After cooling to rt the reaction mixture was poured in H2O 
and extracted with  EtOAc. The organic layer was dried and concentrated under 
vacuum to give 74a without further purification (1.13 g, 4.46 mmol, yield 41%) 
1H-NMR (CDCl3) δ : 2.86 (dd, 1H, J = 3.1, 16.8 Hz, CH2); 3.12 (dd, 1H, J = 
13, 16.8 Hz, CH2); 3.84 (s, 3H, OMe); 5.44 (dd, 1H, J = 3.1, 13 Hz, CH); 6.94-
7.09 (m, 4H, Ar); 7.38-7.55 (m, 4H, Ar); 7.93 (dd, 1H, J = 1.7, 8.1 Hz, Ar) 
ppm. 
 
6-bromo-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one 74b.  
Compound 74b was obtained from 72b (2.3 g, 6.9 mmol) following the 
procedure described for 74a. The crude product was used for the next reaction 
without further purification. 74b (1.15 g, 3.45 mmol, yield 50 %):  1H-NMR 
(CDCl3) δ : 2.87 (dd, 1H, J = 3.2, 16.8 Hz, CH2); 3.10 (dd, 1H, J = 12.8, 16.8 
Hz, CH2); 3.84 (s, 3H, OMe); 5.42 (dd, 1H, J = 3.2, 12.8 Hz, CH); 6.92-6.99 
(m, 3H, Ar); 7.57 (dd, 1H, J = 2.6, 8.6 Hz, Ar); 7.66 (d, 2H, J  = 9.0 Hz, Ar); 
8.03 (d, 1H, J = 2.6 Hz, Ar) ppm. 
 
2-(4-chlorophenyl)-2,3-dihydro-4H-chromen-4-one 75a.  
Compound 75a was obtained from 73a (1.18 g, 4.56 mmol) following the 
procedure described for 74a.The crude product was directly used for the next 
reaction without further purification. 75a (0.28 g, 1.09 mmol, yield 24%): 1H-
NMR (CDCl3) δ : 2.88 (dd, 1H, J = 3.5, 16.9 Hz, CH2); 3.05 (dd, 1H, J = 12.6, 
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16.9 Hz, CH2); 5.47 (dd, 1H, J = 3.5, 12.6 Hz, CH); 6.91-7.11 (m, 2H, Ar); 
7.40-7.67 (m, 5H, Ar); 7.84-7.96 (m, 1H, Ar) ppm. 
 
6-bromo-2-(4-chlorophenyl)-2,3-dihydro-4H-chromen-4-one 75b. 
Compound 75b was obtained from 73b (1.38 g, 4.09 mmol) purification 
following the procedure described for 74a.The crude product was directly used 
for the next reaction without further purification. 75b (1.05 g, 3.1 mmol, yield 
76%): 1H-NMR (CDCl3) δ :  2.88 (dd, 1H, J  = 3.7, 17.2 Hz, CH2); 3.04 (dd, 
1H, J = 12.4, 17.2 Hz, CH2); 5.45 (dd, 1H, J = 3.7, 12.4 Hz, CH); 6.96 (d, 1H, 
J = 8.8 Hz, Ar); 7.38-7.44 (m, 4H, Ar); 7.59 (dd, 1H, J = 2.5, 8.8 Hz, Ar); 8.03 
(d, 1H, J = 2.5 Hz, Ar) ppm. 
 
2-(2,4-dichlorophenyl)-2,3-dihydro-4H-chromen-4-one 76a. 
To a solution of  2,4 dichlorobenzaldheyde (2.57 g, 14.68 mmoli) in MeOH was 
added 2-hydroxy acetophenone (2.00 g, 14.68 mmoli) and KOH (0.33 g, 5.87 
mmoli). The reaction mixture was refluxed for 7h. The solvent was evaporated 
under reduced pressure and the curde product was purified by flash column 
chromatography eluted with Hex/EtOAc (9/1) to give 76a (4.00 g, 13.8 mmol, 
yield 94%): 1H-NMR (CDCl3) δ : 2.76-3.10 (m, 2H, CH2); 5.82 (dd, 1H, J = 
13.0, 3.1 Hz, CH); 7.05-7.13 (m, 1H, Ar); 7.31-7.58 (m, 3H, Ar); 7.68-7.73 (m, 
1H, Ar); 7.93-7.98 (m, 1H, Ar) ppm. 
 
6-bromo-2-(2,4-dichlorophenyl)-2,3-dihydro-4H-chromen-4-one 76b. 
Compound 76b was obtained from 5-bromo-2hydroxyacetophenone (2.00 g, 
9.30 mmol) and 2,4 dichlorobenzaldheyde (1.63 g; 9.30 mmoli) following the 
procedure described for 76a. The crude product was directly used for the next 
reaction without further purification. 76b ( 2.2 g, 5.95 mmol, yield 64%): mp 
133-135°C. 1H-NMR (CDCl3) δ : 2.82 (dd, 1H, J = 13.2, 17.0 Hz, CH2); 3.03 
(dd, 1H, J = 3.0, 17.0 Hz, CH2); 5.80 (dd, 1H, J = 3.0, 13.2 Hz, CH); 6.98 (d, 
1H, J = 8.8 Hz, Ar); 7.38 (dd, 1H, J = 1.9, 8.4 Hz, Ar); 7.45 (d, 1H, J = 1.9 Hz, 
Ar); 7.61 (dd, 1H, J = 2.6, 8.8 Hz, Ar); 7.67 (d, 1H, J = 8.4 Hz, Ar); 8.06 (d, 
1H, J = 2.6 Hz, Ar) ppm. 
 
6-bromo-2-(2,4-difluorophenyl)-2,3-dihydro-4H-chromen-4-one 77b. 
Compound 77b was obtained from 5-bromo-2hydroxyacetophenone (1.00 g, 
4.65 mmol) and 2,4-difluorobenzaldehyde  (0.66 g; 4.65 mmoli) following the 
synthestic procedure described above for 76a. The crude product was purified 
by crystallizzation from EtOH to give 77b (0.38 g, 1.12 mmol, yield 24%): 1H-
NMR (CDCl3) δ : 2.85-3.12 (m, 2H, CH2); 5.71 (dd, 1H, J  = 12.4, 3.7 Hz, CH); 
6.83-7.02 (m, 3H, Ar); 7.53-7.65 (m, 2H, Ar); 8.05 (d, 1H, J  = 2.4 Hz, Ar) 
ppm. 
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6-bromo-2-(4-bromo-2-fluorophenyl)-2,3-dihydro-4H-chromen-4-one 78b. 
Compound 78b was synthesised from 5-bromo-2hydroxyacetophenone (1.00 g, 
4.65) and 4-bromo-2-fluorobenzaldehyde (0.94 g, 4.65 mmol) following the 
synthetic procedure described for 76a The crude product was purified by flash 
column chromatography eluted with Hex/EtOAc (9/1) to give 78b (0.65 g, 1.62 
mmol, yield 35%): 1H-NMR (CDCl3) δ : 2.87-3.09 (m, 2H, CH2); 5.70 (dd, 1H, 
J  = 4.8, 11.3 Hz, CH); 6.96 (d, 1H, J  = 8.8 Hz, Ar); 7.29-7.57 (m, 3H, Ar); 
7.60 (dd, 1H, J  = 2.5, 8.8 Hz, Ar); 8.05 (d, 1H, J  = 2.5 Hz, Ar) ppm. 
 
4-[(trimethylsilyl)oxy]-2-(4-methoxyphenyl)-3,4-dihydro-2H-chromene-4-
carbonitrile 79a. 
Compound 79a was obtained from 74a (1.13 g, 4.46 mmol) following the 
procedure described for 49a. The crude product was purified by flash column 
chromatography eluted with Hex/EtOAc (9/1) to give 79a (0.17 g, 0.48 mmol, 
yield 10%):  1H-NMR (CDCl3) δ : 0.30 (s, 9H, Me); 2.42-2.68 (m, 2H, CH2); 
3.84 (s, 3H, OMe); 5.30-5.37 (m, 1H, CH); 6.87-7.07 (m, 2H, Ar); 6.97 (d, 2H, 
J = 8.7 Hz, Ar); 7.23-7.32 (m, 1H, Ar); 7.40 (d, 2H, J = 8.7 Hz, Ar); 7.57 (dd, 
1H, J = 1.6, 7.9 Hz, Ar) ppm. 
 
6-bromo-4-[(trimethylsilyl)oxy]-2-(4-methoxyphenyl)-3,4-dihydro-2H-
chromene-4 -carbonitrile 79b. 
Compound 79b was obtained from 74b (1.15 g, 3.45 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 79b (1.15 g, 2.65 mmol, yield 77 %):  1H-
NMR (CDCl3) δ : 0.32 (s, 9H, Me); 2.34-2.66 (m, 2H, CH2); 3.81 (s, 3H, 
OMe); 5.38 (dd, 1H, J = 3.4, 12.9 Hz, CH); 6.85-7.05 (m, 3H, Ar); 7.26-7.43 
(m, 3H, Ar); 7.65-7.72 (m, 1H, Ar) ppm. 
 
2-(4-chlorophenyl)-4-[(trimethylsilyl)oxy]-3,4-dihydro-2H-chromene-4-
carbo nitrile 80a. 
Compound 80a was obtained from 75a (0.37 g, 1.30 mmol) following the 
procedure described for 49a. The crude product was used in the next reaction 
without further purification. 80a (0.39 g, 1.1 mmol, yield 84 %):  1H-NMR 
(CDCl3) δ : 0.29 (s, 9H, Me); 2.36-2.67 (m, 2H, CH2); 5.35 (m 1H, CH); 6.89-
6.93 (m, 1H, Ar); 7.01-7.09 (m, 1H, Ar); 7.30-7.42 (m, 5H, Ar); 7.65-7.72 (dd, 
1H, J = 1.5, 7.8 Hz, Ar) ppm. 
 
6-bromo-2-(4-chlorophenyl)-4-[(trimethylsilyl)oxy]-3,4-dihydro-2H-
chromene-4-carbonitrile 80b. 
Compound 80b was obtained from 75b (1.05 g, 3.1 mmol) following the 
procedure described for 49a. The crude product was purified by flash column 
chromatography eluted with CHCl3/Hex (1/1) to give 80b (0.58 g, 1.33 mmol, 
yield 43 %): 1H-NMR (CDCl3) δ : 0.31 (s, 9H, Me); 2.32-2.44 (m, 1H, CH2); 
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2.62 (dd, 1H, J  = 2.0, 13.4 Hz, CH2); 5.36 (dd, 1H, J =2.0, 11.8 Hz, CH); 6.80 
(d, 1H, J  = 8.8 Hz, Ar); 7.35-7.47 (m, 5H, Ar); 7.65 (d, 1H, J  = 2.4 Hz, Ar) 
ppm. 
 
2-(2,4-dichlorophenyl)-4-[(trimethylsilyl)oxy]-3,4-dihydro-2H-chromene-4-
carbonitrile 81a. 
Compound 81a was obtained from 76a (0.56 g, 1.91 mmoli) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 81a  (0.52 g, 1.32 mmoli, yield 69%): 1H-
NMR (CDCl3) δ : 0.21 (s, 9H, Me); 2.22 (dd, 1H, J = 13.6, 11.8 Hz, CH2); 2.70 
(dd, 1H, J = 13.6, 1.9 Hz, CH2); 5.70 (dd, 1H, J = 1.9, 11.8 Hz, CH); 6.98 (dd, 
1H, J = 1.1, 8.3 Hz, Ar); 7.07 (dt, 1H, J = 1.1, 7.6 Hz, Ar); 7.32-7.46 (m, 3H, 
Ar); 7.59-7.65 (m, 1H, Ar) ppm. 
 
6-bromo-2-(2,4-dichlorophenyl)-4-[(trimethylsilyl)oxy]-3,4-dihydro-2H-
chromene-4-carbonitrile 81b. 
Compound 81b was obtained from 76b ( 2.2 g, 5.95 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 81b (1.68 g, 3.57 mmol, yield 60%) mp139-
142°C: 1H-NMR (CDCl3) δ : 0.31 (s, 9H, Me); 2.17 (dd, 1H, J = 11.7, 13.4 Hz, 
CH2); 2.82 (dd, 1H, J = 1.7, 13.4 Hz, CH2); 5.72 (dd, 1H, J = 1.7, 11.7 Hz, CH); 
6.84 (d, 1H, J = 8.8 Hz, Ar); 7.33-7.38 (m, 1H, Ar); 7.40 (dd, 1H, J = 2.4, 8.8 
Hz, Ar); 7.46 (d, 1H, J = 2.0 Hz, Ar); 7.57 (d, 1H, J = 8.4 Hz, Ar); 7.66 (d, 1H, 
J = 2.4 Hz, Ar) ppm. 
 
6-bromo-2-(2,4-difluorophenyl)-4-[(trimethylsilyl)oxy]-3,4-dihydro-2H-
chromene-4-carbonitrile 82b. 
Compound 82b was obtained from 77b (0.38 g, 1.12 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 82b (0.23 g, 0.54 mmol, yield 48%): 1H-NMR 
(CDCl3) δ : 0.31 (s, 9H, Me); 2.43 (dd, 1H, J  = 13.3, 11.9 Hz, CH2); 2.68 (dd, 
1H, J  = 2.0, 13.3 Hz, CH2); 5.62 (dd, 1H, J  = 2.0, 11.9 Hz, CH); 6.80 (d, 1H, J  
=  8.8 Hz, Ar); 6.84-7.01 (m, 2H, Ar); 7.39 (dd, 1H, J  = 2.4, 8.8 Hz, Ar); 7.45-
7.57 (m, 1H, Ar); 7.65 (d, 1H, J  = 2.4 Hz, Ar) ppm. 
 
6-bromo-2-(4-bromo-2-fluorophenyl)- 4-[(trimethylsilyl)oxy] -3,4-dihydro-
2H-chromene-4-carbonitrile 83b. 
Compound 83b was obtained from 78b (0.45 g, 1.12 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification yield 83b (0.5 g, 1.00 mmol, 89%): 1H-NMR 
(CDCl3) δ : 0.31 (s, 9H, Me); 2.40 (dd, 1H, J  = 13.3, 11.7 Hz, CH2); 2.68 (dd, 
1H, J  = 1.7, 13.3 Hz, CH2); 5.61 (dd, 1H, J  = 1.7, 11.7 Hz, CH); 6.81 (d, 1H,  
J  = 8.8 Hz, Ar); 7.30-7.42 (m, 4H, Ar); 7.64 (d, 1H, J  = 2.4 Hz, Ar) ppm. 
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4-(aminomethyl)-2-(4-methoxyphenyl)-3,4-dihydro-2H-chromen-4-ol 84a. 
Compound 84a was obtained from 79a (0.48 g, 1.17 mmol)following the 
procedure described for 50a. The crude product was directly used in the next 
step without further purification. 84a (0.25 g, 0.89 mmol, yield 76%) 1H-NMR 
(CDCl3) δ : 2.15-2.33 (m, 2H, CH2); 3.02 (d, 1H J = 13.2 Hz, CH2); 3.11 (d, 
1H, J = 13.2 Hz, CH2); 3.83 (s, 3H, OMe); 5.09 (dd, 1H, J = 4.2, 10.4 Hz, CH); 
6.73-7.08 (m, 4H, Ar); 7.15-7.23 (m, 1H, Ar); 7.38 (d, 2H, J = 8.6 Hz, Ar); 
7.47-7.50 (m, 1H, Ar) ppm. 
 
4-(aminomethyl)-6-bromo-2-(4-methoxyphenyl)-3,4-dihydro-2H-chromen-
4-ol 84b. 
Compound 84b was obtained from 79b (1.15 g, 2.65 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 84b (0.41 g, 1.14 mmol, yield 43 %): 1H-
NMR (CDCl3) δ : 1.90-2.55 (m, 2H, CH2); 3.53-3.94 (m, 5H, CH2, OMe); 4.96-
5.13 (m, 1H, CH); 6.71-6.96 (m, 3H, Ar); 7.03-7.39 (m, 3H, Ar); 7.54-7.64 (m, 
1H, Ar) ppm. 
 
4-(aminomethyl)-2-(4-chlorophenyl)-3,4-dihydro-2H-chromen-4-ol 85a. 
Compound 85a was obtained from 80a (0.39 g, 1.10 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 85a (0.31 g, 1.09 mmol, yield 99%). 1H-NMR 
(CDCl3) δ : 2.06-2.37 (m, 2H, CH2); 2.89-3.25 (m, 2H, CH2); 5.14 (dd, 1H, J = 
2.6, 12.3 Hz, CH); 6.85-7.02 (m, 2H, Ar); 7.16-7.25 (m, 1H, Ar); 7.33-7.41 (m, 
4H, Ar); 7.49 (dd, 1H, J = 1.7, 7.8 Hz, Ar) ppm. 
 
4-(aminomethyl)-6-bromo-2-(4-chlorophenyl)-3,4-dihydro-2H-chromen-4-
ol 85b. 
Compound 85b was obtained from 80b (0.58 g, 1.33 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 85b (0.4 g, 1.08 mmol, yield 81 %). 1H-NMR 
(CDCl3) δ : 2.01-2.35 (m, 2H, CH2); 2.89-3.13 (m, 2H, CH2); 5.08-5.17 (m, 1H, 
CH); 6.75 (d, 1H, J = 8.6 Hz, Ar); 7.16-7.50 (m, 5H, Ar); 7.60-7.62 (m, 1H, 
Ar) ppm. 
 
4-(aminomethyl)-2-(2,4-dichlorophenyl)-3,4-dihydro-2H-chromen-4-ol 86a. 
Compound 86a was obtained from 81a (0.52 g, 1.32 mmoli) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 86a (0.32 g, 1.00 mmol, yield 76%): 1H-NMR 
(CDCl3) δ : 1.78-2.47 (m, 2H, CH2); 2.96-3.35 (m, 2H, CH2); 5.45-5.52 (m, 1H, 
CH); 6.88-7.04 (m, 2H, Ar); 7.18-7.66 (m, 4H, Ar) ppm. 
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4-(aminomethyl)-6-bromo-2-(2,4-dichlorophenyl)-3,4-dihydro-2H-
chromen-4-ol 86b. 
Compound 86b was obtained from 81b (1.68 g, 3.57 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 86b (1.25 g, 3.1 mmol, yield 87 %): mp 75-
77°C. 1H-NMR (CDCl3) δ :  1.81-1.94 (m, 1H, CH2); 2.41 (dd, 1H, J = 1.8, 
13.7 Hz, CH2); 2.94 (d, 1H, J = 13.4 Hz, CH2); 3.23 (d, 1H, J = 13.4 Hz, CH2); 
5.46 (dd, 1H, J = 1.8, 12.8 Hz, CH); 6.79 (d, 1H, J = 8.8 Hz, Ar); 7.29 (dd, 1H, 
J = 2.4, 8.8 Hz, Ar); 7.36-7.41 (m, 2H, Ar); 7.58-7.62 (m, 2H, Ar) ppm. 
 
4-(aminomethyl)-6-bromo-2-(2,4-difluorophenyl)-3,4-dihydro-2H-
chromen-4-ol 87b. 
Compound 87b was obtained from 82b (0.23 g, 0.54 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 87b (0.13 g, 0.36 mmol, yield 67%): 1H-NMR 
(CDCl3) δ : 2.10-2.56 (m, 2H, CH2); 2.93-3.20 (m, 2H, CH2); 5.34-5.47 (m, 1H, 
CH); 6.77 (d, 1H, J  = 8.6 Hz, Ar); 6.85-7.02 (m, 2H, Ar); 7.17-7.30 (m, 1H, 
Ar); 7.39-7.64 (m, 2H, Ar) ppm. 
 
4-(aminomethyl)-6-bromo-2-(4-bromo-2-fluorophenyl)-3,4-dihydro-2H-
chromen-4-ol 88b. 
Compound 88b was obtained from 83b (0.27 g, 0.54 mmol) following the 
procedure described for 50a.The crude product was directly used in the next 
step without further purification. 88b (0.18 g, 0.42 mmol, yield 77%): 1H-NMR 
(CDCl3) δ : 1.98-2.40 (m, 2H, CH2); 2.92-3.21 (m, 2H, CH2); 5.37-5.50 (m, 1H, 
CH); 6.77 (dd, 1H,  J  = 8.6 , 2.6 Hz, Ar); 6.90-7.62 (m, 5H, Ar) ppm. 
 
2-(4-methoxyphenyl)-2,3-dihydro-2'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-2'-one 89a. 
Compound 89a was obtained from 84a ( 0.25 g, 0.89 mmol) following the 
procedure described for 57a.The crude product was purified by flash column 
chromatography eluted by Hex/EtOAc (2/3) to give 89a (0.04 g, 0.13 mmol, 
yield 15%) 1H-NMR (CDCl3) δ : 2.41-2.69 (m, 2H, CH2); 3.73-3.88 (m, 5H, 
CH2, OMe); 5.00-5.07 (m, 1H, CH); 6.86-7.07 (m, 4H Ar); 7.23-7.30 (m, 1H, 
Ar); 7.39 (d, 2H, J =8.7 Hz, Ar); 7.44-7.48 (m, 1H, Ar) ppm. 
 
6-bromo-2-(4-methoxyphenyl)-2,3-dihydro-2'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-2'-one 89b. 
Compound 89b was obtained from 84b (0.41 g, 1.14 mmol) following the 
procedure described for 57a.The crude product was directly used in the next 
step without further purification. 89b (0.41 g, 1.05 mmol, yield 92 %): 1H-
NMR (CDCl3) δ : 2.04-2.65 (m, 2H, CH2); 3.68-3.87 (m, 5H, CH2, OMe); 5.00-
Experimental section 
 167
5.13 (m, 1H, CH); 6.64-6.96 (m, 3H Ar); 7.03-7.39 (m, 3H, Ar) 7.54-7.64 (m, 
1H, Ar) ppm. 
 
2-(4-chlorophenyl)-2,3-dihydro-2'H-spiro[chromene-4,5'-[1,3]oxazolidin]-
2'-one 90a. 
Compound 90a was obtained from 85a (0.31 g, 1.09 mmol) following the 
procedure described for 57a.The crude product product was directly used in the 
next step without further purification. 90a (0.35 g, 1.03 mmol, yield 95%): 1H-
NMR (CDCl3) δ : 2.36-2.57 (m, 2H, CH2); 3.73 (d, 1H, J = 9 Hz, CH2); 3.82 (d, 
1H, J = 9 Hz, CH2);  5.04 (dd, 1H, J = 3.6, 10.9 Hz, CH); 6.91 (dd, 1H, J  = 0.9, 
8.2 Hz, Ar); 6.98-7.07 (m, 1H, Ar); 7.23-7.32 (m, 1H, Ar); 7.37-7.45 (m, 4H, 
Ar) ppm. 
 
6-bromo-2-(4-chlorophenyl)-2,3-dihydro-2'H-spiro[chromene-4,5'-[1,3] 
oxazolidin]-2'-one 90b. 
Compound 90b was obtained from 85b (0.4 g, 1.08 mmol) following the 
procedure described for 57a.The crude product was directly used in the next 
step without further purification. 90b (0.31 g, 0.79 mmol, yield 73 %): 1H-
NMR (CDCl3) δ : 2.41-2.62 (m, 2H, CH2); 3.73-3.89 (m, 2H, CH2); 5.01-5.11 
(m, 1H, CH); 6.81 (d, 1H, J  = 8.8 Hz, Ar); 7.29-7.49 (m, 5H, Ar); 7.58 (d, 1H, 
J = 2.3 Hz, Ar) ppm. 
 
2-(2,4-dichlorophenyl)-2,3-dihydro-2'H-spiro[chromene-4,5'-
[1,3]oxazolidin]-2'-one 91a. 
Compound 91a was obtained from 86a (0.2 g, 0.62 mmoli) following the 
procedure described for 57a.The crude product was directly used in the next 
step without further purification. 91a (0.17 g, 0.5 mmol, yield: 80%): 1H-NMR 
(CDCl3) δ : 2.23-2.39 (m, 1H, CH2); 2.58-269 (m, 1H, CH2); 3.85-3.95 (m, 2H, 
CH2); 5.40-5.54 (m, 1H, CH); 6.93-6.99 (m, 1H, Ar); 7.02-7.11 (m, 1H, Ar); 
7.25-7.50 (m, 3H, Ar); 7.65-7.76 (m, 1H, Ar) ppm. 
 
6-bromo-2-(2,4-dichlorophenyl)-2,3-dihydro-2'H-spiro[chromene-4,5'-[1,3] 
oxazolidin]-2'-one 91b. 
Compound 91b was obtained from 86b (1.25 g, 3.1 mmol) following the 
procedure described for 57a.The crude product was purified by crystallization 
from EtOH to give 91b (0.58 g, 1.36 mmol, yield 44 %): mp 216-219°C. 1H-
NMR (CDCl3) δ : 2.20-2.33 (m, 1H, CH2); 2.61 (dd, 1H, J = 1.4, 13.6 Hz, 
CH2); 3.87 (s, 2H, CH2); 5.41 (dd, 1H, J = 1.4, 12.3 Hz, CH); 6.85 (d, 1H, J = 
8.9 Hz, Ar); 7.35-7.44 (m, 3H, Ar); 7.60 (d, 1H, J = 2.4 Hz, Ar); 7.63 (d, 1H, J 
= 8.4 Hz, Ar) ppm. 
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6-bromo-2-(2,4-difluorophenyl)-2,3-dihydro-2'H-spiro[chromene-4,5'-[1,3] 
oxazolidin]-2'-one 92b. 
Compound 92b was obtained from 87b (0.43 g, 1.18 mmol) following the 
procedure described for 57a.The crude product was directly used in the next 
step without further purification. 92b (0.31g, 0.79 mmol, yield 66%): 1H-NMR 
(CDCl3) δ : 2.45-2.54 (m, 2H, CH2); 3.79 (d, 1H, J  = 8.9 Hz, CH2); 3.86 (d, 
1H, J  = 8.9 Hz, CH2); 5.26-5.45 (m, 1H, CH); 6.74-7.14 (m, 3H, Ar); 7.21-7.67 
(m, 3H, Ar) ppm. 
 
6-bromo-2-(4-bromo-2-fluorophenyl)-2,3-dihydro-2'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-2'-one 93b. 
 Compound 93b was obtained from 88b (0.5 g, 1.18 mmol) following the 
procedure described for 57a.The crude product was purified by crystallization 
from EtOH to give 93b (0.41 g, 0.91 mmol, yield 77%): 1H-NMR (CDCl3) δ : 
2.31-2.56 (m, 2H, CH2); 3.79 (d, 1H, J  = 9.1 Hz, CH2); 3.86 (d, 1H, J  = 9.1 
Hz, CH2); 5.35 (dd, 1H, J  = 10.7, 3.3 Hz, CH); 5.79 (br s, 1H, NH); 6.82 (d, 
1H, J = 8.8 Hz, Ar); 7.28-7.53 (m, 4H, Ar); 7.59 (d, 1H, J  = 2.4 Hz, Ar) ppm. 
 
ethyl[2-(4-methoxyphenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3] oxazolidin]-3'-yl]acetate 94a. 
Compound 94a was obtained from 89a (0. 48 g, 1.00 mmol) and 
ethylbromoacetate (0.17 g, 1.00 mol) following the procedure described for 
67a.The crude product product was directly used in the next step without 
further purification. 94a (0.3 g, 0.63 mmol, yield 63%)1H-NMR (CDCl3) δ : 
1.22-1.33 (m, 3H, Me); 2.47-2.69 (m, 2H, CH2); 3.78-3.94 (m, 5H, CH2, OMe); 
4.06-4.29 (m, 4H, CH2); 4.99-5.07 (m, 1H, CH); 6.88-7.07 (m, 4H, Ar); 7.23-
7.30 (m, 1H, Ar); 7.39 (d, 2H, J = 8.4 Hz, Ar); 7.49-7.53 (m, 1H, Ar) ppm. 
 
ethyl[6-bromo-2-(4-methoxyphenyl)-2'-oxo-2,3-dihydro-3'H-
spiro[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetate 94b. 
Compound 94b was obtained from 89b (0.41 g, 1.05 mmol) and 
ethylbromoacetate (0.17 g, 1.05 mmol) following the procedure described for 
67a.The crude product was directly used in the next step without further 
purification. 94b (0.17 g, 0.37 mmol, yield 35%): 1H-NMR (CDCl3) δ : 1.25-
1.58 (m, 3H, Me); 2.83-2.86 (m, 2H, CH2); 3.79-3.89 (m, 5H, CH2, OMe); 
3.97-4.26 (m, 4H, CH2); 5.46-5.50 (m, 1H, CH); 6.88-6.96 (m, 3H, Ar); 7.51-
7.74 (m, 3H, Ar) 7.92-7.97 (m, 1H, Ar) ppm. 
 
ethyl[2-(4-chlorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-[1,3] 
oxazolidin]-3'-yl]acetate 95a. 
Compound 95a was obtained from 90a (0.35 g, 1.03 mmol) and 
ethylbromoacetate (0.17 g, 1.03 mmol) following the procedure described for 
67a.The crude product was purified by flash column chromatography eluted 
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with Hex/EtOAc (3/2) to give 95a (0.05 g, 0.11 mmol, yield 10%): 1H-NMR 
(CDCl3) δ: 1.30 (t, 3H, J = 7.1 Hz, Me); 2.45-2.62 (m, 2H, CH2); 3.83 (d, 1H, J 
= 8.5 Hz, CH2); 3.91 (d, 1H, J = 8.5 Hz, CH2); 4.05 (d, 1H, J = 18.1 Hz, CH2);  
4.15(d, 1H, J = 18.1 Hz, CH2); 4.24 (q, 2H, J = 7.1 Hz, CH2); 5.00-5.15 (m, 1H, 
CH); 6.90-6.94 (m, 1H, Ar); 7.00-7.09 (m, 1H, Ar); 7.24-7.33 (m, 1H, Ar); 7.41 
(s, 4H, Ar); 7.51( dd, 1H, J = 1.5, 7.8 Hz, Ar) ppm. 
  
ethyl[6-bromo-2-(4-chlorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-
4,5'-[1,3]oxazolidin]-3'-yl]acetate 95b. 
Compound 95b was obtained from 90b (0.31 g, 0.79 mmol) and 
ethylbromoacetate (0.13 g, 0.79 mmol) following the procedure described for 
67a.The crude product was purified by flash column chromatography eluted 
with Hex/EtOAc 8/2 to give 95b (0.32 g, 0.68 mmol, yield 86%): 1H-NMR 
(CDCl3) δ: 1.22-1.38 (m, 3H, Me); 2.24-2.62 (m, 2H, CH2); 3.73-4.02 (m, 2H, 
CH2); 4.05-4.30 (m, 4H, CH2); 5.00-5.13 (m, 1H, CH); 6.80 (d, 1H, J = 8.8 Hz, 
Ar); 7.24-7.40 (m, 5H, Ar); 7.60 (d, 1H, J = 2.4 Hz, Ar) ppm. 
 
ethyl[2-(2,4-dichlorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro[chromene-4,5'-
[1,3] oxazolidin]-3'-yl]acetate 96a 
Compound 96a was obtained from 91a (0.17 g, 0.5 mmol) and 
ethylbromoacetate (0.08 g, 0.5 mmol) following the procedure described for 
67a.The crude product was directly used in the next step without further 
purification. 96a (0.14 g, 0.32 mmol, yield 65%). 1H-NMR (CDCl3) δ : 1.25-
1.34 (m, 3H, Me); 2.25-2.41 (m, 1H, CH2); 2.62-2.70 (m, 1H, CH2); 3.83-4.01 
(m, 2H, CH2); 4.10-4.13 (m, 2H, CH2); 4.19-4.30 (m, 2H, CH2); 5.40-5.51 (m, 
1H, CH); 6.92-6.96 (m, 1H, Ar); 7.04-7.11 (m, 1H, Ar); 7.30-7.43 (m, 2H, Ar); 
7.54 (d, 1H, J  = 7.7 Hz, Ar); 7.68 (d, 1H, J  = 8.4 Hz, Ar) ppm. 
 
ethyl[6-bromo-2-(2,4-dichlorophenyl)-2'-oxo-2,3-dihydro-3'H-
spiro[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetate 96b. 
Compound 96b was obtained from 91b (0.4 g, 0.93 mmol) and 
ethylbromoacetate (0.15 g, 0.93 mmol) following the procedure described for 
67a.The crude product was directly used in the next step without further 
purification. 96b (0.38 g, 0.73 mmol, yield 79 %): 1H-NMR (CDCl3) δ : 1.21-
1.34 (m, 3H, Me); 2.18-2.33 (m, 1H, CH2); 2.57-2.68 (m, 1H, CH2); 3.82-3.91 
(m, 2H, CH2); 4.06-4.20 (m, 2H, CH2); 4.20-4.30 (m, 2H, CH2); 5.40 (d, 1H, J 
= 12.3 Hz, CH); 6.83 (d, 1H, J = 8.8 Hz, Ar); 7.34-7.43 (m, 3H, Ar); 7.58-7.65 
(m, 2H, Ar) ppm. 
 
ethyl[6-bromo-2-(2,4-difluorophenyl)-2'-oxo-2,3-dihydro-3'H-
spiro[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetate 97b. 
Compound 97b was obtained from 92b (0.3 g, 0.77 mmol) and 
ethylbromoacetate (0.13 g, 0.77mmol) following the procedure described for 
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67a.The crude product was purified by flash column chromatography eluted 
with Hex/EtOAc (7/3) to give 97b (0.09 g, 0.18 mmol, yield 24%): 1H-NMR 
(CDCl3) δ :  1.31 (t, 3H, J = 7.1 Hz, Me); 2.41-2.59 (m, 2H, CH2); 3.84 (d, 1H, 
J  = 8.4 Hz, CH2); 3.92 (d, 1H, J  = 8.4 Hz, CH2); 4.14 (d, 2H, J = 3.0 Hz, 
CH2); 4.26 (q, 2H, J = 7.1 Hz, CH2); 5.31-5.38 (m, 1H, CH); 6.82 (d, 1H, J  = 
8.8 Hz, Ar); 6.87-7.11 (m, 2H, Ar); 7.38 (dd, 1H, J = 2.3, 8.8 Hz, Ar); 7.51- 
7.60 (m, 1H, Ar); 7.62 (d, 1H, J  = 2.3 Hz, Ar) ppm. 
 
ethyl[6-bromo-2-(4-bromo-2-fluorophenyl)-2'-oxo-2,3-dihydro-3'H-spiro 
[chromene-4,5'-[1,3]oxazolidin]-3'-yl]acetate 98b. 
Compound 98b was obtained from 93b (0.35 g, 0.77 mmol) and 
ethylbromoacetate (0.13 g, 0.77 mmol) following the procedure described for 
67a.The crude product was directly used in the next step without further 
purification. 93b (0.38 g, 0.7 mmol, yield 87%): 1H-NMR (CDCl3) δ : 1.32 (t, 
3H, J = 7.1 Hz, Me); 2.38-2.54 (m, 2H, CH2); 3.81-3.95 (m, 2H, CH2); 4.12 (s, 
2H, CH2); 4.26 (q, 2H, J = 7.1 Hz,; CH2); 5.32-5.45 (m, 1H, CH); 6.83 (d, 1H, J 
= 8.8 Hz, Ar); 7.07-7.16 (m, 1H, Ar); 7.33-7.54 (m, 3H, Ar); 7.62 (d, 1H, J = 
2.1 Hz, Ar) ppm.  
 
1-{2-[(4-methoxybenzyl)oxy]phenyl}ethanone 102a 
To a solution of 2-hydroxyacetophenone (1.5 g, 11.03 mmol) in DMSO (7 mL) 
was added KOH (1.86 g, 33.09 mmol) and the resulting mixture was stirred at 
50°C for 15 min. After cooling to rt 4-methoxybenzyl chloride (1.73 g, 11.03 
mmol) was added. The reaction mixture was stirred at rt for 4h and then washed 
with H2O and NaHCO3sat. The organic layer was dried, filtered and evaporated 
under vacuum to give …a without further purification. 102a (1.5 g, 5.83 mmol, 
yield 53%): 1H-NMR (CDCl3) δ : 2.57 (s, 3H, Me); 3.83 (s, 3H, OMe); 5.09 (s, 
2H, OCH2); 6.93 (d, 2H, J = 8.6 Hz, Ar); 6.96-7.05 (m, 2H, Ar); 7.36 (d, 2H, J 
= 8.6 Hz, Ar); 7.40-7.49 (m, 1H, Ar); 7.75 (dd, 1H, J = 2.0, 7.7, Hz, Ar) ppm.   
 
1-{2-[(3,4-dimethoxybenzyl)oxy]phenyl}ethanone 103a 
Compound 103a was synthesised from 2-hydroxyacetophenone (1.5 g, 11.03 
mmol) and 3,4-dimethoxybenzyl chloride (2.06 g, 11.03 mmol) following the 
same procedure described for 102a. The crude product was directly used for the 
next reaction without further purification.103a (1.83 g, 9.81 mmol, yield 89%): 
1H-NMR (CDCl3) δ : 2.59 (s, 3H, Me); 3.89 (s, 3H, OMe); 3.90 (s, 3H, OMe); 
5.09 (s, 2H, OCH2); 6.85-7.05 (m, 5H, Ar); 7.41-7.49 (m, 1H, Ar); 7.74 (dd; 
1H, J =1.8, 7.5 Hz, Ar) ppm. 
 
1-{2-[(3,4,5-trimethoxybenzyl)oxy]phenyl}ethanone 104a 
Compound 104a was synthesised from 2-hydroxyacetophenone (0.9 g, mmol) 
and 3,4,5-trimethoxybenzyl chloride (1.5 g, 6.93 mmol) following the same 
procedure described for 102a. The crude product was directly used for the next 
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reaction without further purification. 104a (1.9 g, 6.03 mmol, yield 87%): 1H-
NMR (CDCl3) δ : 2.63 (s, 3H, Me); 3.86 (s, 9H, OMe); 5.09 (s, 2H, CH2); 6.67 
(s, 2H, Ar); 6.99-7.06 (m, 2H, Ar); 7.41-7.50 (m, 1H, Ar); 7.74 (dd; 1H, J = 
1.7, 8.0 Hz, Ar) ppm. 
 
2-[2-(benzyloxy)phenyl]-2- [(trimethylsilyl)oxy] propanenitrile 105a 
Compound 105a was synthesised from 102a (1.5 g, 5.83 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 105a (1.74 g, 4.88 mmol, yield 84%): 1H-
NMR (CDCl3) δ : 0.31 (s, 9H, Me); 1.89 (s, 3H, Me); 3.82 (s, 3H, OMe); 5.05-
5.16 (m, 2H, CH2); 6.77-7.04 (m, 4H, Ar); 7.19-7.35 (m, 1H, Ar); 7.46 (d, 2H, J 
= 8.8 Hz; Ar); 7.56 (dd, 1H, J = 2.0, 8.1 Hz, Ar) ppm.  
 
2-{2-[(3,4-dimethoxybenzyl)oxy]phenyl}-2-[(trimethylsilyl)oxy] 
propanenitrile 106a 
Compound 106a was synthesised from 103a (1.09 g, 5.83 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 106a (1.91 g, 4.95 mmol, yield 85%): 1H-
NMR (CDCl3) δ : 0.29 (s, 9H, Me); 1.89 (s, 3H, Me); 3.89 (s, 3H, OMe); 3.90 
(s, 3H, OMe); 5.03-5.18 (m, 2H, CH2); 6.67-7.03 (m, 5H, Ar); 7.18-7.41 (m, 
1H, Ar); 7.56 (dd, 1H, J =1.8, 8.1 Hz) ppm. 
 
2-[(trimethylsilyl)oxy]-2-{2-[(3,4,5-trimethoxybenzyl)oxy]phenyl}propane 
nitrile 107a 
Compound 107a was synthesised from 104a (1.90 g, 6.03 mmol) following the 
procedure described for 49a. The crude product was directly used in the next 
step without further purification. 107a (2.22 g, 5.37 mmol, yield 89%): 1H-
NMR (CDCl3) δ : 0.06 (s, 9H, Me); 2.01 (s, 3H, Me); 3.88 (s, 9H, OMe); 5.18 
(s, 2H, CH2); 6.80 (s, 2H, Ar); 7.01-7.08 (m, 2H, Ar); 7.35-7.42 (m, 2H, Ar) 
ppm. 
 
1-amino-2-{2-[(4-methoxybenzyl)oxy]phenyl}propan-2-ol 108a 
Compound 108a was synthesised from 105a (1.74 g, 4.88 mmol) following the 
procedure described for 50a. The crude product was directly used in the next 
step without further purification. 108a (0.83 g, 2.88 mmol, yield 59%)1H-NMR 
(CDCl3) δ : 1.49 (s, 3H, Me); 3.31 (d, 1H, J = 12.7 Hz, CH2); 3.51 (d, 1H, J = 
12.7 Hz, CH2); 3.83 (s, 3H, OMe); 5.00-5.14 (m, 2H, CH2); 6.87-7.05 (m, 4H, 
Ar); 7.18-7.28 (m, 1H, Ar); 7.35 (d, 2H, J  = 8.6 Hz, Ar); 7.68 (d, 1H, J = 8.1, 
2.0, Ar) ppm.  
1-amino-2-{2-[(3,4-dimethoxybenzyl)oxy]phenyl}propan-2-ol 109a 
Compound 109a was synthesised from 106a (1.91 g, 4.95 mmol) following the 
procedure described for 50a. The crude product was directly used in the next 
step without further purification. 109a (1.19 g, 3.76 mmol, yield 76%): 1H-
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NMR (CDCl3) δ : 1.54 (s, 3H, Me); 2.77 (d, 1H, J =12.7 Hz, CH2); 3.29 (d, 1H, 
J=12.7 Hz, CH2); 3,88 (s, 3H, OMe); 3,89 (s, 3H, OMe); 5.03 (s, 2H, CH2); 
6.62-7.02 (m, 5H, Ar); 7.20-7.28 (m, 1H, Ar); 7.45-7.50 (m, 1H, Ar) ppm. 
 
1-amino-2-{2-[(3,4,5-trimethoxybenzyl)oxy]phenyl}propan-2-ol 110a 
Compound 110a was synthesised from 107a (2.22 g, 5.37 mmol) following the 
procedure described for 50a. The crude product was directly used in the next 
step without further purification. 110a (1.21 g, 3.49 mmol, yield 65%) 1H-NMR 
(CDCl3) δ : 1.57 (s, 3H, Me); 2.80 (d, 1H, J =12.7 Hz, CH2); 3.31 (d, 1H, 
J=12.7 Hz, CH2); 3.85 (s, 9H, OMe); 5.03 (s, 2H, CH2); 6.65 (s, 2H, Ar); 6.90-
7.02 (m, 2H, Ar); 7.18-7.28 (m, 1H, Ar); 7.48-7.53 (m, 1H, Ar) ppm. 
 
5-{2-[(4-methoxybenzyl)oxy]phenyl}-5-methyl-1,3-oxazolidin-2-one 111a 
Compound 111a was synthesised from 108a (0.48 g, 1.67 mmol) following the 
procedure described for 57a. The crude product was purified by flash column 
chromatography eluted by Hex/EtOAc (5.5/4.5) to give 111a (0.16 g, 0.5 mmol, 
yield 30%): 1H-NMR (CDCl3) δ : 1.73 (s, 3H, Me); 3.62 (d, 1H, J = 9.1 Hz, 
CH2); 3.72 (d, 1H, J = 9.1 Hz, CH2); 3.83 (s, 3H, OMe); 4.99 (s, 2H, OCH2); 
6.93 (d, 2H, J = 8.4 Hz, Ar); 6.96-7.04 (m, 2H, Ar); 7.25-7.33 (m, 3H, Ar); 
7.59-7.63 (m, 1H, Ar) ppm. 
 
5-{2-[(3,4-dimethoxybenzyl)oxy]phenyl}-5-methyl-1,3-oxazolidin-2-one 
112a 
Compound 112a was synthesised from 109a (0.53 g, 1.67 mmol) following the 
procedure described for 57a. The crude product was directly used in the next 
step without further purification. 112a (0.45 g, 1.30 mmol, yield 78%): 1H-
NMR (CDCl3) δ: 1.75 (s, 3H, Me); 3.63 (d, 1H, J = 9,1 Hz, CH2); 3.73 (d, 1H, 
J = 9,1 Hz, CH2); 3.89 (s, 3H, OMe); 3.90 (s, 3H, OMe); 4.92-5.09 (m, 2H, 
CH2); 6.70-7.04 (m, 5H, Ar); 7.25-7.33 (m, 1H, Ar); 7.58-7.63 (m, 1H, Ar) 
ppm. 
 
5-methyl-5-{2-[(3,4,5-trimethoxybenzyl)oxy]phenyl}-1,3-oxazolidin-2-one 
113a 
Compound 113a was synthesised from 110 (1.21 g, 3.49 mmol) following the 
procedure described for 57a. The crude product was directly used in the next 
step without further purification. 113a (1.07 g, 2.86 mmol, yield 82%): 1H-
NMR (CDCl3) δ: 1.80 (s, 3H, Me); 3.67-3.93 (m, 11H, CH2, OMe); 4.92-5.45 
(m, 2H, CH2); 6.60 ( s, 2H, Ar); 6.92-7.06 (m, 2H, Ar); 7.20-7.30 (m, 1H, Ar); 
7.62 (dd, 1H, J = 1.6, 7.7 Hz, Ar) ppm. 
 
ethyl(5-{2-[(4-methoxybenzyl)oxy]phenyl}-5-methyl-2-oxo-1,3-oxazolidin-
3-yl) acetate 114a 
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Compound 114a was synthesised from 111a (0.16 g, 0.5 mmol) and 
ethylbromoacetate (0.08 g, 0.5 mmol) following the procedure described for 
67a. The crude product was directly used in the next step without further 
purification. 114a (0.16 g, 0.4 mmol, yield 81%): 1H-NMR (CDCl3) δ:1.18-
1.27 (m, 3H, Me); 1.77 (s, 3H, Me); 3.66-3.78 (m, 2H, CH2); 3.83 (s, 3H, 
OMe); 4.02-4.26 (m, 4H, CH2); 5.01 (s, 2H, OCH2); 6.91-7.04 (m, 4H, Ar); 
7.26-7.33 (m, 3H, Ar); 7.59-7.63 (m, 1H, Ar) ppm. 
 
ethyl(5-{2-[(3,4-dimethoxybenzyl)oxy]phenyl}-5-methyl-2-oxo-1,3-
oxazolidin-3-yl)acetate 115a 
Compound 115a was synthesised from 112a (0.17 g, 0.5 mmol) and 
ethylbromoacetate (0.08 g, 0.5 mmol) following the procedure described for 
67a. The crude product was directly used in the next step without further 
purification. 115a (0.17 g, 0.4 mmol, yield 81%): 1H-NMR (CDCl3) δ:1.14-
1.33 (m, 3H, Me); 1.79 (s, 3H, Me); 3.65-3.98 (m, 8H, CH2, OMe); 4.02-4.25 
(m, 2H, CH2); 5.01 (s, 2H, OCH2); 6.70-6.79 (m, 1H, Ar); 6.83-7.03 (m, 4H, 
Ar); 7.24-7.33 (m, 1H, Ar); 7.58-7.62 (m, 1H, Ar) ppm. 
 
ethyl(5-{2-[(3,4,5-trimethoxybenzyl)oxy]phenyl}-5-methyl-2-oxo-1,3-
oxazolidin -3-yl) acetate 116a 
Compound 116a was synthesised from 113a (0.50 g, 1.34 mmol) and 
ethylbromoacetate (0.22 g, 1.34 mmol) following the procedure described for 
67a. The crude product was directly used in the next step without further 
purification. 116a (0.54 g, 1.18 mmol, yield 88%): 1H-NMR (CDCl3) δ:1.14-
1.33 (m, 3H, Me); 1.84 (s, 3H, CH3); 3.70-3.92 (m, 11H, CH2, OMe); 4.06-4.22 
(m, 2H, CH2); 4.94-5.17 (m, 2H, CH2); 6.61 (s, 2H, Ar); 6.93-7.05 (m, 2H, Ar); 
7.20-7.30 (m, 1H, Ar); 7.63 (dd, 1H, J = 1.6, 7.7 Hz, Ar) ppm. 
 
 
3,4-dimethoxybenzyl chloride 100  
To a stirred solution of 3,4-dimethoxybenzyl alcohol (1.72 g, 10.26 mmol) in 
CHCl3 (20 mL) was added dropwise SOCl2 (2.24 ml, 30.78 mmol) at 0 ºC. The 
resulting mixture was stirred rt for 20h, then washed with H2O and brine. The 
organic phase was dried, filtered and the solvent was evaporated under vacuum 
to give 100 (1.65 g, 8.83 mmol, yield 86 %). 1H-NMR (CDCl3) δ: 3.85 (s, 3H, 
OCH3); 3.87 (s, 3H, OCH3); 4.54 (s, 2H, CH2); 6.78-6.94 (m, 3H, Ar) ppm. 
 
3,4,5-trimethoxybenzyl chloride 101 
Compound 101 was synthesised from 3,4-dimethoxybenzyl alcohol (2.00 g, 
10.10 mmol) following the same procedure described for 100. The crude 
product was used in the next reaction without further purification. 101 (1.94 g, 
8.99 mmol, yield 89%).1H-NMR (CDCl3) δ: 3.85 (s, 3H, OCH3); 3.87 (s, 3H, 
OCH3); 4.54 (s, 2H, CH2); 6.78-6.94 (m, 3H, Ar) ppm. 
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5.2 Enantiomeric resolution 
HPLC enantioseparations were performed by using stainless-steel Chiralpak IA 
(250 x 4.6 mm I.D. and 250 x 10 mm I.D.) (Daicel, Chemical Industries, 
Tokyo, Japan) columns. HPLC-grade solvents were supplied by Carlo Erba 
(Milan, Italy). HPLC apparatus consisted in a Perkin Elmer (Norwalk, CT, 
USA) 200 lc pump equipped with a Rheodyne (Cotati, CA, USA) inJector, a 
HPLC Dionex (CA, USA) Model TCC-100 oven and a Jasco (Jasco, Ishikawa-
cho, HachioJi City, Tokyo, Japan) Model 2095 Plus UV/CD detector.  
The HPLC enantioseparation of compounds 1a and 2b was carried out on the 
amylose-based Chiralpak IA 250 x 4.6 mm I.D (for evaluation of 
chromatographic data and enantiomeric excess) and 250 x 10 mm I.D. (for 
semipreparative enantioseparations); temperature, 25°C, flow-rate, 1 ml/min 
(for analytical enantioseparations) and 5 ml/min (for semipreparative 
enantioseparations); detection: UV at 225 nm (for analytical enantioseparation 
of 1a); 280 nm (for analytical enantioseparation of 2b); 290 and 300 nm (for 
semipreparative enantioseparations of 2b and 1a, respectively).  
The mobile phases were filtered and degassed by sonication immediately before 
using. In analytical enantioseparations, standard solutions were prepared by 
dissolving about 2 mg of sample, into 10 ml of mobile phase. The inJection 
volume was 10-20 µl. In semipreparative enantioseparation a 1 mL sample loop 
was used. After semipreparative separation, the collected fractions were 
analyzed by chiral analytical columns to determine their enantiomeric excess 
(ee). 
The column hold-up time (t0 = 3.0 min for 250 x 4.6 mm I.D column) was 
determined from the elution of an unretained marker (toluene); using ethanol as 
eluent, delivered at a flow-rate of 1.0 mL/min. 
The eluent composition and the corresponding analytical chromatographic data 
for each resolved compound are summarized as follows: 1a: n-Hexane-ethanol 
75/25 (v/v); k1 = 2.27, α = 1.45, Rs = 4.55; 2b: n-Hexane-ethyl acetate-
trifluoroacetic acid 40/60/0.1 (v/v/v); k1 = 0.88, α = 1.36, Rs = 2.92. k1: 
retention factor of the first eluted enantiomer, defined as (t1 – t0)/t0 where t0 is 
the void time of the column; α: enantioselectivity factor defined as k2/k1; Rs: 
resolution factor defined as 2(t2-t1)/(w1+w2) where t1 and t2 are retention times 
and w1 and w2 are band widths at the baseline in time units. Other analytical 
chromatographic conditions: flow-rate, 1.0 mL/min; temperature, 25 °C; 
detector: UV and CD at 225 nm (for 1a) and 280 nm (for 2b). 
Specific rotations of enantiomers of 1a and 2b, dissolved in ethanol, were 
measured at 589 nm by a Perkin-Elmer polarimeter model 241 equipped with a 
Na lamp. The volume of the cell was 1 ml and the optical path was 10 cm. The 
system was at a temperature of 20°C by a Neslab RTE 740 cryostat. The 
circular dichroism (CD) spectra of stereoisomers of 1a and 2b, dissolved in 
ethanol (concentration about 0.2 mg/mL); in a quartz cell (0.1 cm-path length) 
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at 25°C, were measured by using a Jasco Model J-700 spectropolarimeter. The 
spectra are average computed over three instrumental scans and the intensities 
are presented in terms of ellipticity values (mdeg). 
RX-analysis was carried out with a Goniometer Oxford Diffraction KM4 
Xcalibur2 at room temperature. 
Graphite-monochromated Mo/Kα radiation (40mA/-40KV) and a KM4 
CCD/SAPPHIRE detector were  used for cell parameter determination and data 
collection. 
The integrated intensities, measured using the ω scan mode, were corrected for 
Lorentz and polarization effects.10 The substantial redundancy in data allows 
empirical absorption corrections (SADABS)11 to be applied using multiple 
measurements of symmetry-equivalent reflections. 
The structure was solved by direct methods of SIR200412 and refined using the 
full-matrix least squares on F2 provided by SHELXL97.13 
The stereochemical correspondences between the couples of the isolated 
enantiomers of 1a and 2b were established by CD analysis. The structures and 
the absolute configurations of (+)-2b and (-)-2b, and therefore of (+)-1a and (-)-
1a, was readily secured by X-ray crystallography and dextrorotatory and 
levorotatory enantiomers showed to have (R) and (S) configuration, 
respectively.  
 
X-ray structural analysis of compounds R-(+)-2b and S-(-)-2b 
R-(+)-2b. C22H25N2O5BrS , M =509.41, Trigonal, space group P31, a 
=12.161(1); b =12.161(1); c =13.193(1)Å, V =1689.7(2)Å3,Z =3  Dc =1.502, µ 
=1.955 mm-1, F(000) =786. 
8157 reflections were collected with a 4.40<θ< 31.92 range; 6123 were 
independent; the parameters were 298 and the final R index was 0.0571 for 
reflections having I>2σI and 0.0967 for all data. 
S-(-)-2b. C22H25N2O5BrS , M =509.41, Trigonal, space group P31, a 
=12.161(1); b =12.161(1); c =13.184(1)Å, V =1688.6(2)Å3, Z =3  Dc =1.503, µ 
=1.953 mm-1, F(000) =786. 
3906 reflections were collected with a 4.56<θ< 28.75 range; 2862 were 
independent; the parameters were 284 and the final R index was 0.0464 for 
reflections having I>2σI and 0.0959 for all data. 
In both compounds the non-hydrogen atoms were refined anisotropically. 
Aromatic, methylic and methylenic hydrogens were assigned in calculated 
positions, whereas hydrogen on N2 was found in the Fourier synthesis; all of 
them were refined as isotropic. 
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5.3 Pharmacological procedures 
All the experimental procedures were carried out following the guidelines of 
the European Community Council Directive 86-609. 
 
In vitro vascular protocols 
The effects of the compounds were tested on isolated thoracic aortic rings of 
male normotensive Wistar rats (250-350 g). 
After a light ether anaesthesia, the rats were sacrificed by cervical dislocation 
and bleeding. 
The aortas were immediately excised and freed of extraneous tissues, and the 
endothelial layer was removed by gently rubbing the intimal surface of the 
vessels with a hypodermic needle. Five millimeter wide aortic rings were 
suspended, under a preload of 2 g, in 20 mL organ baths, containing Tyrode 
solution (composition of saline in mM: NaCl 136.8; KCl 2.95; CaCl2 1.80; 
MgSO4 7H2O 1.05; NaH2PO4 0.41; NaHCO3 11.9; Glucose 5.5); thermostated 
at 37°C and continuously gassed with a mixture of O2 (95%) and CO2 (5%). 
Changes in tension were recorded by means of an isometric transducer (Grass 
FTO3); connected with a preamplifier (Buxco Electronics) and with a software 
of data acquisition (BIOPAC Systems Inc., MP 100). 
After an equilibration period of 60 minutes, endothelium removal was 
confirmed by the administration of acetylcholine (ACh) (10 µM) to  KCl (20 
mM)-precontracted rings. A relaxation < 10% of the KCl-induced contraction 
was considered to be indicative of an acceptable lack of the endothelial layer, 
while the organs showing a relaxation ≥ 10% (i.e., significant presence of the 
endothelium) were discarded. 
From 30 to 40 minutes after the confirmation of the endothelium removal, the 
aortic preparations were contracted by a single concentration of KCl (20mM); 
and when the contraction reached a stable plateau, 3-fold increasing 
concentrations of the test substances (from 10 nM to 100 µM) were added. 
Preliminary experiments showed that the KCl (20 mM)-induced contractions 
remained in a stable tonic state for at least 40 minutes. 
 
Data analysis 
The vasorelaxing efficacy was evaluated as the maximal vasorelaxing response, 
expressed as a percentage (%) of the contractile tone induced by 20mM KCl. 
When the limit concentration of 100 µM (the highest concentration that could 
be administered) of the tested compounds did not reach the maximal effect, the 
parameter of efficacy represented the vasorelaxing response, expressed as a 
percentage (%) of the contractile tone induced by 20mM KCl, evoked by this 
limit concentration. The parameter of potency was expressed as pIC50, 
calculated as negative logarithm of the molar concentration of the test 
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compounds, evoking a 50% reduction of the contractile tone induced by 20mM 
KCl. The pIC50 could not be calculated for those compounds showing an 
efficacy parameter lower than 50%.  The parameters of efficacy and potency 
were expressed as means ± standard error, for 5-10 experiments. Student t test 
was selected for statistical analysis, P < 0.05 was considered to be indicative of 
a significant statistical differences. Experimental data were analysed by a 
computer fitting procedure (software: GraphPad Prism 4.0). 
 
In vitro cardiac protocols 
Adult male Wistar rats (260-350 g) were treated by an i.p. inJection (about 0.3 
ml)  with a dose of 40mg/Kg with the following compounds: diazoxide, 1a,b, 
2b, 3a,b, 4b, vehicle (DMSO) or with a dose of 1mg/Kg as concerns 
cromakalim. After 2 hours, all the animals were anaesthetised with sodium 
pentobarbital (100 mg/Kg i.p.) and heparinised (100 UI i.p.) to prevent blood 
clotting. In order to verify the effective selectivity towards the mitochondrial 
KATP channels, in another series of experiments a selective mito-KATP blocker 
was administered, in a 10mg/Kg dose to the rats, 20 minutes before the 
administration of the tested compounds. After the opening of the chest, the 
hearts were quickly excised and placed in a 4°C Krebs solution (composition 
mM: NaHCO3 25.0, NaCl 118.1, KCl 4.8, MgSO4 1.2, CaCl2.2H2O 1.6, 
KH2PO4 1.2, glucose 11.5) equilibrated with 95% O2 5% CO2, to stop the 
contraction and to reduce oxygen consumption. Rapidly, the ascending aorta 
was cannulated and hearts mounted on a Langendorff apparatus, then the 
perfusion with Krebs solution (thermostated at 37°C and continuously bubbled 
with a gas mixture of 95% O2 and 5% CO2) was started at constant pressure 
(70-80 mmHg). The above procedure was executed within 2 min. A water-filled 
latex balloon connected to a pressure transducer (Bentley Trantec, mod 800) 
was introduced into the left ventricle via the mitral valve and the volume was 
adJusted to achieve a stable left ventricular end-diastolic pressure of 5-10 
mmHg during initial equilibration. The heart rate (HR) and left ventricular 
developed pressure (LVDP) were monitored by a Biopac system (California, 
USA) and the parameter of Rate Pressure Product (RPP) was calculated as RPP 
= HR x LVDP. In order to avoid that a physiological fall in the contractile 
activity, due to a long period of reperfusion, (which could cause a damage not 
exclusively related to ischemia) could influence the corrected analysis of the 
functional data, the RPP value recorded at the 30th minute of reperfusion (RPP-
30’) was considered more reliable than the RPP value recorded at the last 
minute of reperfusion (RPP-120’). The RPP-30’ and the RPP-120’ parameters 
have been expressed as % of the RPP value recorded at the last minute of the 
pre-ischemic period. The coronary flow (CF) was measured volumetrically and 
was expressed as mL of the perfusate collected in 1 min. After a 30 min 
equilibration pre-ischemic period, the hearts were subJected to 30 min of global 
ischemia (no flow). Hearts showing severe arrhythmia or unstable LVDP and 
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HR values were excluded from the experiments. At the end of the ischemic 
period the hearts were reperfused  for a period of 120 minutes. Moreover, the 
lactate de-hydrogenase enzyme ( LDH, a biochemical marker of the ischemic 
damage) collected in the last 5 minutes of the pre-ischemic phase and that 
collected every five minutes during all the reperfusion period, was measured by 
a spectrophotometric method. The amount of  released LDH has been expressed 
in enzymatic mU released in 120 minutes of reperfusion (without the small 
amount recorded in the pre-ischemic phase); resulting from the AUC analysis ( 
area under curve in the Cartesian graph of the LDH amount recorded at the 
determined intervals vs time) and related to1 g of the heart weight. At the end of 
the reperfusion period the hearts were removed from the Langendorff apparatus 
and the left ventricle has been cut in 2mm large slices which first have been 
bathed in a 10% aqueous solution of 2,3,5-triphenyltetrazolium chloride (TTC) 
for 20 minutes and then in a 20% aqueous solution of formaldehyde. After 24 
hours, the ventricular slices have been photographed and analysed in order to 
highlight the necrotic areas due to the ischemic process (visible as white or light 
pink colour) and the healthy areas (visible as strong red due to the TCC 
reaction) and then to calculate the % of ischemic area in front of the total 
myocardial area. 
 
In vivo model of coronary occlusion-reperfusion 
Two hours before the experimental procedures, rats received an i.p. inJection of 
compound a (2, 10 or 40 mg/Kg); reference drug diazoxide (40 mg/Kg, Sigma-
Aldrich); or vehicle (dimethylsulphoxide, DMSO, Sigma-Aldrich). When 
required by the experimental protocol, the mito-KATP blocker, 5-HD (10 mg/Kg, 
Sigma-Aldrich); was inJected 20 min before the treatment with the mito-KATP 
openers. 
Then, rats were anesthetised with sodium pentobarbital (70 mg/kg, i.p.). The 
trachea was intubated and connected to a rodent ventilator (mod. 7025 Ugo 
Basile, Comerio-Italy) for artificial ventilation with room air (stroke volume, 1 
ml/100 g of animal body weight; 70 strokes/min). Electrocardiogram (ECG) 
was continuously measured by lead II (Mindray, PM5000). The chest was 
opened by a left thoracotomy and the heart was gently exteriorized. A 6-0 
surgical needle was passed around the left anterior descending coronary artery 
(LAD); located between the base of the pulmonary artery and left atrium. The 
ends of the suture were passed through a polypropylene tube (PE50) to form a 
snare. To induce infarction, the LAD was occluded by pulling the snare and 
then fixing it in place by clamping the tube with a haemostat, when the snare 
was released the reperfusion was initiated. The acute infarct protocol consisted 
of 30’ occlusion/120’ reperfusion, successful occlusion was confirmed visually 
by regional cyanosis downstream of the ligature and by ST elevation on the 
ECG. 
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A group of animals was submitted to an IPC procedure, achieved by 2 cycles of 
5’ occlusion/10’ reperfusion, followed by 30’ coronary occlusion and 120’ 
reperfusion. Each experimental group was composed by at least 6 animals. At 
the end of reperfusion, rats were euthanised by an overdose of pentobarbital 
sodium, then hearts were quickly excised, mounted on a Langendorff apparatus 
and perfused for 10’ with Krebs solution to wash out the coronary blood 
vessels. Then, hearts were deprived of atria and right ventricle. 
The left ventricular tissue was dried, frozen, and cut into 4-5 transverse slices 
from apex to base of equal thickness (about 2 mm). The slices were then 
incubated in a 1% 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich) 
solution in a phosphate buffer (pH 7.4) at 37 °C for 20 min.  
TTC reacts with NADH in the presence of dehydrogenase enzymes, to form a 
formazan derivative, thus, causing the staining of viable cells with intense red 
colour.  
Subsequently, the slices were fixed overnight in 10% formaldehyde and then 
were photographed. Red-stained viable tissue was easily distinguished from the 
infracted white-unstained necrotic tissue. The infarct area (Ai) was 
planimetrically evaluated using an image analyzer program (The GIMP 2). The 
infarct size was calculated as a percentage of the whole area of left ventricle 
(Ai/ALV%).  
 
Cell culture 
H9c2 cells, derived from embryonic rat ventricular myocytes (ATTC, 
Manassas, VA); were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, 
Sigma-Aldrich); 100 units/ml penicillin and 100µg/ml streptomycin in tissue 
culture flasks at 37°C in humidified atmosphere of 5% CO2. 
H9c2 cells were cultured up to about 80% confluence in DMEM medium and 
24 hours before the experiment, cells were seeded onto 96-well plates at a 
density of 8×103 per well. After 24 hours to allow cell attachment, the medium 
was replaced in each 96-well plate and cells received different treatments such 
as: vehicle (that is 0.05% DMSO); diazoxide 100µM, compound a 10µM, 5-HD 
500 µM plus diazoxide 100 µM, 5-HD plus compound a 10µM. Then, one plate 
was placed for 16 hours in an airtight AtmosBag (Sigma-Aldrich) which was 
saturated with 95% N2 and 5% CO2 to simulate ischemia, while the twin plate 
was placed for 16 hours in an airtight AtmosBag which was saturated with 95% 
air and 5% CO2. At the end of the hypoxia period all the cells were subJected to 
reperfusion by replacing of the medium with the culture DMEM above 
described and incubation for 2 hours in an athmosphere containing 5% CO2 / 95 
% air at 37°C. After reperfusion, cell viability was assessed using the Cell 
Proliferation Reagent WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolium]-1,3-benzene disulphonate) (Roche, Mannheim, Germany) based on 
the cellular cleavage of the WST-1 to formazan. WST-1 Reagent was added at 
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1/10 of the total volume and after 60 min of incubation at 37°C, the absorbance 
was measured at 450 nm with a microplate reader (Wallac; PerkinElmer, 
Wellesley, MA, USA). Absorbance values have been normalised as a % of the 
absorbance shown by vehicle-treated cells exposed in the non-hypoxic 
atmosphere (Viab. %). Three different experiments have been performed in 
sixtuplicate. 
 
Isolation of rat mitochondria 
Rat cardiac mitochondria were isolated by differential centrifugation in 
agreement with the method of Chappel and Hansford 21. Male Wistar rats were 
killed by cervical dislocation, the heart was removed immediately and placed in 
ice cold isolation buffer (composition: sucrose 250 mM, Tris 5 mM, EGTA 
1mM, pH 7.4 adJusted with HCl). Atria were removed and ventricular tissue 
was finely minced with surgical scissors (about 2 mm3 pieces) and 
homogenised using an Ultra-Turrax homogeniser (20 ml of isolation buffer per 
heart). 
Three 20s homogenisation cycles were performed on ice, and then the 
suspension was centrifuged at 1075xg for 3 min at 4°C. The resulting 
supernatant was centrifuged at 11950xg for 10 min at 4°C. The pellet 
containing the mitochondrial fraction was further re-suspended in isolation 
buffer (without EGTA) and centrifuged at 11950xg for 10 min at 4°C, this step 
was repeated once more. 
The final mitochondrial pellet was re-suspended in minimal volume of 400 µl 
of the isolation buffer (without EGTA) and stored on ice throughout the 
experiment, which was performed within 2 hours. Mitochondrial protein 
concentrations were determined using the Bradford reaction 22.  
Previous experiments (data not shown) confirmed the reliability of the isolation 
procedures, by measurement of mitochondrial respiratory function through ATP 
bioluminescence assay, in agreement with the method of Drew and 
Leeuwenburgh 23. Briefly, mitochondria (1 mg protein/ml) were suspended in 
isolation buffer (without EGTA) plus succinate 20 mM, KH2PO4 30 mM and 
ADP 5’ diphosphate 200 µM. The reaction was initiated by the addition of 
luciferin-luciferase reagent. ADP 5’ diphosphate replaced by bidistilled water 
was used as a blank. 3 min after the start of reaction, the measurement was 
performed using a luminometer (Wallac, Perkin Elmer, Wellesley, MA, USA). 
In all the tested preparations, the assay really detected the light produced by the 
ATP-dependent oxidation of luciferin by means of luciferase enzyme. The 
ATP-synthase inhibitor olygomicin 2 µg/ml (Sigma-Aldrich) or the uncoupler 
of oxidative phosphorylation 2,4-dinitrophenol (DNF, 100 µM, Sigma-Aldrich) 
inhibited ATP production. 
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Mitochondrial swelling 
Mitochondrial swelling was assessed spectrophotometrically by measuring the 
change in absorbance of the suspension at 520 nm (Wallac, Perkin Elmer, 
Wellesley, MA, USA). 
Mitochondria (1mg protein/ml) were suspended under gently stirring in 
incubation medium (composition: KCl 120 mM, K2HPO4 5 mM, Hepes 10 mM, 
succinic acid 10 mM, MgCl2 2 mM, ATP 200 µM, pH 7.4 adJusted with KOH). 
The decrease of absorbance was monitored for 15 min after the addition of a 
(100µM); diazoxide (100 µM); or vehicle (DMSO 1%). Each time-response 
curve was obtained with mitochondria isolated from hearts of at least 6 different 
animals. 
 
Enzymatic inhibition 
Aldose reductase (ALR2) and aldehyde reductase (ALR1) were obtained from 
Sprague-Dawley albino rats, 120-140 g body weight, supplied by Harlan 
Nossan, Italy. To minimize cross-contamination between ALR2 and ALR1 in 
the enzyme preparation, rat lens, in which ALR2 is the predominant enzyme, 
and kidney, where ALR1 shows the highest concentration, were used for the 
isolation of ALR2 and ALR1, respectively. Pyridine coenzyme, D,L-
glyceraldehyde, and sodium D-glucuronate were from Sigma-Aldrich. Tolrestat 
was obtained from Lorestat Recordati, Italy. All other chemicals were of 
reagent grade. 
 
Enzyme Preparation.  
Aldose Reductase (ALR2). A purified rat lens extract was prepared in 
accordance with the method of Hayman and Kinoshita44 with slight 
modifications. Lenses were quickly removed from rats following euthanasia 
and were homogenized (Glas-Potter) in 3 volumes of cold deionized water. The 
homogenate was centrifuged at 12000 rpm at 0-4 °C for 30 min. Saturated 
ammonium sulfate solution was added to the supernatant fraction to form a 40% 
solution, which was stirred for 30 min at 0-4 °C and then centrifuged at 12000 
rpm for 15 min. Following this same procedure, the recovered supernatant was 
subsequently fractionated with saturated ammonium sulfate solution using first 
a 50% and then a 75% salt saturation. The precipitate recovered from the 75% 
saturated fraction, possessing ALR2 activity, was redissolved in 0.05 M NaCl 
and dialyzed overnight in 0.05 M NaCl. The dialyzed material was used for the 
enzymatic assay. 
Aldehyde Reductase (ALR1). Rat kidney ALR1 was prepared in accordance 
with a previously reported method.33 Kidneys were quickly removed from 
normal killed rats and homogenized (Glas- Potter) in 3 volumes of 10 mM 
sodium phosphate buffer, pH 7.2, containing 0.25 M sucrose, 2.0 mM EDTA 
dipotassium salt, and 2.5 mM _-mercaptoethanol. The homogenate was 
centrifuged at 12000 rpm at 0-4 °C for 30 min, and the supernatant was 
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subJected to a 40-75% ammonium sulfate fractionation, following the same 
procedure previously described for ALR2. The precipitate obtained from the 
75% ammonium sulfate saturation, possessing ALR1 
activity, was redissolved in 50 volumes of 10 mM sodium phosphate buffer, pH 
7.2, containing 2.0 mM EDTA dipotassium salt and 2.0 mM _-
mercaptoethanol, and was dialyzed overnight using the same buffer. The 
dialyzed material was used in the enzymatic assay. 
 
Enzymatic Assays.  
The activity of the two test enzymes was determined spectrophotometrically by 
monitoring the change in absorbance at 340 nm, which is due to the oxidation 
of NADPH catalyzed by ALR2 and ALR1. The change in pyridine coenzyme 
concentration/min was determined using a Beckman DU-64 kinetics software 
program (Solf Pack TM Module). ALR2 activity was assayed at 30 °C in a 
reaction mixture containing 0.25 mL of 10 mM d,L-glyceraldehyde, 0.25 mL of 
0.104 mM NADPH, 0.25 mL of 0.1 M sodium phosphate buffer (pH 6.2); 0.1 
mL of enzyme extract, and 0.15 mL of deionized water in a total volume of 1 
mL. All the above reagents, except D,Lglyceraldehyde, were incubated at 30 °C 
for 10 min; the substrate was then added to start the reaction, which was 
monitored for 5 min. Enzyme activity was calibrated by diluting the enzymatic 
solution to obtain an average reaction rate of 0.011 ( 0.0010 absorbance 
units/min for the sample. 
ALR1 activity was determined at 37 °C in a reaction mixture containing 0.25 
mL of 20 mM sodium D-glucuronate, 0.25 mL of 0.12 mM NADPH, 0.25 mL 
of dialyzed enzymatic solution, and 0.25 mL of 0.1 M sodium phosphate buffer 
(pH 7.2) in a total volume of 1 mL. The enzyme activity was calibrated by 
diluting the dialyzed enzymatic solution to obtain an average reaction rate of 
0.015 ( 0.0010 absorbance/min for the sample. 
 
Enzymatic Inhibition.  
The inhibitory activity of the new synthesised compounds against ALR2 and 
ALR1 was assayed by adding 0.1 mL of the inhibitor solution to the reaction 
mixture described above. All the inhibitors were solubilized in water and the 
solubility was facilitated by adJustment to a favorable pH. After complete 
solution, the pH was readJusted to 7. To correct for the non enzymatic 
oxidation of NADPH and for absorption by the compounds tested, a reference 
blank containing all the above assay components except the substrate was 
prepared. The inhibitory effect of the new derivatives was routinely estimated at 
a concentration of 10-4 M. Those compounds found to be active were tested at 
additional concentrations between 10-5 and 10-8 M. The determination of the 
IC50 values was performed by linear regression analysis of the log-dose 
response curve, which was generated using at least four concentrations of the 
inhibitor causing an inhibition between 20% and 80%, with two replicates at 
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each concentration. The 95% confidence limits (95% CL) were calculated from 
t values for n-2, where n is the total number of determinations. 
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5.4 Elemental composition 
 
Calculated % Found %  
Compound
 
Formula C H N C H N 
15a C22H25NO4 71.91 6.86 3.81 71.63 6.83 3.80 
15b C22H24BrNO4 59.20 5.42 3.14 58.96 5.40 3.12 
16a C22H25NO4 71.91 6.86 3.81 71.76 6.84 3.80 
16b C22H24BrNO4 59.20 5.42 3.14 59.02 5.40 3.13 
17a C21H22BrNO3 60.59 5.33 3.36 60.53 5.32 3.35 
17b C21H21Br2NO3 50.93 4.27 2.83 50.80 4.26 2.82 
18a C22H27NO3·HCl 67.77 7.24 3.59 67.97 7.25 3.60 
18b C22H26BrNO3·HCl 56.36 5.80 2.99 56.40 5.82 3.02 
19a C22H27NO3·HCl 67.77 7.24 3.59 67.85 7.25 3.60 
19b C22H26BrNO3·HCl 56.36 5.80 2.99 56.41 5.85 3.02 
20a C21H24BrNO2·HCl 57.48 5.74 3.19 57.65 5.76 3.20 
20b C21H23Br2NO2·HCl 48.72 4.67 2.71 48.74 4.48 2.75 
21a C21H23NO2S 71.36 6.56 3.96 71.07 6.53 3.94 
21b C21H22BrNO2S   58.33 5.13 3.24 58.33 5.25 3.27 
22a C22H25NO2S 71.90 6.86 3.81 71.68 6.84 3.79 
23a C21H22BrNO2S  58.33 5.13 3.24 58.35 5.11 3.23 
24a C21H21NO4 71.78 6.02 3.99 71.16 5.67 1.71 
24b C21H20BrNO4 58.62 4.68 3.26 58.53 4.43 3.59 
25a C20H21NO5S 62.00 5.46 3.62 61.05 5.32 2.25 
25b C20H20BrNO5S 51.51 4.32 3.00 51.53 4.32 3.00 
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26a C21H23NO3 74.75 6.87 4.15 74.45 6.84 4.13 
26b C21H22BrNO3 60.59 5.33 3.36 60.65 5.45 3.40 
27a C22H25NO3 75.19 7.17 3.99 75.11 7.16 3.98 
28a C21H22FNO3 70.97 6.24 3.94 71.18 6.26 3.97 
29a C21H23NO2S 71.36 6.56 3.96 71.64 6.58 3.97 
30a C21H24N2O3 71.57 6.86 7.95 71.42 6.84 7.93 
31a C23H26N2O4 70.03 6.64 7.10 69.82 6.62 7.07 
32a C22H26NO2S 61.38 6.09 6.51 61.62 6.11 6.53 
33a C20H23NO4S 64.32 6.21 3.75 63.81 6.04 2.79 
33b C20H22BrNO4S 53.10 4.90 3.10 52.88 4.88 3.08 
54a C21H22N2O5 65.96 5.80 7.33 66.01 5.73 6.98 
54b C21H21BrN2O5 54.68 4.59 6.07 54.86 4.47 6.02 
5a C21H24N2O3 71.57 6.86 7.95 71.44 6.67 7.78 
5b C21H23BrN2O3 58.48 5.37 6.49 58.09 5.15 6.29 
1a C23H26N2O4 70.03 6.64 7.10 69.85 6.36 7.02 
2b C22H25BrN2O5S 51.87 4.95 5.50 51.28 4.90 5.47 
34a C16H19NO5 62.94 6.27 4.59 62.40 5.83 4.09 
34b C16H18BrNO5 50.02 4.72 3.65 49.00 4.18 2.58 
35a C16H21NO4 65.96 7.27 4.81 65.69 7.24 4.79 
35b C16H20BrNO4 51.90 5.44 3.78 51.74 5.42 3.76 
36a C15H17NO5 61.85 5.88 4.81 61.60 5.85 4.79 
36b C15H16BrNO5 48.67 4.36 3.78 48.3 4.7 3.4 
37a C21H21NO6 65.79 5.52 3.65 65.92 5.53 3.65 
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37b C21H20BrNO6 54.56 4.36 3.03 54.04 3.93 2.63 
38a C20H18ClNO5 61.94 4.68 3.61 62.18 4.71 3.63 
38b C20H17BrClNO5 51.47 3.76 3.00 51.12 3.57 2.76 
39a C22H23NO6 66.49 5.83 3.52 63 6.0 3.2 
39b C22H22BrNO6 55.47 4.66 2.94 55.52 4.66 2.94 
40a C20H19NO6 65.03 5.18 3.79 64.83 5.16 3.77 
40b C20H18BrNO6 53.59 4.05 3.12 53.37 4.03 3.10 
41a C19H16ClNO5 61.05 4.31 3.75 60.80 4.29 3.73 
41b C19H15BrClNO5 50.41 3.34 3.09 50.67 3.15 3.22 
42a C19H15Cl2NO5 55.90 3.70 3.43 56.15 3.55 3.47 
42b C19H14BrCl2NO5 46.85 2.90 2.88 46.89 2.61 2.83 
43b C19H14BrF2NO5 50.24 3.11 3.08 50.46 3.30 2.80 
44b C19H14Br2FNO5 44.30 2.74 2.72 44.30 2.69 2.51 
45a C20H21NO6 64.68 5.70 3.77 64.98 5.84 3.57 
46a C21H23NO7 62.83 5.78 3.49 63.02 5.67 3.44 
47a C22H25NO8 61.25 5.84 3.25 61.06 5.82 3.24 
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